WO2006011631A2 - Thiazole derivatives having vap-1 inhibitory activity - Google Patents

Thiazole derivatives having vap-1 inhibitory activity Download PDF

Info

Publication number
WO2006011631A2
WO2006011631A2 PCT/JP2005/014136 JP2005014136W WO2006011631A2 WO 2006011631 A2 WO2006011631 A2 WO 2006011631A2 JP 2005014136 W JP2005014136 W JP 2005014136W WO 2006011631 A2 WO2006011631 A2 WO 2006011631A2
Authority
WO
WIPO (PCT)
Prior art keywords
amino
methyl
thiazol
ethyl
phenyl
Prior art date
Application number
PCT/JP2005/014136
Other languages
French (fr)
Other versions
WO2006011631A3 (en
Inventor
Takayuki Inoue
Takashi Tojo
Masataka Morita
Original Assignee
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2004904196A external-priority patent/AU2004904196A0/en
Application filed by Astellas Pharma Inc. filed Critical Astellas Pharma Inc.
Priority to EP05768525A priority Critical patent/EP1786792B1/en
Priority to US11/572,772 priority patent/US20070254931A1/en
Priority to CA002575411A priority patent/CA2575411A1/en
Priority to JP2007504792A priority patent/JP4978464B2/en
Priority to DE602005013793T priority patent/DE602005013793D1/en
Publication of WO2006011631A2 publication Critical patent/WO2006011631A2/en
Publication of WO2006011631A3 publication Critical patent/WO2006011631A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to a compound or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 inhibitor, a pharmaceutical composition comprising the compound or salt thereof as an active ingredient, a method for preventing or treating a vascular adhesion protein-1 associated disease, especially macular edema, use of the compound, salt thereof or composition, and the like.
  • Vascular adhesion protein-1 (hereinafter to be abbreviated as VAP-I) is an amine oxidase (semicarbazide sensitive amine oxidase, SSAO) which is abundant in human plasma, and shows remarkably increased expression in vascular endothelium and vascular smooth muscle of the inflammatory region. While the physiological role of VAP-I has not been clarified until recently, VAP-I gene was cloned in 1998, and VAP-I has been reported to be a membrane protein that regulates rolling and migration of lymphocyte and NK cell as an adhesion molecule under regulation of expression by inflammatory cytokine. Although the amine to be a substrate is unknown, it is considered to be methylamine generated in any part of living organisms. It is also known that hydrogen peroxide and aldehydes produced due to the amine oxidase activity in the molecule are important factors of adhesion activity.
  • SSAO amine sensitive amine oxidase
  • VAP-I enzyme activity in plasma increases in diabetic patients, whether type I or type II, and the increase is particularly remarkable in diabetic patients suffering from retinopathy complications (Diabetologia, 42 (1999) 233-237 and Diabetic Medicine, 16 ( 1999 ) 514-521 ) .
  • VAP-I is associated with the following diseases:
  • endothelium damage in diabetes, atherosclerosis and hypertension
  • a cardiovascular disorder associated with diabetes and uremia pain associated with gout and arthritis
  • retinopathy in diabetes patients
  • an (connective tissue) inflammatory disease or condition rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and osteoarthritis or degenerative joint disease, Reiter's syndrome, Sjogren's syndrome, Beh ⁇ et's syndrome, relapsing polychondritis, systemic lupus erythematosus, discoid lupus erythematosus, systemic sclerosis, eosinophilic fasciitis, polymyositis, dermatomyositis, polymyalgia rheumatica, vasculitis, temporal arteritis, polyarteritis nodosa, Wegener's granulomatosis
  • stomatitis a central nervous system inflammatory disease or condition (multiple sclerosis, Alzheimer's disease, and ischemia- reperfusion injury associated with ischemic stroke) ; a pulmonary inflammatory disease or condition (asthma, adult respiratory distress syndrome, and chronic obstructive pulmonary disease) ; a (chronic) skin inflammatory disease or condition (psoriasis, allegic lesions, lichen planus, pityriasis rosea, contact dermatitis, atopic dermatitis, and pityriasis rubra pilaris) ; a disease related to carbohydrate metabolism (diabetes and complications from diabetes) including microvascular and i ⁇ acrovascular disease (atherosclerosis, vascular retinopathies, retinopathy, nephropathy, nephrotic syndrome and neuropathy (polyneuropathy, mononeuropathies and autonomic neuropathy) , foot ulcers, joint problems, and increased risk of
  • SSAO-mediated complication [diabetes (insulin dependent diabetes mellitus (IDDM) and non-insulin dependent diabetes mellitus (NIDDM) ) and vascular complication (heart attack, angina, strokes, amputations, blindness and renal failure) ] (see WO 02/38153) ;
  • macular edema is a common ocular abnormality resulting from a vast etiology and characterized by perturbation of the integrity of the blood-retinal barrier of the perifoveal capillaries and the optic nerve head.
  • Macular edema is known to include diabetic and non- diabetic macular edema.
  • Macular edema as a diabetic complication is a disease state that can occur in any stage of diabetic retinopathy, emerges before the onset of neovascularization and causes serious visual disorders.
  • Macular area is a highly evolved part in retina and plays a key role in controlling the eyesight.
  • the macular area suffers from edema, how mild the change may be, it causes a significant failure of eyesight, and when left unattended, the edema causes irreversible changes of macular tissue, and it is considered to encourage progress .of retinopathy.
  • the present inventors have intensively worked on the problem of the drug treatment of a VAP-I associated disease and found that a VAP-I inhibitor is useful for the prophylaxis or treatment of the disease, particularly macular edema, and completed the present invention.
  • the present invention provides the following.
  • a compound of the formula (I), (II), (III) or (IV) [hereinafter sometimes referred to as Compound (I), (II), (III) or (IV), or VAP-I inhibitor] : wherein
  • R 1 is alkylcarbonyl; Xi is a bond or lower alkylene; Yi is a bond, lower alkylene, -CH 2 -CO-, -CH 2 -CH 2 -CO-, -CH 2 -CH 2 -CO-CH 2 - or -NH-CH 2 -CH 2 -; and Zi is -NH 2 , -NH (lower alkyl) or lower alkyl; provided that when Xi is ethylene, then Yi should be C 2 -C6 alkylene, -CH 2 -CO-, -CH 2 -CH 2 -CO-, -CH 2 -CH 2 -CO-CH 2 - or -NH-CH 2 -CH 2 -, when Xi is a bond, then Yi should be a bond, methylene, C 3 -C 6 alkylene, -CH 2 -CO-, -CH 2 -CH 2 -CO-, -CH 2 -CH 2 -CO-CH 2
  • R 1 is alkylcarbonyl
  • R a is (lower alkyl) sulfonyl, aminosulfonyl or di (lower alkyl) aminosulfonyl
  • R b is mono- or di- (lower alkyl) amino, wherein R c is lower alkyl and R d is (lower alkyl) sulfonyl, di (lower alkyl) aminocarbonyl, alkylcarbonyl or nitro, or
  • -CH CH-CO-di (lower alkyl) amino
  • X 2 is a bond or lower alkylene
  • Y 2 is a bond, lower alkylene, -CH 2 -CO- or -NH-CO-CH 2 -; and Z 2 is -NH 2 ; provided that when R 1 is acetyl, X 2 is ethylene, Y 2 is a bond and Z 2 is -NH 2 , then R 2 should not be 3- (methanesulfonyl)benzyl, 4- (methanesulfonyl)benzyl, 4- (ethanesulfonyl)benzyl and 2- (dimethylaminocarbonyl)pyrrolidin-1-ylmethyl;
  • R 1 is alkylcarbonyl
  • R 3 is -O N ° r • H X 3 is lower alkylene - ; and.
  • Y 3 is lower alkylene r
  • R 1 is alkylcarbonyl; and X 4 is lower alkylene; or a pharmaceutically acceptable salt thereof.
  • a pharmaceutical composition which comprises, as an active ingredient, the compound of [1] or a pharmaceutically acceptable salt thereof.
  • [7] A use of the compound of [1] or a pharmaceutically acceptable salt thereof for preparing a medicament as a VAP-I inhibitor.
  • VAP-I associated disease is selected from the group consisting of cirrhosis, essential stabilized hypertension, diabetes, arthrosis, endothelium damage (in diabetes, atherosclerosis and hypertension) , a cardiovascular disorder associated with diabetes and uremia, pain associated with gout and arthritis, retinopathy (in diabetes patients) , an (connective tissue) inflammatory disease or condition (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and osteoarthritis or degenerative joint disease, Reiter's syndrome, Sjogren's syndrome, Beh ⁇ et's syndrome, relapsing polychondritis, systemic lupus erythematosus, discoid lupus erythematosus, systemic sclerosis, eosinophilic fasciitis, polymyositis, dermatomyositis, polymyalgia rheumatica,
  • a VAP-I inhibitor which comprises the compound of [1] or a pharmaceutically acceptable salt thereof.
  • a method for preventing or treating macular edema which method comprises administering to a subject in need thereof a VAP-I inhibitor in an amount sufficient to treat said subject for macular edema.
  • a method for preventing or treating a VAP-I associated disease comprises administering an effective amount of the compound of [1] or a pharmaceutically acceptable salt thereof to a mammal.
  • VAP-I associated disease is selected from the group consisting of cirrhosis, essential stabilized hypertension, diabetes, arthrosis, endothelium damage (in diabetes, atherosclerosis and hypertension) , a cardiovascular disorder associated with diabetes and uremia, pain associated with gout and arthritis, retinopathy (in diabetes patients), an (connective tissue) inflammatory disease or condition (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and osteoarthritis or degenerative joint disease, Reiter's syndrome, Sjogren's syndrome, Behcet's syndrome, relapsing polychondritis, systemic lupus erythematosus, discoid lupus erythematosus, systemic sclerosis, eosinophilic fasciitis, polymyositis, dermatomyositis, polymyalgia rheumatica, vasculitis
  • the present invention is predicated on the discovery that an inhibitor for vascular adhesion protein-1 (VAP-I; also referred to as semicarbazide sensitive amine oxidase (SSAO) or copper-containing amine oxidase) is effective in treating or ameliorating VAP-I associated diseases, especially macular edema, and the like.
  • VAP-I vascular adhesion protein-1
  • SSAO semicarbazide sensitive amine oxidase
  • copper-containing amine oxidase copper-containing amine oxidase
  • the present invention provides Compounds (I), (II), (III) and (IV) and a pharmaceutically acceptable salt thereof useful as a VAP-I inhibitor, a pharmaceutical composition, a method for preventing or treating a VAP-I associated disease, and the like.
  • Suitable "halogen” includes fluorine, chlorine, bromine and iodine.
  • lower is used to intend a group having 1 to 6, preferably 1 to 4, carbon atom(s), unless otherwise provided.
  • Suitable “lower alkyl” includes straight or branched alkyl having 1 to 6 carbon atom(s) (i.e., Ci-C ⁇ alkyl), such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec- butyl, tert-butyl, pentyl, tert-pentyl and hexyl, in which more preferred one is C 1 -C 4 alkyl.
  • Suitable "lower alkylene” includes straight or branched alkylene having 1 to 6 carbon atom(s) (i.e., Ci-C 6 alkylene), such as methylene, ethylene, trimethylene, tetramethylene, propylene, ethylidene and propylidene, in which more preferred one is Ci-C 4 alkylene, still more preferred one is C 2 -C 4 alkylene.
  • alkylcarbonyl includes alkylcarbonyl wherein the alkyl moiety has 1 to 6 carbon atom(s) [i.e. the alkyl moiety is Ci-C ⁇ alkyl of the above “lower alkyl”] , such as acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl and heptanoyl, in which more preferred one is C 1 -C 4 alkyl-carbonyl.
  • Suitable "-NH(lower alkyl) " includes an amino group substituted with the "lower alkyl” defined above (i.e., Ci-C ⁇ alkyl amino) , such as methylamino, ethylamino, propylamino, isopropylamino, butylamino, isobutylamino, sec-butylamino, tert-butylamino, pentylamino, tert-pentylamino, hexylamino and the like.
  • Suitable "mono- or di- (lower alkyl) amino” includes an amino group substituted with 1 or 2 of the "lower alkyl” defined above (i.e., mono- or di-(Ci-C ⁇ alkyl) amino) , such as methylamino, ethylamino, propylamino, isopropylamino, butylamino, isobutylamino, sec-butylamino, tert-butylamino, pentylamino, tert-pentylamino, hexylamino, dimethylamino, diethylamino, dipropylamino, diisopropylamino, dibutylamino, diisobutylamino, di (sec-butyl) amino, di (tert-butyl) amino, dipentylamino, di (tert-pentyl) amino, dihexylamino and the like.
  • Suitable "(lower alkyl) sulfonyl” includes a sulfonyl group having the "lower alkyl” defined above (i.e., (Ci-Ce alkyl) sulfonyl) , such as methylsulfonyl, ethylsulfonyl, propylsulfonyl, isopropylsulfonyl, butylsulfonyl, isobutylsulfonyl, sec-butylsulfonyl, tert-butylsulfonyl, pentylsulfonyl, tert-pentylsulfonyl, hexylsulfonyl and the like.
  • Suitable "di (lower alkyl) aminosulfonyl” includes a sulfonyl group ⁇ having the "di (lower alkyl) amino" defined above (i.e., di (C x -Ce alkyl) aminosulfonyl) , such as dimethylaminosulfonyl, diethylaminosulfonyl, dipropylaminosulfonyl, diisopropylaminosulfonyl, dibutylaminosulfonyl, diisobutylaminosulfonyl, di (sec- butyl) aminosulfonyl, di (tert-butyl) aminosulfonyl, dipentylaminosulfonyl, di (tert-pentyl) aminosulfonyl, dihexylaminosulfonyl and the like.
  • the lower alkyls may be same or different.
  • Suitable “di (lower alkyl) aminocarbonyl” includes a carbonyl group having the "di (lower alkyl) amino" defined above (i.e., di (Ci-C 6 alkyl) aminocarbonyl) , such as dimethylaminocarbonyl, diethylaminocarbonyl, dipropylaminocarbonyl, diisopropylaminocarbonyl, dibutylaminocarbonyl, diisobutylaminocarbonyl, di(sec- butyl) aminocarbonyl, di (tert-butyl) aminocarbonyl, dipentylaminocarbonyl, di (tert-pentyl) aminocarbonyl, dihexylaminocarbonyl and the like.
  • the lower alkyls may be same or different.
  • Yi may be attached to ortho, meta or para position of the phenyl group.
  • Y 1 when Xi is ethylene, then Y 1 should be C 2 -C 6 alkylene, -CH 2 -CO-, -CH 2 -CH 2 -CO-, -CH 2 -CH 2 -CO-CH 2 - or -NH-CH 2 -CH 2 -, when X x is a bond, then Yi should be a bond, methylene, C 3 -C 6 alkylene, -CH 2 -CO-, -CH 2 -CH 2 -CO-, -CH 2 -CH 2 -CO-CH 2 - or -NH-CH 2 -CH 2 -, and when R 1 is acetyl, X x is ethylene, Yi is ethylene and Zi is -NH 2 , then Yi should be attached to ortho or meta position of the phenyl group.
  • Y ⁇ may be attached to ortho, meta or para position of the phenyl group.
  • the substitution site of R a on the phenyl is not particularly limited.
  • substitution site of -COR b on the pyrrolidinyl is not particularly limited.
  • substitution site of R d on .the phenyl is not particularly limited.
  • R 2 when R 1 is acetyl, X 2 is ethylene, Y 2 is a bond and Z 2 is -NH2, then R 2 should not be 3- (methanesulfonyl)benzyl, 4- (methanesulfonyl)benzyl, 4- (ethanesulfonyl)benzyl and 2- (dimethylaminocarbonyl) - pyrrolidin-1-ylmethyl.
  • X 3 may be attached to 4- or 5- position of the thiazolyl group.
  • Y3 may be attached to ortho, meta or para position of the phenyl group.
  • X4 may be attached to 4- or 5- position of the thiazolyl group.
  • VAP-I vascular adhesion protein-1 associated disease
  • a disease selected from the group consisting of cirrhosis, essential stabilized hypertension, diabetes, arthrosis, endothelium damage (in diabetes, atherosclerosis and hypertension) , a cardiovascular disorder associated with diabetes and uremia, pain associated with gout and arthritis, retinopathy (in diabetes patients) , an (connective tissue) inflammatory disease or condition
  • rheumatoid arthritis ankylosing spondylitis, psoriatic arthritis and osteoarthritis or degenerative joint disease, Reiter' s syndrome, Sjogren's syndrome, Beh ⁇ et's syndrome, relapsing polychondritis, systemic lupus erythematosus, discoid lupus erythematosus, systemic sclerosis, eosinophilic fasciitis, polymyositis, dermatomyositis, polymyalgia rheumatica, vasculitis, temporal arteritis, polyarteritis nodosa, Wegener's granulomatosis, mixed connective tissue disease, and juvenile rheumatoid arthritis) , a gastrointestinal inflammatory disease or condition [Crohn's disease, ulcerative colitis, irritable bowel syndrome (spastic colon) , fibrotic conditions of the liver, inflammation of the oral mucosa (
  • IDM insulin dependent diabetes mellitus
  • NIDDM non-insulin dependent diabetes mellitus
  • vascular complication heart attack, angina, strokes, amputations, blindness and renal failure
  • macular edema e.g., diabetic and non-diabetic macular edema
  • transplantation e.g., transplantation and the like.
  • VAP-I vascular adhesion protein-1
  • VAP-I inhibitor a compound having VAP-I inhibitory activity
  • the subject is meant a target of the administration of VAP-I inhibitor in the present invention, which is specifically various animals such as mammal, e.g., human, mouse, rat, swine, dog, cat, horse, bovine and the like, especially human.
  • mammal e.g., human, mouse, rat, swine, dog, cat, horse, bovine and the like, especially human.
  • the therapeutic method comprises administration of a VAP-I inhibitor in an amount sufficient to treat the VAP-I associated disease, especially macular edema.
  • a VAP-I inhibitor can be used in the method of the present invention as long as it is safe and effective.
  • the "VAP-I inhibitor” will be used to refer to such compounds/medicaments, which include Compound (I), (II), (III) or (IV), and is intended to encompass all compounds that inhibit enzyme activity of VAP-I at any and all points in the action mechanism thereof.
  • the VAP-I inhibitor used in the present invention may further include fluoroallylamine derivatives, semicarbazide derivatives, hydrazide derivatives, hydrazino derivatives, 1, 3, 4-oxadiazine derivatives, 4-alkyl-5- alkoxycarbonyl-4, 5, 6, 7-tetrahydroimidazo [4, 5-c]pyridine derivatives, 2, 6-diethoxybenzylamine, 2, 6-di (n- propoxy)benzylamine, 2, 6-diisopropoxybenzylamine, 2, 6-di (n- butoxy)benzylamine, 2, 6-bis (methoxymethoxy)benzylamine, 2,6- bis (methoxymethyl)benzylamine, 2, 6-diethylbenzylamine, 2,6- di-n-propylbenzylamine, 2, 6-bis (2-hydroxyethoxy)benzylamine, and the like.
  • fluoroallylamine derivatives 1,carbazide derivatives, hydrazide derivatives, hydrazino
  • the term "derivative” is intended to include all compounds derived from the original compound.
  • the VAP-I inhibitor can be administered as a prodrug to a subject.
  • prodrug is intended to include all compounds that convert to the VAP-I inhibitor in the body of the administration subject.
  • the prodrug can be any pharmaceutically acceptable prodrug of VAP-I inhibitor.
  • the VAP-I inhibitor can be administered to the administration subject as a pharmaceutically acceptable salt.
  • the pharmaceutically acceptable salt of the VAP-I inhibitor is nontoxic and a pharmaceutically acceptable conventional salt, which is exemplified by salts with inorganic or organic base such as alkali metal salt (e.g., sodium salt, potassium salt and the like) , alkaline earth metal salt (e.g., calcium salt, magnesium salt and the like), ammonium salt, and amine salt (e.g., triethylamine salt, N- benzyl-N-methylamine salt and the like) .
  • alkali metal salt e.g., sodium salt, potassium salt and the like
  • alkaline earth metal salt e.g., calcium salt, magnesium salt and the like
  • ammonium salt e.g., triethylamine salt, N- benzyl-N-methylamine salt and the like
  • the pharmaceutically acceptable salt of the VAP-I inhibitor includes a pharmaceutically acceptable acid addition salt.
  • the pharmaceutically acceptable acid addition salts include those derived from mineral acids, such as hydrochloric, hydrobromic, hydriodic, phosphoric, metaphosphoric, nitric and sulfuric acids, and organic acids, such as tartaric, acetic, citric, malic, lactic, fumaric, benzoic, glycolic, gluconic, succinic and arylsulfonic acids, for example, p-toluenesulfonic acid.
  • a pharmaceutically acceptable acid addition salt such as hydrochloride and hydriodide, particularly (mono-, di- or tri-)hydrochloride, is preferable.
  • VAP-I inhibitors except Compound (I), (II), (III) and (IV) may be commercially available or can be produced based on known references.
  • Compounds (I), (II), (III) and (IV) can be synthesized according to the following Production Method, Reference Example, Production Examples, the analogous methods thereto and the organic synthetic methods known to the art.
  • the VAP-I inhibitor or a pharmaceutically acceptable salt thereof can be administered in accordance with the present inventive method via any suitable route.
  • Suitable routes of administration include systemic, such as orally or by injection, topical, periocular (e.g., subTenon's), subconjunctival, intraocular, subretinal, suprachoroidal and retrobulbar administrations.
  • periocular e.g., subTenon's
  • subconjunctival e.g., intraocular, subretinal, suprachoroidal and retrobulbar administrations.
  • the manner in which the VAP-I inhibitor is administered is dependent, in part, upon whether the treatment of a VAP-I associated disease is prophylactic or therapeutic.
  • the VAP-I inhibitor is preferably administered as soon as possible after it has been determined that a subject such as mammal, specifically a human, is at risk for a VAP-I associated disease (prophylactic treatments) or has begun to develop a VAP-I associated disease (therapeutic treatments) . Treatment will depend, in part, upon the particular VAP-I inhibitor to be used, the amount of the VAP-I inhibitor to be administered, the route of administration, and the cause and extent, if any, of a VAP-I associated disease realized.
  • suitable methods of administering a VAP-I inhibitor which is useful in the present inventive method, are available.
  • a particular route can provide a more immediate and more effective reaction than another route. Accordingly, the described routes of administration are merely exemplary and are in no way limiting.
  • the dose of the VAP-I inhibitor administered to the administration subject such as animal including human, particularly a human, in accordance with the present invention, should be sufficient to effect the desired response in the subject over a reasonable time frame.
  • dosage will depend upon a variety of factors, including the strength of the particular VAP-I inhibitor to be employed/ the age, species, conditions or disease states, and body weight of the subject; and the degree of a VAP-I associated disease.
  • the size of the dose also will be determined depending on the route, timing and frequency of administration; the existence, nature and extent of any adverse side effects that might accompany the administration of a particular VAP- 1 inhibitor; and the desired physiological effect. It will be appreciated by one of ordinary skill in the art that various conditions or disease states may require prolonged treatment involving multiple administrations.
  • Suitable doses and dosage regimens can be determined by conventional range-finding techniques known to those of ordinary skill in the art. Generally, treatment is initiated with smaller dosages, which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. Generally, the VAP-I inhibitor can be administered in the dose of from about 1 ⁇ g/kg/day to about 300 mg/kg/day, preferably from about 0.1 mg/kg/day to about 10 mg/kg/day, which is given in a single dose or 2 to 4 doses a day or in a sustained manner.
  • compositions for use in the present inventive method preferably comprise a "pharmaceutically acceptable carrier" and an amount of a VAP-I inhibitor sufficient to treat a VAP-I associated disease, especially macular edema, prophylactically or therapeutically as an active ingredient.
  • the carrier can be any of those conventionally used and is limited only by chemico-physical considerations, such as the solubility and lack of the reactivity of the compound, and by the route of administration.
  • the VAP-I inhibitor can be administered in various manners to achieve the desired VAP-I inhibitory effect.
  • the VAP-I inhibitor can be administered alone or in combination with pharmaceutically acceptable carriers or diluents, the properties and nature of which are determined by the solubility and chemical properties of the inhibitor selected, the chosen administration route, and standard pharmaceutical practice.
  • the VAP-I inhibitor may be administered orally in solid dosage forms, e.g., capsules, tablets, powders, or in liquid forms, e.g., solutions or suspensions.
  • the inhibitor may also be injected parenterally in the form of sterile solutions or suspensions.
  • Solid oral forms may contain conventional excipients, for instance, lactose, sucrose, magnesium stearate, resins, and similar materials.
  • Liquid oral forms may contain various flavoring, coloring, preserving, stabilizing, solubilizing or suspending agents.
  • Parenteral preparations are sterile aqueous or non-aqueous solutions or suspensions which may contain certain various preserving, stabilizing, buffering, solubilizing or suspending agents.
  • additives such as saline or glucose, may be added to make the solutions isotonic.
  • the present inventive method also can involve the co ⁇ administration of other pharmaceutically active compound(s) .
  • co-administration is meant administration of the other pharmaceutically active compound(s) before, concurrently with, e.g., in combination with a VAP-I inhibitor in the same formulation or in separate formulations, or after administration of the VAP-I inhibitor as described above.
  • corticosteroids prednisone, methylprednisolone, dexamethasone or -triamcinolone acetinide, or noncorticosteroid anti-inflammatory compounds, such as ibuprofen or flubiprofen, can be co-administered.
  • vitamins and minerals e.g., zinc
  • anti-oxidants e.g., carotenoids (such as a xanthophyll carotenoid like zeaxanthin or lutein)
  • micronutrients can be co- administered.
  • VAP-I inhibitor according to the present invention is useful for preparing a medicament such as a therapeutic or prophylactic agent for the VAP-I associated diseases.
  • R 1 and R 2 are as defined above;
  • Li is a leaving group such as halogen (e.g., chlorine, bromine, iodine) ;
  • T is alkylcarbonyloxy(lower alkyl) wherein the alkylcarbonyl and the lower alkyl are defined above (e.g., acetyloxymethyl) ,
  • R 3 , Xi, X 2 , X 3 / X4, Yi, Y2/ Y3/ Zi and Z 2 are as defined above;
  • L 2 is a leaving group such as -OH, halogen (e.g., chlorine, bromine, iodine) , -O-alkylcarbonyl wherein the alkylcarbonyl is as defined above (e.g., -O-acetyl and the like) .
  • halogen e.g., chlorine, bromine, iodine
  • -O-alkylcarbonyl wherein the alkylcarbonyl is as defined above (e.g., -O-acetyl and the like) .
  • Suitable salt of Compound (2) may be the same as those exemplified for Compound (I), (II), (III) or (IV) .
  • Compounds (1) and (2) or its salt may be commercially available or can be prepared in accordance with the methods known per se.
  • the reaction is usually carried out in a conventional solvent such as ethanol, acetone, dichloromethane, acetic acid, and other organic solvent which does not adversely affect the reaction, or a mixture thereof.
  • the reaction temperature is not critical, and the reaction can be carried out under cooling to heating.
  • Compound (3) thus obtained can be isolated or purified by known separation or purification means, such as concentration, concentration in vacuo, solvent extraction, crystallization, recrystallization, phase transfer, chromatography and the like, and can be converted to a salt same as those exemplified for Compound (I), (II), (III) or (IV) .
  • Compound (4) may be commercially available or can be prepared in accordance with the methods known per se.
  • the reaction is usually carried out in a conventional solvent such as dichloromethane, chloroform, methanol, and other organic solvent which does not adversely affect the reaction, or a mixture thereof.
  • a conventional solvent such as dichloromethane, chloroform, methanol, and other organic solvent which does not adversely affect the reaction, or a mixture thereof.
  • the reaction is also preferably carried out in the presence of a conventional base such as 4-dimethylamino- pyridine, pyridine etc.
  • a liquid base can be also used as the solvent.
  • the reaction temperature is not critical, and the reaction can be carried out under cooling to heating.
  • Compound (5) thus obtained can be isolated or purified by known separation or purification means, such as concentration, concentration in vacuo, solvent extraction, crystallization, recrystallization, phase transfer, chromatography and the like, and can be converted to a salt same as those exemplified for Compound (I), (II), (III) or (IV) .
  • the acylation may be applied to Compound (1) in advance.
  • the nitrogen atom(s) in Compound (1), (2), (3) ox (5) may be protected or deprotected, as necessary, in accordance with methods known per se such as the methods described in Protective Groups in Organic Synthesis, published by John Wiley and Sons (1980), and the like.
  • Procedure B Synthesis of Compounds (I) to (IV) wherein X x , X 2 , X3 and X4 are lower alkylene such as ethylene (i.e. -CH 2 -CH 2 -) , for example,
  • L 3 is a leaving group such as halogen (e.g., chlorine, bromine, iodine) and/or halogenotriphenylphosphinyl (e.g., BrPh 3 P- ); and
  • U is carboxy(lower alkyl)phenyl (e.g., carboxymethylphenyl) ,
  • Compound (6) or its salt is reacted with Compound (7) or its salt to give an olefin compound (8) .
  • Suitable salts of Compounds (6) and (7) may be the same as those exemplified for Compound (I), (II), (III) or (IV) .
  • Compounds (6) and (7) or salts thereof may be commercially available or can be prepared in accordance with the methods known per se.
  • the reaction is usually carried out in a conventional solvent such as N,N-dimethylformamide, dimethylsulfoxide, tetrahydrofuran, dichloromethane, and other organic solvent which does not adversely affect the reaction, or a mixture thereof.
  • the reaction is also usually carried out in the presence of triphenylphosphine and/or a conventional base such as potassium tert-butoxide, sodium hydride, sodium hydroxide and the like.
  • the reaction temperature is not critical, and the reaction can be carried out under cooling to heating.
  • Compound (8) thus obtained can be isolated or purified by known separation or purification means, such as concentration, concentration in vacuo, solvent extraction, crystallization, recrystallization, phase transfer, chromatography and the like, and can be converted to a salt same as those exemplified for Compound (I), (II), (III) or (IV) .
  • Compound (8) or its salt is reduced in accordance with a conventional method to give Compound (9) .
  • the conventional reduction includes hydrogenation, catalytic hydrogenation, etc.
  • catalytic hydrogenation is preferable.
  • the catalytic hydrogenation is carried out in the presence of a catalyst such as palladium on carbon, preferably 10% palladium on carbon.
  • the catalytic hydrogenation is usually carried out in a conventional solvent such as tetrahydrofuran, methanol, ethanol, ethyl acetate, and other solvent which does not adversely affect the reaction, or a mixture thereof.
  • the catalytic hydrogenation is also preferably carried out in the presence of a conventional acid such as acetic acid, hydrochloric acid and the like.
  • a liquid acid can be also used as the solvent.
  • the reaction temperature is not critical, and the reaction can be carried out under cooling to heating.
  • Compound (9) thus obtained can be isolated or purified by known separation or purification means, such as concentration, concentration in vacuo, solvent extraction, crystallization, recrystallization, phase transfer, chromatography and the like, and can be converted to a salt same as those exemplified for Compound (I), (II), (III) or (IV) .
  • Compound (11) or a salt thereof can be prepared from Compound (10) or a salt thereof in a similar manner as described above.
  • Suitable salts of Compounds (10) and (11) may be the same as those exemplified for Compound (I) / (II), (III) or (IV) .
  • the nitrogen atom(s) in Compound (6), (7), (8), (9), (10) or (11) may be protected or deprotected, as necessary, in accordance with methods known per se such as the methods described in Protective Groups in Organic Synthesis, published by John Wiley and Sons (1980), and the like.
  • N- (4- (Hydroxymethyl) -1, 3-thiazol-2-yl) acetamide (2.8 g) was dissolved in methanol (10 ml) and chloroform (200 ml) . Then, manganese (IV) oxide (28.3 g) was added to the solution under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 7 hours, and filtered through a celite pad. The filtrate was concentrated in vacuo. The resulting solid was washed with ethyl ether to give N- (4-formyl-l, 3- thiazol-2-yl) acetamide (2.01 g) as an off-white solid, mp. 195.5-199°C
  • Step 6 of Production Example 2 in a manner similar to Step 7 of Production Example 1.
  • Step 8 Di-tert-butyl ⁇ (E) - [ (4- ⁇ 4- [2- (acetylamino) -1,3-thiazol-4- yl]phenyl ⁇ -2-oxobutyl) amino]methylidene ⁇ biscarbamate was prepared from the compound of Step 7 of Production Example 5 in a manner similar to Step 13 of Production Example 1.
  • Step 9 The title compound was prepared from the compound of Step
  • Step 1 To a solution of N- [4- (chloromethyl) -1, 3-thiazol-2- yl] acetamide (23.6 g) in toluene (200 ml) and acetonitril (80 ml) was added triphenylphosphine (35.7 g) at 25 0 C. The mixture was stirred at 130 0 C for 12 hr. Resulting precipitate was collected by filtration and washed with IPE to give ⁇ [2- (acetylamino) -1, 3-thiazol-4- yl]methyl ⁇ (triphenyl)phosphonium chloride (35.7 g) as colourless powder.
  • Methyl (2E) -3- (4-formylphenyl) acrylate was prepared from benzene-1, 4-dicarbaldehyde in a manner similar to Step 10 of production Example 2.
  • Step 9 Di-tert-butyl ( (Z) - ⁇ [3- (4- ⁇ 2- [2- (acetylamino) -1, 3- thiazol-4-yl] ethyl ⁇ phenyl)propyl]amino ⁇ methylidene) biscarbamate was prepared from the compound of Step 8 of
  • Step 5 To a solution of 4- ⁇ 4- [2- (acetylamino) -1, 3-thiazol-4- yl]phenyl ⁇ butyl pivalate (1.5 g) in MeOH (10 ml) was added sodium methoxide in MeOH (28 %, 0.89 ml) under ice-cooling.
  • Step 6 N- ⁇ 4- [4- (4-Bromobutyl)phenyl]-1, 3-thiazol-2-yl ⁇ acetamide was prepared from the compound of Step 5 of Production Example
  • Step 8 N- ⁇ 4- [4- (4-Aminobutyl)phenyl]-1, 3-thiazol-2-yl ⁇ acetamide was prepared from the compound of Step 7 of Production Example
  • N-(4- ⁇ (E) -2- [3- (2- ⁇ [tert-Butyl (dimethyl) silyl]oxy ⁇ ethyl)- phenyl] vinyl ⁇ -l, 3-thiazol-2-yl) acetamide was prepared from the compound of Step 3 of Production Example 8 in a manner similar to Step 3 of Production Example 2.
  • N- (4- ⁇ 2-[3-(2-Hydroxyethyl)phenyl]ethyl ⁇ -l,3-thiazol-2- yl) acetamide was prepared from the compound of Step 5 of Production Example 8 in a manner similar to Step 11 of Production Example 2.
  • reaction mixture was stirred at 50 0 C for 3 hours. After cooled to r.t., AcOEt and IN-HCl were added to the reaction mixture. The organic layer was washed with water, saturated NaHCO 3 and brine, dried over anhydrous MgSO 4 , and concentrated in vacuo.
  • Step 9 Di-tert-butyl ( (Z) - ⁇ [2- (3- ⁇ 2- [2- (acetylamino) -1, 3- thiazol-4-yl] ethyl ⁇ phenyl) ethyl] amino ⁇ methylidene) biscarbamate was prepared from the compound of Step 8 of
  • Step 1 A mixture of 3-chloro-2-oxopropyl acetate (5 g) and thiourea (2.5 g) in ethanol (25 ml) was refluxed for 4 hours. The reaction mixture was cooled to ambient temperature and the resulting crystalline precipitate was collected by filtration and washed with ethanol (20 ml) to give (2-amino-l, 3-thiazol- 4-yl)methyl acetate hydrochloride (3.5 g) as white crystals.
  • Step 6 To the solution of [4- (carboxymethyl)benzyl] (triphenyl) phosphonium bromide (19.1 g) in DMF (180 ml) was added potassium tert-butoxide (11.9 g) under ice-cooling. This was stirred at 5 0 C for 30 min. To the solution was added N- (4- formyl-l,3-thiazol-2-yl)acetamide (6.0 g) in DMF (18 ml) . This was stirred at 25 0 C for 3 hr. The mixture was poured into water and was extracted with ethyl acetate. The aquaous phase was acidified (pH 4-5) with IN HCl to give colourless precipitate.
  • N- (4- (Hydroxymethyl) -1, 3-thiazol-2-yl) acetamide (2.8 g) was dissolved in methanol (10 ml) and chloroform (200 ml) . Then, manganese (IV) oxide (28.3 g) was added to the solution under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 7 hours, and filtered through a celite pad. The filtrate was concentrated in vacuo. The resulting solid was washed with ethyl ether to give N- (4-formyl-l, 3- thiazol-2-yl) acetamide (2.01 g) as an off-white solid. mp. 195.5-199 0 C
  • N- [4- (2- ⁇ 4- [ (2-Aminoethyl) amino]phenyl ⁇ ethyl) -1, 3- thiazol-2-yl]acetamide dihydrochloride (20.3 mg) , N,N'- bis (tert-butoxycarbonyl)-lH-pyrazole-1-carboxamidine (16.7 mg) , N,N-diisopropylethylamine (28.1 ⁇ l) , THF (0.5 ml) and DMF (0.1 ml) were combined under N 2 atmosphere, and the mixture was stirred at 15 °C for 14 hr. Volatiles were evapolated and the residue was dissolved in MeOH (0.5 ml) .
  • reaction mixture was stirred under 3 atm H 2 at r.t. for 3 hours, and filtered through a celite pad. The filtrate was concentrated in vacuo.
  • IN-NaOH was added to the residue, and the mixture was extracted with AcOEt. The organic layer was washed with water and brine, dried over anhydrous MgSO 1J , and concentrated in vacuo.
  • N- [4- (2- ⁇ 2- (Acetylamino) -5- [4- (methylsulfonyl)benzyl] - 1, 3-thiazol-4-yl ⁇ ethyl)phenyl] -2-aminoacetamide hydrochloride (30 mg) , N,N'-bis (tert-butoxycarbonyl) -IH-pyrazole-l- carboxamidine (17.8 mg) , N,N-diisopropylethylamine (20.0 ⁇ l) , THF (0.5 ml) and DMF (0.1 ml) were combined under N 2 atmosphere. The reaction mixture was stirred at 15 0 C for 14 hr, and concentrated in vacuo.
  • the reaction mixture was diluted with 4ml of dichloromethane and washed with water. The organic layer was dried over diatomaceous earth and evaporated under vaccum to give crude pale yellow oil.
  • the crude oil was purified by preparative silica gel thin-layer chromatography with chloroform / methanol (15:1) as an eluent to give di-tert- butyl ⁇ (Z) -[ (4- ⁇ 2- [2- (acetylamino) -5- ( ⁇ (3R) -3- [ (dimethylamino) carbonyl] -l-pyrrolidinyl ⁇ methyl) -1, 3- thiazol-4-yl] ethyl ⁇ phenyl) amino]methylidene ⁇ biscarbamate (45.4 mg) as a white solid.
  • Step 2 of Production Example 14 in a manner similar to Step 3 of Production Example 12.
  • Step 2 The title compound was prepared from the compound of Step 1
  • Step 4 To a solution of di-tert-butyl ( (E) - ⁇ [4- (2- ⁇ 2- (acetylamino) -5- [ (methylamino)methyl] -1, 3-thiazol-4- yl ⁇ ethyl)phenyl]amino ⁇ methylidene)biscarbamate (20 mg) in dichloromethane (0.5 ml) were added 4-nitrobenzoic acid (6.11 mg), HOBt (7.42 mg) and EDCI HCl (10.5 mg) , and then the mixture was stirred for 3 hr at 20 0 C. The reaction mixture was diluted with dichloromethane (4 ml) and the solution was washed with water.
  • Step 2 Ethyl 2- (acetylamino) -4- [ (E) -2- (4- nitrophenyl) ethenyl]-1, 3-thiazole-5-carboxylate
  • Step 4 Ethyl 2- (acetylamino) -4- [2- (4-aminophenyl) ethyl] -1,3- thiazole-5-carboxylate (310 mg) was dissolved in tetrahydrofuran (6 ml) under nitrogen atmosphere. Then, di (tert-butyl) dicarbonate (223 mg) in tetrahydrofuran (1 ml) was added to the solution at room temperature. The reaction mixture was refluxed for 2 hours. After cooled to room temperature, the mixture was concentrated in vacuo.
  • reaction mixture was stirred at 0 0 C for 10 min, and N- (4-formyl-l, 3-thiazol-2-yl) acetamide (200 mg) was added to the mixture at 0 0 C.
  • the reaction mixture was stirred at 20 0 C for 2 hr.
  • ethyl acetate 50 ml
  • the organic layer was dried over magnesium sulfate and evaporated to give crude brown oil (750 mg) .
  • the filtrate was purified by preparative NH-silica gel thin-layer chromatography with chloroform / methanol (10:1) as an eluent to give a solid (16.4 mg) .
  • the solid was washed with CH 2 Cl 2 to give N- ⁇ 4-[2-(2- amino-lH-benzimidazol-7-yl) ethyl] -1, 3-thiazol-2-yl ⁇ acetamide (15.4 mg) as an off-white solid.
  • Step 2 Di-tert-butyl ⁇ (Z) -[ (4- ⁇ 3- [2- (acetylamino) -1, 3-thiazol-4- yl]propyl ⁇ phenyl) amino]methylidene ⁇ biscarbamate was prepared from the compound of Step 1 of Production Example 22 in a manner similar to Step 4 of Production Example 16.
  • Step 5 tert-Butyl [2- (4- ⁇ 3- [2- (acetylamino) -1, 3-thiazol-4- yl]propyl ⁇ phenyl) ethyl]carbamate was prepared from the compound of Step 4 of Production Example 24 in a manner similar to Step 13 of Production Example 2.
  • the reaction mixture was stirred at 0 0 C for 15 min, and 4- [2- (1, 3-dioxo-l, 3-dihydro-2H-isoindol-2-yl) ethyl]benzaldehyde (19.28 g) was added to the mixture at 0 °C.
  • the reaction mixture was stirred at 20 0 C for 2 hr.
  • the reaction mixture was poured into water, and the resulting precipitate was collected by filtration to give a crude brown solid.
  • reaction mixture was filtered through a celite pad, and the filtrate was concentrated in vacuo.
  • the residue was washed with IPE (200 ml) and purified by flash column chromatography .over silica gel with CHCl 3 / AcOEt (1:1) as an eluent. The fractions containing the object compound were combined, and evaporated under reduced pressure.
  • the mixture was stirred at 20 0 C for 12 hr under H 2 atmosphere (4 atm) .
  • the reaction mixture was filtered through a celite pad, and to the filtrate was added 10 % Pd/C (1.01 g) under N 2 atmosphere.
  • the mixture was stirred at 20 0 C for 12 hr under H 2 atmosphere (4 atm) .
  • the reaction mixture was filtered through a celite pad, and the filtrate was concentrated in vacuo.
  • VAP-I enzyme (SSAO) activity in human plasma was determined by a radiochemical-enzyme assay using 14 C- benzylamine as an artificial substrate.
  • the enzyme suspension prepared from blood plasma was pre-incubated with a control compound (Reference Example 1) in 96-well microplate at room temperature for 30 min.
  • the enzyme suspension was then incubated with 14 C-benzylamine (2xlO ⁇ 5 mol/1 final concentration) in a final volume of 50 ⁇ l at 37°C for 1 hour.
  • the enzyme reaction was terminated by adding 2 mol/1 (50 ⁇ l) citric acid.
  • the oxidized products were directly extracted into a 200 ⁇ l toluene scintillator, and its radioactivity was measured by a scintillation spectrometer. Inhibition activity was expressed as IC 50 ' ( ⁇ mol/1) value.
  • Test compounds i.e., the present compounds inhibited the enzyme activity of human plasma SSAO in comparison with the control compound as shown in Table 1.
  • the present invention provides a compound of the formula (I), (II), (III) or (IV), or a pharmaceutically acceptable salt thereof useful as a VAP-I inhibitor, a pharmaceutical composition, a method for preventing or treating a VAP-I associated disease, especially macular edema such, as diabetic macular edema and non-diabetic macular edema, which method comprises administering to a patient in need thereof a VAP-I inhibitor in an amount sufficient to treat the patient suffering from the VAP-I associated disease, and the like.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A compound of the formula (I), (II), (III) or (IV): wherein each symbol is as defined in the specification,or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, a method for preventing or treating a VAP-1 associated disease, especially macular edema, which method includes administering an effective amount of the compound or a pharmaceutically acceptable salt thereof to a subject, and the like.

Description

DESCRIPTION
THIAZOLE DERIVATIVES HAVING VAP-I INHIBITORY ACTIVITY
TECHNICAL FIELD
The present invention relates to a compound or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 inhibitor, a pharmaceutical composition comprising the compound or salt thereof as an active ingredient, a method for preventing or treating a vascular adhesion protein-1 associated disease, especially macular edema, use of the compound, salt thereof or composition, and the like.
BACKGROUND ART
Vascular adhesion protein-1 (hereinafter to be abbreviated as VAP-I) is an amine oxidase (semicarbazide sensitive amine oxidase, SSAO) which is abundant in human plasma, and shows remarkably increased expression in vascular endothelium and vascular smooth muscle of the inflammatory region. While the physiological role of VAP-I has not been clarified until recently, VAP-I gene was cloned in 1998, and VAP-I has been reported to be a membrane protein that regulates rolling and migration of lymphocyte and NK cell as an adhesion molecule under regulation of expression by inflammatory cytokine. Although the amine to be a substrate is unknown, it is considered to be methylamine generated in any part of living organisms. It is also known that hydrogen peroxide and aldehydes produced due to the amine oxidase activity in the molecule are important factors of adhesion activity.
A recent report has documented that VAP-I enzyme activity in plasma increases in diabetic patients, whether type I or type II, and the increase is particularly remarkable in diabetic patients suffering from retinopathy complications (Diabetologia, 42 (1999) 233-237 and Diabetic Medicine, 16 ( 1999 ) 514-521 ) .
In addition, it has been reported that VAP-I is associated with the following diseases:
(1) cirrhosis, essential stabilized hypertension, diabetes, arthrosis (see JP-A-61-239891 and USP 4,888,283);
(2) endothelium damage (in diabetes, atherosclerosis and hypertension) , a cardiovascular disorder associated with diabetes and uremia, pain associated with gout and arthritis, retinopathy (in diabetes patients) (see WO 93/23023) ; (3) an (connective tissue) inflammatory disease or condition (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and osteoarthritis or degenerative joint disease, Reiter's syndrome, Sjogren's syndrome, Behςet's syndrome, relapsing polychondritis, systemic lupus erythematosus, discoid lupus erythematosus, systemic sclerosis, eosinophilic fasciitis, polymyositis, dermatomyositis, polymyalgia rheumatica, vasculitis, temporal arteritis, polyarteritis nodosa, Wegener's granulomatosis, mixed connective tissue disease, and juvenile rheumatoid arthritis) ; a gastrointestinal inflammatory disease or condition [Crohn's disease, ulcerative colitis, irritable bowel syndrome (spastic colon) , fibrotic conditions of the liver, inflammation of the oral mucosa (stomatitis) , and recurrent aphtous. stomatitis] ; a central nervous system inflammatory disease or condition (multiple sclerosis, Alzheimer's disease, and ischemia- reperfusion injury associated with ischemic stroke) ; a pulmonary inflammatory disease or condition (asthma, adult respiratory distress syndrome, and chronic obstructive pulmonary disease) ; a (chronic) skin inflammatory disease or condition (psoriasis, allegic lesions, lichen planus, pityriasis rosea, contact dermatitis, atopic dermatitis, and pityriasis rubra pilaris) ; a disease related to carbohydrate metabolism (diabetes and complications from diabetes) including microvascular and iαacrovascular disease (atherosclerosis, vascular retinopathies, retinopathy, nephropathy, nephrotic syndrome and neuropathy (polyneuropathy, mononeuropathies and autonomic neuropathy) , foot ulcers, joint problems, and increased risk of infection) / a disease related to aberrations in adipocyte differentiation or function or smooth muscle cell function (atherosclerosis and obesity) ; a vascular disease [atheromatous ateriosclerosis, nonatheromatous ateriosclerosis, ischemic heart disease including myocardial infarction and peripheral arterial occlusion, Raynaud's disease and phenomenon, and thromboangiitis obliterans (Buerger's disease)]; chronic arthritis; inflammatory bowel diseases; skin dermatoses (see WO 02/02090, WO 02/02541 and US patent application publication No. 2002/0173521 Al) ;
(4) diabetes mellitus (see WO 02/38152);
(5) SSAO-mediated complication [diabetes (insulin dependent diabetes mellitus (IDDM) and non-insulin dependent diabetes mellitus (NIDDM) ) and vascular complication (heart attack, angina, strokes, amputations, blindness and renal failure) ] (see WO 02/38153) ;
(6) hepatitis, transplantation, and the like.
Under the present circumstances, a drug treatment or prophylaxis of the above diseases has been demanded. In addition, macular edema is a common ocular abnormality resulting from a vast etiology and characterized by perturbation of the integrity of the blood-retinal barrier of the perifoveal capillaries and the optic nerve head. Macular edema is known to include diabetic and non- diabetic macular edema. Macular edema as a diabetic complication is a disease state that can occur in any stage of diabetic retinopathy, emerges before the onset of neovascularization and causes serious visual disorders. Macular area is a highly evolved part in retina and plays a key role in controlling the eyesight. Once the macular area suffers from edema, how mild the change may be, it causes a significant failure of eyesight, and when left unattended, the edema causes irreversible changes of macular tissue, and it is considered to encourage progress .of retinopathy.
At present, for macular edema, laser beam photocoagulation and vitreous surgery have been tried as a symptomatic therapy. However, irradiation of laser on the macular area is not easy and unnecessary laser treatments may produce side effects (e.g., possible encouragement of edema by causing inflammation) . The vitreous surgery is considered to provide efficacy in 70 percent of macular edema, but physical and economical burden on patients is high, and the incidence of recurrence is also high. These treatment methods are not usually employed in the initial stage of macular edema, particularly so in the stages when the decrease of vision is comparatively small. Accordingly, a drug treatment comparatively easily applicable from the early stages of the disease has been also demanded under the present circumstances.
DISCLOSURE OF INVENTION
The present inventors have intensively worked on the problem of the drug treatment of a VAP-I associated disease and found that a VAP-I inhibitor is useful for the prophylaxis or treatment of the disease, particularly macular edema, and completed the present invention. Thus, the present invention provides the following.
[1] A compound of the formula (I), (II), (III) or (IV) [hereinafter sometimes referred to as Compound (I), (II), (III) or (IV), or VAP-I inhibitor] :
Figure imgf000006_0001
wherein
R1 is alkylcarbonyl; Xi is a bond or lower alkylene; Yi is a bond, lower alkylene, -CH2-CO-, -CH2-CH2-CO-, -CH2-CH2-CO-CH2- or -NH-CH2-CH2-; and Zi is -NH2, -NH (lower alkyl) or lower alkyl; provided that when Xi is ethylene, then Yi should be C2-C6 alkylene, -CH2-CO-, -CH2-CH2-CO-, -CH2-CH2-CO-CH2- or -NH-CH2-CH2-, when Xi is a bond, then Yi should be a bond, methylene, C3-C6 alkylene, -CH2-CO-, -CH2-CH2-CO-, -CH2-CH2-CO-CH2- or -NH-CH2-CH2-, and when R1 is acetyl, Xi is ethylene, Yi is ethylene and Z1 is -NH2, then Y1 should be attached to ortho or meta position of the phenyl group;
Figure imgf000006_0002
wherein R1 is alkylcarbonyl;
Figure imgf000006_0003
wherein Ra is (lower alkyl) sulfonyl, aminosulfonyl or di (lower alkyl) aminosulfonyl,
Figure imgf000006_0004
wherein Rb is mono- or di- (lower alkyl) amino, wherein Rc is lower alkyl and Rd is (lower alkyl) sulfonyl, di (lower alkyl) aminocarbonyl, alkylcarbonyl or nitro, or
-CH=CH-CO-di (lower alkyl) amino; X2 is a bond or lower alkylene;
Y2 is a bond, lower alkylene, -CH2-CO- or -NH-CO-CH2-; and Z2 is -NH2; provided that when R1 is acetyl, X2 is ethylene, Y2 is a bond and Z2 is -NH2, then R2 should not be 3- (methanesulfonyl)benzyl, 4- (methanesulfonyl)benzyl, 4- (ethanesulfonyl)benzyl and 2- (dimethylaminocarbonyl)pyrrolidin-1-ylmethyl;
Figure imgf000007_0001
wherein
R1 is alkylcarbonyl ;
R3 is -O N ° r • H X3 is lower alkylene - ; and.
Y3 is lower alkylene r
Figure imgf000007_0002
wherein
R1 is alkylcarbonyl; and X4 is lower alkylene; or a pharmaceutically acceptable salt thereof.
[2] The compound of [1], wherein R1 is acetyl, or a pharmaceutically acceptable salt thereof.
[3] The compound of [1], wherein Zi is -NH2, or a pharmaceutically acceptable salt thereof.
[4] The compound of [1], wherein the compound is N-{4- [2- (4-{ [amino (imino)methyl]amino}phenyl) ethyl]-5- [4-
(aminosulfonyl)benzyl] -1, 3-thiazol-2-yl}acetamide, N-{4-[4-(4-{ [amino (imino)methyl]amino}butyl)phenyl] -1,3- thiazol-2-yl}acetamide,
2- (4-{2- [2- (acetylamino) -I13-thiazol-4-yl] ethyl}phenyl) -N- [amino (imino)methyl]acetamide,
(3R) -1- ( {2- (acetylamino) -4-[2- (4-{ [amino (imino)methyl]amino}- phenyl) ethyl]-1, 3-thiazol-5-yl}methyl) -N,N-dimethyl-3- pyrrolidinecarboxamide,
(3S) -1- ( {2- (acetylamino) -4- [2- (4-{ [amino (imino)methyl]amino}- phenyl) ethyl] -1, 3-thiazol-5-yl}methyl) -N,N-dimethyl-3- pyrrolidinecarboxamide,
N- ( {2- (acetylamino) -4- [2- (4-{ [amino (imino)methyl]amino}- phenyl) ethyl] -1, 3-thiazol-5-yl}methyl) -N-methyl-4-
(methylsulfonyl)benzamide, or N- ({2- (acetylamino) -4- [2- (4-{ [amino (imino)methyl]amino}- phenyl) ethyl] -1, 3-thiazol-5-yl}methyl) -N-methyl-4- nitrobenzamide, or a pharmaceutically acceptable salt thereof.
[5] The compound of [1] or a pharmaceutically acceptable salt thereof for use as a medicament.
[6] A pharmaceutical composition, which comprises, as an active ingredient, the compound of [1] or a pharmaceutically acceptable salt thereof.
[7] A use of the compound of [1] or a pharmaceutically acceptable salt thereof for preparing a medicament as a VAP-I inhibitor.
[8] The use of [7], wherein the compound is N-{4- [2- (4-{ [amino (imino)methyl] amino}phenyl) ethyl]-5- [4- (aminosulfonyl)benzyl] -1, 3-thiazol-2-yl}acetamide, N-{4- [4- (4-{ [amino (imino)methyl]amino}butyl)phenyl] -1,3- thiazol-2-yl}acetamide,
2- (4-{2- [2- (acetylamino) -1,3-thiazol-4-yl]ethyl}phenyl) -N- [amino (imino)methyl]acetamide,
(3R) -1- ({2- (acetylamino) -4- [2- (4-{ [amino (imino)methyl]amino}- phenyl) ethyl]-1, 3-thiazol-5-yl}methyl) -N,N-dimethyl-3- pyrrolidinecarboxamide,
(3S) -1- ({2- (acetylamino) -4-[2- (4-{ [amino (imino)methyl]amino}- phenyl) ethyl]-1,3-thiazol-5-yl}methyl) -N,N-dimethyl-3- pyrrolidinecarboxamide,
N- ({2- (acetylamino) -4- [2- (4-{ [amino (imino)methyl]amino}- phenyl) ethyl]-1, 3-thiazol-5-yl}methyl) -N-methyl-4-
(methylsulfonyl)benzamide, or N- ({2- (acetylamino) -4- [2- (4-{ [amino (imino)methyl]amino}- phenyl) ethyl]-1, 3-thiazol-5-yl}methyl) -N-methyl-4- nitrobenzamide.
[9] A use of the compound of [1] or a pharmaceutically acceptable salt thereof for preparing a medicament for the prophylaxis or treatment of a VAP-I associated disease.
[10] The use of [9], wherein said VAP-I associated disease is selected from the group consisting of cirrhosis, essential stabilized hypertension, diabetes, arthrosis, endothelium damage (in diabetes, atherosclerosis and hypertension) , a cardiovascular disorder associated with diabetes and uremia, pain associated with gout and arthritis, retinopathy (in diabetes patients) , an (connective tissue) inflammatory disease or condition (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and osteoarthritis or degenerative joint disease, Reiter's syndrome, Sjogren's syndrome, Behςet's syndrome, relapsing polychondritis, systemic lupus erythematosus, discoid lupus erythematosus, systemic sclerosis, eosinophilic fasciitis, polymyositis, dermatomyositis, polymyalgia rheumatica, vasculitis, temporal arteritis, polyarteritis nodosa, Wegener's granulomatosis, mixed connective tissue disease, and juvenile rheumatoid arthritis) , a gastrointestinal inflammatory disease or condition [Crohn's disease, ulcerative colitis, irritable bowel syndrome (spastic colon) , fibrotic conditions of the liver, inflammation of the oral mucosa (stomatitis) , and recurrent aphtous stomatitis], a central nervous system inflammatory disease or condition (multiple sclerosis, Alzheimer's disease, and ischemia-reperfusion injury associated with ischemic stroke) , a pulmonary inflammatory disease or condition (asthma, adult respiratory distress syndrome, and chronic obstructive pulmonary disease) , a (chronic) skin inflammatory disease or condition (psoriasis, allegic lesions, lichen planus, pityriasis rosea, contact dermatitis, atopic dermatitis, and pityriasis rubra pilaris) , a disease related to carbohydrate metabolism (diabetes and complications from diabetes) including microvascular and macrovascular disease (atherosclerosis, vascular retinopathies, retinopathy, nephropathy, nephrotic syndrome and neuropathy (polyneuropathy, mononeuropathies and autonomic neuropathy) , foot ulcers, joint problems, and increased risk of infection) , a disease related to aberrations in adipocyte differentiation or function or smooth muscle cell function (atherosclerosis and obesity) , a vascular disease [atheromatous ateriosclerosis, nonatheromatous ateriosclerosis, ischemic heart disease including myocardial infarction and peripheral arterial occlusion, Raynaud' s disease and phenomenon, and thromboangiitis obliterans (Buerger's disease)], chronic arthritis, inflammatory bowel diseases, skin dermatoses, diabetes mellitus, SSAO-mediated complication [diabetes (insulin dependent diabetes mellitus (IDDM) and non-insulin dependent diabetes mellitus (NIDDM) ) and vascular complication (heart attack, angina, strokes, amputations, blindness and renal failure) ] , macular edema (diabetic and non-diabetic macular edema) , hepatitis and transplantation.
[11] The use of [10], wherein said VAP-I associated disease is macular edema.
[12] The use of [11], wherein said macular edema is diabetic macular edema.
[13] The use of [11], wherein said macular edema is non- diabetic macular edema. [14] A VAP-I inhibitor, which comprises the compound of [1] or a pharmaceutically acceptable salt thereof.
[15] A method for preventing or treating macular edema, which method comprises administering to a subject in need thereof a VAP-I inhibitor in an amount sufficient to treat said subject for macular edema.
[16] The method of [15], wherein the VAP-I inhibitor is N-{4- [2- (4-{ [amino (imino)methyl] amino}phenyl) ethyl]-5- [4-
(aminosulfonyl)benzyl] -1, 3-thiazol-2-yl}acetamide, N-{4- [4- (4-{ [amino (imino)methyl] amino}butyl)phenyl]-1,3- thiazol-2-yl}acetamide,
2- (4-{2- [2- (acetylamino) -1, 3-thiazol-4-yl] ethyl}phenyl) -N-
[amino (imino)methyl]acetamide,
(3R) -1- ( {2- (acetylamino) -4- [2- (4-{ [amino (imino)methyl]amino}- phenyl) ethyl]-l,3-thiazol-5-yl}methyl)-N,N-dimethyl-3- pyrrolidinecarboxamide,
(3S)-1- ({2- (acetylamino) -4- [2- (4-{ [amino (imino)methyl]amino}- phenyl) ethyl]-1,3-thiazol-5-yl}methyl) -N,N-dimethyl-3- pyrrolidinecarboxamide,
N- ( {2- (acetylamino) -4- [2- (4-{ [amino (imino)methyl] amino}- phenyl) ethyl]-l, 3-thiazol-5-yl}methyl) -N-methyl-4-
(methylsulfonyl)benzamide, or
N- ({2- (acetylamino) -4- [2- (4-{ [amino (imino)methy1]amino}- phenyl) ethyl]-1, 3-thiazol-5-yl}methyl) -N-methyl-4- nitrobenzamide, or a pharmaceutically acceptable salt thereof. [17] A method for preventing or treating a VAP-I associated disease, which method comprises administering an effective amount of the compound of [1] or a pharmaceutically acceptable salt thereof to a mammal.
[18] The method of [17], wherein said VAP-I associated disease is selected from the group consisting of cirrhosis, essential stabilized hypertension, diabetes, arthrosis, endothelium damage (in diabetes, atherosclerosis and hypertension) , a cardiovascular disorder associated with diabetes and uremia, pain associated with gout and arthritis, retinopathy (in diabetes patients), an (connective tissue) inflammatory disease or condition (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and osteoarthritis or degenerative joint disease, Reiter's syndrome, Sjogren's syndrome, Behcet's syndrome, relapsing polychondritis, systemic lupus erythematosus, discoid lupus erythematosus, systemic sclerosis, eosinophilic fasciitis, polymyositis, dermatomyositis, polymyalgia rheumatica, vasculitis, temporal arteritis, polyarteritis nodosa, Wegener's granulomatosis, mixed connective tissue disease, and juvenile rheumatoid arthritis), a gastrointestinal inflammatory disease or condition [Crohn' s disease, ulcerative colitis, irritable bowel syndrome (spastic colon) , fibrotic conditions of the liver, inflammation of the oral mucosa (stomatitis) , and recurrent aphtous stomatitis], a .central nervous system inflammatory disease or condition (multiple sclerosis, Alzheimer's disease, and ischemia-reperfusion injury associated with ischemic stroke) , a pulmonary inflammatory disease or condition (asthma, adult respiratory distress syndrome, and chronic obstructive pulmonary disease), a (chronic) skin inflammatory disease or condition (psoriasis, allegic lesions, lichen planus, pityriasis rosea, contact dermatitis, atopic dermatitis, and pityriasis rubra pilaris) , a disease related to carbohydrate metabolism (diabetes and complications from diabetes) including microvascular and macrovascular disease (atherosclerosis, vascular retinopathies, retinopathy, nephropathy, nephrotic syndrome and neuropathy (polyneuropathy, mononeuropathies and autonomic neuropathy), foot ulcers, joint problems, and increased risk of infection) , a disease related to aberrations in adipocyte differentiation or function or smooth muscle cell function (atherosclerosis and obesity) , a vascular disease [atheromatous ateriosclerosis, nonatheromatous ateriosclerosis, ischemic heart disease including myocardial infarction and peripheral arterial occlusion, Raynaud' s disease and phenomenon, and thromboangiitis obliterans (Buerger's disease)], chronic arthritis, inflammatory bowel diseases, skin dermatoses, diabetes mellitus, SSAO-mediated complication [diabetes (insulin dependent diabetes mellitus (IDDM) and non-insulin dependent diabetes mellitus (NIDDM) ) and vascular complication (heart attack, angina, strokes, amputations, blindness and renal failure) ] , macular edema (diabetic and non-diabetic macular edema) , hepatitis and transplantation. [19] The method of [18], wherein said VAP-I associated disease is macular edema.
[20] The method of [19], wherein said macular edema is diabetic macular edema. [21] The method of [19], wherein said macular edema is non- diabetic macular edema.
DETAILED DESCRIPTION OF THE INVENTION
The present invention is predicated on the discovery that an inhibitor for vascular adhesion protein-1 (VAP-I; also referred to as semicarbazide sensitive amine oxidase (SSAO) or copper-containing amine oxidase) is effective in treating or ameliorating VAP-I associated diseases, especially macular edema, and the like. Accordingly, the present invention provides Compounds (I), (II), (III) and (IV) and a pharmaceutically acceptable salt thereof useful as a VAP-I inhibitor, a pharmaceutical composition, a method for preventing or treating a VAP-I associated disease, and the like.
In the above and subsequent descriptions of the present specification, suitable examples and illustration of the various definitions to be included within the scope of the invention are explained in detail as follows. Suitable "halogen" includes fluorine, chlorine, bromine and iodine.
The term "lower" is used to intend a group having 1 to 6, preferably 1 to 4, carbon atom(s), unless otherwise provided. Suitable "lower alkyl" includes straight or branched alkyl having 1 to 6 carbon atom(s) (i.e., Ci-Cβ alkyl), such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec- butyl, tert-butyl, pentyl, tert-pentyl and hexyl, in which more preferred one is C1-C4 alkyl. Suitable "lower alkylene" includes straight or branched alkylene having 1 to 6 carbon atom(s) (i.e., Ci-C6 alkylene), such as methylene, ethylene, trimethylene, tetramethylene, propylene, ethylidene and propylidene, in which more preferred one is Ci-C4 alkylene, still more preferred one is C2-C4 alkylene.
Suitable "alkylcarbonyl" includes alkylcarbonyl wherein the alkyl moiety has 1 to 6 carbon atom(s) [i.e. the alkyl moiety is Ci-Cβ alkyl of the above "lower alkyl"] , such as acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl and heptanoyl, in which more preferred one is C1-C4 alkyl-carbonyl.
Suitable "-NH(lower alkyl) " includes an amino group substituted with the "lower alkyl" defined above (i.e., Ci-Cβ alkyl amino) , such as methylamino, ethylamino, propylamino, isopropylamino, butylamino, isobutylamino, sec-butylamino, tert-butylamino, pentylamino, tert-pentylamino, hexylamino and the like. Suitable "mono- or di- (lower alkyl) amino" includes an amino group substituted with 1 or 2 of the "lower alkyl" defined above (i.e., mono- or di-(Ci-Cδ alkyl) amino) , such as methylamino, ethylamino, propylamino, isopropylamino, butylamino, isobutylamino, sec-butylamino, tert-butylamino, pentylamino, tert-pentylamino, hexylamino, dimethylamino, diethylamino, dipropylamino, diisopropylamino, dibutylamino, diisobutylamino, di (sec-butyl) amino, di (tert-butyl) amino, dipentylamino, di (tert-pentyl) amino, dihexylamino and the like. The lower alkyls may be same or different. Suitable "(lower alkyl) sulfonyl" includes a sulfonyl group having the "lower alkyl" defined above (i.e., (Ci-Ce alkyl) sulfonyl) , such as methylsulfonyl, ethylsulfonyl, propylsulfonyl, isopropylsulfonyl, butylsulfonyl, isobutylsulfonyl, sec-butylsulfonyl, tert-butylsulfonyl, pentylsulfonyl, tert-pentylsulfonyl, hexylsulfonyl and the like.
Suitable "di (lower alkyl) aminosulfonyl" includes a sulfonyl group ■having the "di (lower alkyl) amino" defined above (i.e., di (Cx-Ce alkyl) aminosulfonyl) , such as dimethylaminosulfonyl, diethylaminosulfonyl, dipropylaminosulfonyl, diisopropylaminosulfonyl, dibutylaminosulfonyl, diisobutylaminosulfonyl, di (sec- butyl) aminosulfonyl, di (tert-butyl) aminosulfonyl, dipentylaminosulfonyl, di (tert-pentyl) aminosulfonyl, dihexylaminosulfonyl and the like. The lower alkyls may be same or different.
Suitable "di (lower alkyl) aminocarbonyl" includes a carbonyl group having the "di (lower alkyl) amino" defined above (i.e., di (Ci-C6 alkyl) aminocarbonyl) , such as dimethylaminocarbonyl, diethylaminocarbonyl, dipropylaminocarbonyl, diisopropylaminocarbonyl, dibutylaminocarbonyl, diisobutylaminocarbonyl, di(sec- butyl) aminocarbonyl, di (tert-butyl) aminocarbonyl, dipentylaminocarbonyl, di (tert-pentyl) aminocarbonyl, dihexylaminocarbonyl and the like. The lower alkyls may be same or different.
Suitable "-CH=CH-CO-di (lower alkyl) amino" includes a carbonylvinyl group having the Λλdi (lower alkyl) amino" defined above (i.e., -CH=CH-CO-di (Ci-C6 alkyl) amino) , such as (E) or (Z) dimethylaminocarbonylvinyl, diethylaminocarbonylvinyl, dipropylaminocarbonylvinyl, diisopropylaminocarbonylvinyl, dibutylaitiinocarbonylvinyl, diisobutylaminocarbonylvinyl, di (sec- butyl) aminocarbonylvinyl, di (tert-butyl) aminocarbonylvinyl, dipentylaminocarbonylvinyl, di (tert- pentyl) aminocarbonylvinyl, dihexylaminocarbonylvinyl and the like. The lower alkyls may be same or different. In Compound (I) , Xi may be attached to 4- or 5-position of the thiazolyl group.
In Compound (I) , Yi may be attached to ortho, meta or para position of the phenyl group.
In Compound (I) , when Xi is ethylene, then Y1 should be C2-C6 alkylene, -CH2-CO-, -CH2-CH2-CO-, -CH2-CH2-CO-CH2- or -NH-CH2-CH2-, when Xx is a bond, then Yi should be a bond, methylene, C3-C6 alkylene, -CH2-CO-, -CH2-CH2-CO-, -CH2-CH2-CO-CH2- or -NH-CH2-CH2-, and when R1 is acetyl, Xx is ethylene, Yi is ethylene and Zi is -NH2, then Yi should be attached to ortho or meta position of the phenyl group.
In Compound (II), Y∑ may be attached to ortho, meta or para position of the phenyl group. The substitution site of Ra on the phenyl is not particularly limited.
The substitution site of -CORb on the pyrrolidinyl is not particularly limited.
The substitution site of Rd on .the phenyl is not particularly limited.
In Compound (II), when R1 is acetyl, X2 is ethylene, Y2 is a bond and Z2 is -NH2, then R2 should not be 3- (methanesulfonyl)benzyl, 4- (methanesulfonyl)benzyl, 4- (ethanesulfonyl)benzyl and 2- (dimethylaminocarbonyl) - pyrrolidin-1-ylmethyl.
In Compound (III), X3 may be attached to 4- or 5- position of the thiazolyl group.
In Compound (III), Y3 may be attached to ortho, meta or para position of the phenyl group. In Compound (IV) , X4 may be attached to 4- or 5- position of the thiazolyl group.
Any nitrogen atom in the amino (i.e. -NH2), imino (i.e. =NH or -NH-) or the like in Compound (I), (II), (III) or (IV) may be protected according to the methods, which are known to those skilled in the art, such as the methods described in Protective Groups in Organic Synthesis, published by John Wiley and Sons (1980), and the like.
When Compound (I), (II), (III) or (IV) has an asymmetric carbon atom in the structure, those skilled in the art will recognize that Compound (I), (II), (III) or (IV) includes all stereoisomers.
When Compound (I), (II), (III) or (IV) has a double bond (i.e., >C=C<) in the structure, those skilled in the art will recognize that Compound (I), (H)/ (HI) or (IV) includes E or Z isomer and mixture thereof.
The "vascular adhesion protein-1 (VAP-I) associated disease" comprise a disease selected from the group consisting of cirrhosis, essential stabilized hypertension, diabetes, arthrosis, endothelium damage (in diabetes, atherosclerosis and hypertension) , a cardiovascular disorder associated with diabetes and uremia, pain associated with gout and arthritis, retinopathy (in diabetes patients) , an (connective tissue) inflammatory disease or condition
(rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and osteoarthritis or degenerative joint disease, Reiter' s syndrome, Sjogren's syndrome, Behςet's syndrome, relapsing polychondritis, systemic lupus erythematosus, discoid lupus erythematosus, systemic sclerosis, eosinophilic fasciitis, polymyositis, dermatomyositis, polymyalgia rheumatica, vasculitis, temporal arteritis, polyarteritis nodosa, Wegener's granulomatosis, mixed connective tissue disease, and juvenile rheumatoid arthritis) , a gastrointestinal inflammatory disease or condition [Crohn's disease, ulcerative colitis, irritable bowel syndrome (spastic colon) , fibrotic conditions of the liver, inflammation of the oral mucosa (stomatitis), and recurrent aphtous stomatitis] , a central nervous system inflammatory disease or condition (multiple sclerosis, Alzheimer's disease, and ischemia-reperfusion injury associated with ischemic stroke) , a pulmonary inflammatory disease or condition (asthma, adult respiratory distress syndrome, and chronic obstructive pulmonary disease) , a (chronic) skin inflammatory disease or condition (psoriasis, allegic lesions, lichen planus, pityriasis rosea, contact dermatitis, atopic dermatitis, and pityriasis rubra pilaris) , a disease related to carbohydrate metabolism (diabetes and complications from diabetes) including microvascular and macrovascular disease (atherosclerosis, vascular retinopathies, retinopathy, nephropathy, nephrotic syndrome and neuropathy (polyneuropathy, mononeuropathies and autonomic neuropathy), foot ulcers, joint problems, and increased risk of infection) , a disease related to aberrations in adipocyte differentiation or function or smooth muscle cell function (atherosclerosis and obesity) , a vascular disease [atheromatous ateriosclerosis, nonatheromatous ateriosclerosis, ischemic heart disease including myocardial infarction and peripheral arterial occlusion, Raynaud' s disease and phenomenon, and thromboangiitis obliterans (Buerger's disease)], chronic arthritis, inflammatory bowel diseases, skin dermatoses, diabetes mellitus, SSAO-mediated complication [diabetes
(insulin dependent diabetes mellitus (IDDM) and non-insulin dependent diabetes mellitus (NIDDM) ) and vascular complication (heart attack, angina, strokes, amputations, blindness and renal failure)], macular edema (e.g., diabetic and non-diabetic macular edema) , hepatitis, transplantation and the like.
The "preventing or treating a vascular adhesion protein-1 (VAP-I) associated disease" and "prophylaxis or treatment of a vascular adhesion protein-1 (VAP-I) associated disease", particularly "preventing or treating macular edema" and "prophylaxis or treatment of macular edema" are intended to include administration of a compound having VAP-I inhibitory activity (i.e. VAP-I inhibitor) to a subject for therapeutic purposes, which may include prophylaxis, amelioration, prevention and cure of the above described VAP-I associated disease, particularly macular edema. As used herein, by the "subject" is meant a target of the administration of VAP-I inhibitor in the present invention, which is specifically various animals such as mammal, e.g., human, mouse, rat, swine, dog, cat, horse, bovine and the like, especially human.
The therapeutic method comprises administration of a VAP-I inhibitor in an amount sufficient to treat the VAP-I associated disease, especially macular edema. Any VAP-I inhibitor can be used in the method of the present invention as long as it is safe and effective. Herein, the "VAP-I inhibitor" will be used to refer to such compounds/medicaments, which include Compound (I), (II), (III) or (IV), and is intended to encompass all compounds that inhibit enzyme activity of VAP-I at any and all points in the action mechanism thereof.
For example, the VAP-I inhibitor used in the present invention may further include fluoroallylamine derivatives, semicarbazide derivatives, hydrazide derivatives, hydrazino derivatives, 1, 3, 4-oxadiazine derivatives, 4-alkyl-5- alkoxycarbonyl-4, 5, 6, 7-tetrahydroimidazo [4, 5-c]pyridine derivatives, 2, 6-diethoxybenzylamine, 2, 6-di (n- propoxy)benzylamine, 2, 6-diisopropoxybenzylamine, 2, 6-di (n- butoxy)benzylamine, 2, 6-bis (methoxymethoxy)benzylamine, 2,6- bis (methoxymethyl)benzylamine, 2, 6-diethylbenzylamine, 2,6- di-n-propylbenzylamine, 2, 6-bis (2-hydroxyethoxy)benzylamine, and the like. The above compounds can be exemplified as follows.
1) fluoroallylamine derivatives, semicarbazide derivatives and hydrazide derivatives described in WO 93/23023,
2) hydrazino derivatives described in WO 02/02090,
3) 1,3,4-oxadiazine derivatives described in WO 02/02541, 4) 4-alkyl-5-alkoxycarbonyl-4, 5, 6,7-tetrahydroimidazo[4, 5- c]pyridine derivatives described in WO 02/38153,
5) 2, 6-diethoxybenzylamine, 2, 6-di (n-propoxy)benzylamine, 2,6- diisopropoxybenzylamine, 2, 6-di (n-butoxy)benzylamine, 2,6- bis (methoxymethoxy)benzylamine, 2, 6- bis (methoxymethyl)benzylamine, 2, 6-diethylbenzylamine, 2,6-di- n-propylbenzylamine and 2, 6-bis (2-hydroxyethoxy)benzylamine described in USP 4,888,283. The compounds exemplified in the description of the present invention, in WO 93/23023 as an SSAO inhibitor, such as those described by Lyles et al. (Biochem. Pharmacol. 36:2847, 1987), and in USP 4,650,907, USP 4,916,151, USP 4,943,593, USP 4,965,288, USP 5,021,456, USP 5,059,714, USP 4,699,928, European patent application No. 295604, European patent application No. 224924 and European patent application No. 168013, are also encompassed in the VAP-I inhibitor.
Of the above-mentioned compounds, preferred are Compound (I), (II), (III) and (IV), more preferably,
N-{4- [2- (4-{ [amino (imino)methyl]amino}phenyl) ethyl]-5- [4- (aminosulfonyl)benzyl] -1, 3-thiazol-2-yl}acetamide (Production Example 3) , N-{4- [4- (4-{ [amino (imino)methyl]amino}butyl)phenyl]-1,3- thiazol-2-yl}acetamide (Production Example 7),
2- (4-{2- [2- (acetylamino) -1, 3-thiazol-4-yl]ethyl}phenyl) -N- [amino (imino)methyl] acetamide (Production Example 9), (3R) -1- ({2- (acetylamino) -4- [2- (4-{ [amino (imino)methyl] amino}- phenyl) ethyl]-1, 3-thiazol-5-yl}methyl) -N,N-dimethyl-3- pyrrolidinecarboxamide (Production Example 12) ,
(3S)-1- ({2- (acetylamino) -4- [2- (4-{ [amino (imino)methyl]amino}- phenyl) ethyl] -l,3-thiazol-5-yl}methyl)-N,N-dimethyl-3- pyrrolidinecarboxamide (Production Example 14) , N- ( {2- (acetylamino) -4- [2- (4-{ [amino (imino)methyl] amino}- phenyl) ethyl]-1, 3-thiazol-5-yl}methyl) -N-methyl-4-
(methylsulfonyl)benzamide (Production Example 16), and N- ( {2- (acetylamino) -4- [2- (4-{ [amino (imino)methyl] amino}- phenyl) ethyl]-1, 3-thiazol-5-yl}methyl) -N-methyl-4- nitrobenzamide (Production Example 19) , and derivatives thereof.
The term "derivative" is intended to include all compounds derived from the original compound. In the present invention, the VAP-I inhibitor can be administered as a prodrug to a subject. The term "prodrug" is intended to include all compounds that convert to the VAP-I inhibitor in the body of the administration subject. The prodrug can be any pharmaceutically acceptable prodrug of VAP-I inhibitor.
Moreover, the VAP-I inhibitor can be administered to the administration subject as a pharmaceutically acceptable salt.
The pharmaceutically acceptable salt of the VAP-I inhibitor is nontoxic and a pharmaceutically acceptable conventional salt, which is exemplified by salts with inorganic or organic base such as alkali metal salt (e.g., sodium salt, potassium salt and the like) , alkaline earth metal salt (e.g., calcium salt, magnesium salt and the like), ammonium salt, and amine salt (e.g., triethylamine salt, N- benzyl-N-methylamine salt and the like) .
In addition, the pharmaceutically acceptable salt of the VAP-I inhibitor includes a pharmaceutically acceptable acid addition salt. Examples of the pharmaceutically acceptable acid addition salts include those derived from mineral acids, such as hydrochloric, hydrobromic, hydriodic, phosphoric, metaphosphoric, nitric and sulfuric acids, and organic acids, such as tartaric, acetic, citric, malic, lactic, fumaric, benzoic, glycolic, gluconic, succinic and arylsulfonic acids, for example, p-toluenesulfonic acid.
As a pharmaceutically acceptable salt of the VAP-I inhibitor represented by the formula (I), (II), (III) or (IV), a pharmaceutically acceptable acid addition salt such as hydrochloride and hydriodide, particularly (mono-, di- or tri-)hydrochloride, is preferable.
Some VAP-I inhibitors except Compound (I), (II), (III) and (IV) may be commercially available or can be produced based on known references.
Also, Compounds (I), (II), (III) and (IV) can be synthesized according to the following Production Method, Reference Example, Production Examples, the analogous methods thereto and the organic synthetic methods known to the art.
The VAP-I inhibitor or a pharmaceutically acceptable salt thereof can be administered in accordance with the present inventive method via any suitable route. Suitable routes of administration include systemic, such as orally or by injection, topical, periocular (e.g., subTenon's), subconjunctival, intraocular, subretinal, suprachoroidal and retrobulbar administrations. The manner in which the VAP-I inhibitor is administered is dependent, in part, upon whether the treatment of a VAP-I associated disease is prophylactic or therapeutic.
The VAP-I inhibitor is preferably administered as soon as possible after it has been determined that a subject such as mammal, specifically a human, is at risk for a VAP-I associated disease (prophylactic treatments) or has begun to develop a VAP-I associated disease (therapeutic treatments) . Treatment will depend, in part, upon the particular VAP-I inhibitor to be used, the amount of the VAP-I inhibitor to be administered, the route of administration, and the cause and extent, if any, of a VAP-I associated disease realized. One skilled in the art will appreciate that suitable methods of administering a VAP-I inhibitor, which is useful in the present inventive method, are available. Although more than one route can be used to administer a particular VAP-I inhibitor, a particular route can provide a more immediate and more effective reaction than another route. Accordingly, the described routes of administration are merely exemplary and are in no way limiting. The dose of the VAP-I inhibitor administered to the administration subject such as animal including human, particularly a human, in accordance with the present invention, should be sufficient to effect the desired response in the subject over a reasonable time frame. One skilled in the art will recognize that dosage will depend upon a variety of factors, including the strength of the particular VAP-I inhibitor to be employed/ the age, species, conditions or disease states, and body weight of the subject; and the degree of a VAP-I associated disease. The size of the dose also will be determined depending on the route, timing and frequency of administration; the existence, nature and extent of any adverse side effects that might accompany the administration of a particular VAP- 1 inhibitor; and the desired physiological effect. It will be appreciated by one of ordinary skill in the art that various conditions or disease states may require prolonged treatment involving multiple administrations.
Suitable doses and dosage regimens can be determined by conventional range-finding techniques known to those of ordinary skill in the art. Generally, treatment is initiated with smaller dosages, which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. Generally, the VAP-I inhibitor can be administered in the dose of from about 1 μg/kg/day to about 300 mg/kg/day, preferably from about 0.1 mg/kg/day to about 10 mg/kg/day, which is given in a single dose or 2 to 4 doses a day or in a sustained manner.
Pharmaceutical compositions for use in the present inventive method preferably comprise a "pharmaceutically acceptable carrier" and an amount of a VAP-I inhibitor sufficient to treat a VAP-I associated disease, especially macular edema, prophylactically or therapeutically as an active ingredient. The carrier can be any of those conventionally used and is limited only by chemico-physical considerations, such as the solubility and lack of the reactivity of the compound, and by the route of administration.
The VAP-I inhibitor can be administered in various manners to achieve the desired VAP-I inhibitory effect. The VAP-I inhibitor can be administered alone or in combination with pharmaceutically acceptable carriers or diluents, the properties and nature of which are determined by the solubility and chemical properties of the inhibitor selected, the chosen administration route, and standard pharmaceutical practice. The VAP-I inhibitor may be administered orally in solid dosage forms, e.g., capsules, tablets, powders, or in liquid forms, e.g., solutions or suspensions. The inhibitor may also be injected parenterally in the form of sterile solutions or suspensions. Solid oral forms may contain conventional excipients, for instance, lactose, sucrose, magnesium stearate, resins, and similar materials. Liquid oral forms may contain various flavoring, coloring, preserving, stabilizing, solubilizing or suspending agents. Parenteral preparations are sterile aqueous or non-aqueous solutions or suspensions which may contain certain various preserving, stabilizing, buffering, solubilizing or suspending agents. If desired, additives, such as saline or glucose, may be added to make the solutions isotonic. The present inventive method also can involve the co¬ administration of other pharmaceutically active compound(s) . By "co-administration" is meant administration of the other pharmaceutically active compound(s) before, concurrently with, e.g., in combination with a VAP-I inhibitor in the same formulation or in separate formulations, or after administration of the VAP-I inhibitor as described above. For example, corticosteroids, prednisone, methylprednisolone, dexamethasone or -triamcinolone acetinide, or noncorticosteroid anti-inflammatory compounds, such as ibuprofen or flubiprofen, can be co-administered. Similarly, vitamins and minerals (e.g., zinc), anti-oxidants (e.g., carotenoids (such as a xanthophyll carotenoid like zeaxanthin or lutein) ) , and micronutrients can be co- administered.
In addition, the VAP-I inhibitor according to the present invention is useful for preparing a medicament such as a therapeutic or prophylactic agent for the VAP-I associated diseases.
Compounds (I), (II), (III) and (IV) can be synthesized according to the Production Method given below.
Production Method Compounds (I), (II), (III) and (IV) are prepared in accordance with, but is not limited to, the following procedures. Those skilled in the art will recognize that these procedures can be modified according to the conventional methods known per se.
Procedure A: Synthesis of Compounds (I) to (IV)
Figure imgf000027_0001
(D (2) (3)
Figure imgf000027_0002
(5) wherein
R1 and R2 are as defined above;
Li is a leaving group such as halogen (e.g., chlorine, bromine, iodine) ;
T is alkylcarbonyloxy(lower alkyl) wherein the alkylcarbonyl and the lower alkyl are defined above (e.g., acetyloxymethyl) ,
Figure imgf000027_0003
wherein R3, Xi, X2, X3/ X4, Yi, Y2/ Y3/ Zi and Z2 are as defined above; and
L2 is a leaving group such as -OH, halogen (e.g., chlorine, bromine, iodine) , -O-alkylcarbonyl wherein the alkylcarbonyl is as defined above (e.g., -O-acetyl and the like) .
Formation of Thiazole Moiety
Compound (1) is reacted with Compound (2) or its salt to give Compound (3) .
Suitable salt of Compound (2) may be the same as those exemplified for Compound (I), (II), (III) or (IV) .
Compounds (1) and (2) or its salt may be commercially available or can be prepared in accordance with the methods known per se. The reaction is usually carried out in a conventional solvent such as ethanol, acetone, dichloromethane, acetic acid, and other organic solvent which does not adversely affect the reaction, or a mixture thereof.
The reaction temperature is not critical, and the reaction can be carried out under cooling to heating.
Compound (3) thus obtained can be isolated or purified by known separation or purification means, such as concentration, concentration in vacuo, solvent extraction, crystallization, recrystallization, phase transfer, chromatography and the like, and can be converted to a salt same as those exemplified for Compound (I), (II), (III) or (IV) .
Acylation Compound (3) or its salt is reacted with Compound (4) to give Compound (5) . Since R1 is an alkylcarbonyl group, this reaction is an acylation.
The conventional acylation methods may be employed in the present invention. Compound (4) may be commercially available or can be prepared in accordance with the methods known per se.
The reaction is usually carried out in a conventional solvent such as dichloromethane, chloroform, methanol, and other organic solvent which does not adversely affect the reaction, or a mixture thereof.
The reaction is also preferably carried out in the presence of a conventional base such as 4-dimethylamino- pyridine, pyridine etc. A liquid base can be also used as the solvent.
The reaction temperature is not critical, and the reaction can be carried out under cooling to heating.
Compound (5) thus obtained can be isolated or purified by known separation or purification means, such as concentration, concentration in vacuo, solvent extraction, crystallization, recrystallization, phase transfer, chromatography and the like, and can be converted to a salt same as those exemplified for Compound (I), (II), (III) or (IV) .
The acylation may be applied to Compound (1) in advance.
The nitrogen atom(s) in Compound (1), (2), (3) ox (5) may be protected or deprotected, as necessary, in accordance with methods known per se such as the methods described in Protective Groups in Organic Synthesis, published by John Wiley and Sons (1980), and the like.
Procedure B: Synthesis of Compounds (I) to (IV) wherein Xx, X2, X3 and X4 are lower alkylene such as ethylene (i.e. -CH2-CH2-) , for example,
Figure imgf000029_0001
RβdUCtiθn .
Figure imgf000029_0002
(9) wherein R1 and R2 are as defined above;
L3 is a leaving group such as halogen (e.g., chlorine, bromine, iodine) and/or halogenotriphenylphosphinyl (e.g., BrPh3P- ); and
U is carboxy(lower alkyl)phenyl (e.g., carboxymethylphenyl) ,
Figure imgf000030_0001
wherein R3, Yi, Y2, Y3/ Z1 and Z2 are as defined above.
Formation of Olefin Compound
Compound (6) or its salt is reacted with Compound (7) or its salt to give an olefin compound (8) . Suitable salts of Compounds (6) and (7) may be the same as those exemplified for Compound (I), (II), (III) or (IV) . Compounds (6) and (7) or salts thereof may be commercially available or can be prepared in accordance with the methods known per se. The reaction is usually carried out in a conventional solvent such as N,N-dimethylformamide, dimethylsulfoxide, tetrahydrofuran, dichloromethane, and other organic solvent which does not adversely affect the reaction, or a mixture thereof. The reaction is also usually carried out in the presence of triphenylphosphine and/or a conventional base such as potassium tert-butoxide, sodium hydride, sodium hydroxide and the like.
The reaction temperature is not critical, and the reaction can be carried out under cooling to heating.
Compound (8) thus obtained can be isolated or purified by known separation or purification means, such as concentration, concentration in vacuo, solvent extraction, crystallization, recrystallization, phase transfer, chromatography and the like, and can be converted to a salt same as those exemplified for Compound (I), (II), (III) or (IV) .
Reduction
Compound (8) or its salt is reduced in accordance with a conventional method to give Compound (9) . The conventional reduction includes hydrogenation, catalytic hydrogenation, etc.
Among others, catalytic hydrogenation is preferable.
The catalytic hydrogenation is carried out in the presence of a catalyst such as palladium on carbon, preferably 10% palladium on carbon.
The catalytic hydrogenation is usually carried out in a conventional solvent such as tetrahydrofuran, methanol, ethanol, ethyl acetate, and other solvent which does not adversely affect the reaction, or a mixture thereof. The catalytic hydrogenation is also preferably carried out in the presence of a conventional acid such as acetic acid, hydrochloric acid and the like. A liquid acid can be also used as the solvent.
The reaction temperature is not critical, and the reaction can be carried out under cooling to heating.
Compound (9) thus obtained can be isolated or purified by known separation or purification means, such as concentration, concentration in vacuo, solvent extraction, crystallization, recrystallization, phase transfer, chromatography and the like, and can be converted to a salt same as those exemplified for Compound (I), (II), (III) or (IV) .
Therefore, as indicated in the following scheme, Compound (11) or a salt thereof can be prepared from Compound (10) or a salt thereof in a similar manner as described above. Suitable salts of Compounds (10) and (11) may be the same as those exemplified for Compound (I)/ (II), (III) or (IV) .
alkenylene) -U (10)
Figure imgf000032_0001
Reduction *■ alkylene ) -U ( 11)
Figure imgf000032_0002
wherein R1, R2 and U are as defined above.
Suitable "lower alkenylene" includes straight or branched alkenylene having 2 to 6 carbon atom(s), wherein the position and the number of the double bond are not particularly limited, such as -CH=CH-, -CH2-CH=CH-, -CH2-CH=CH-CH2-, -CH2-CH2-CH=CH-, -CH=CH-CH=CH-, -CH=CH-CH2-CH2-CH2-, -CH=CH-CH=CH-CH2-CH2- and -CH=CH-CH=CH-CH=CH- etc.
The nitrogen atom(s) in Compound (6), (7), (8), (9), (10) or (11) may be protected or deprotected, as necessary, in accordance with methods known per se such as the methods described in Protective Groups in Organic Synthesis, published by John Wiley and Sons (1980), and the like.
The present invention is explained in more detail in the following by way of Reference Example, Production Examples and Example, which .are not to be construed as limitative.
Reference Example 1: Synthesis of N-{4-[2-(4-
{ [amino (imino)methyl] aminojphenyl) ethyl] -1, 3-thiazol-2- yl}acetamide
Step 1
Figure imgf000033_0001
A mixture of 3-chloro-2-oxopropyl acetate (5 g) and thiourea (2.5 g) in ethanol (25 ml) was refluxed for 4 hours. The reaction mixture was cooled to ambient temperature and the resulting crystalline precipitate was collected by filtration and washed with ethanol (20 ml) to give (2-amino-l, 3-thiazol- 4-yl)methyl acetate hydrochloride (3.5 g) as white crystals. 1H-NMR (DMSO-de) , δ (ppm) : 2.07(3H, s) , 4.92 (2H, s) , 6.87 (IH, S) . MS : 173 (MH-H) + Step 2
Figure imgf000033_0002
To a mixture of (2-amino-l, 3-thiazol-4-yl)methyl acetate hydrochloride (56 g) and pyridine (45 g) in dichloromethane (560 ml) was added acetyl chloride (23 g) over a period of 30 minutes at 5°C, and the reaction mixture was stirred for 10 minutes at the same temperature. The reaction mixture was poured into water (500 ml) and extracted with chloroform (1 L) The organic layer was dried over sodium sulfate and concentrated in vacuo. The residual solid was collected by filtration with isopropyl ether to give (2- (acetylamino) -1, 3- thiazol-4-yl)methyl acetate (47 g) as white crystals.
1H-NMR (CDCl3), δ (ppm) : 2.12(3H, s) , 2.29 (3H, s) , 5.08(2H, s) , 6.93(1H, s) . MS: 215(M+H)+ Step 3
Figure imgf000034_0001
A mixture of (2- (acetylamino) -1,3-thiazol-4-yl)methyl acetate (46 g) and potassium carbonate (30 g) in methanol (640 ml) was stirred for 3 hours at ambient temperature. The reaction mixture was concentrated in vacuo. The residue was diluted with chloroform, and the insoluble material was filtered off. The resulting solution was purified by flash column chromatography on silica-gel with methanol / chloroform (1/99) . The resulted solid was collected by filtration with isopropyl ether to give N- (4- (hydroxymethyl) -1, 3-thiazol-2- yl)acetamide (35 g) as white crystals.
1H-NMR (DMSO-d6) , δ (ppm) : 2.12(3H, s) , 4.44 (2H, d, J=5.0Hz), 5.2O(1H, t, J=5.0Hz), 6.88 (IH, s) , 12.02 (IH, brs) . MS: 173(M+H)+ Step 4
Figure imgf000034_0002
N- (4- (Hydroxymethyl) -1, 3-thiazol-2-yl) acetamide (2.8 g) was dissolved in methanol (10 ml) and chloroform (200 ml) . Then, manganese (IV) oxide (28.3 g) was added to the solution under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 7 hours, and filtered through a celite pad. The filtrate was concentrated in vacuo. The resulting solid was washed with ethyl ether to give N- (4-formyl-l, 3- thiazol-2-yl) acetamide (2.01 g) as an off-white solid, mp. 195.5-199°C
1H-NMR (DMSO-d6), δ (ppm) : 2.17(3H, s), 8.28 (IH, s) , 9.79 (IH, s) , 12.47 (IH, brs) . Step 5
Figure imgf000035_0001
1- (Bromomethyl) -4-nitrobenzene (1.9 g) , triphenylphosphine (2.31 g) and N,N-dimethylformamide (20 ml) were combined under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 2.5 hours. Then, potassium tert-butoxide (1.19 g) and N- (4-formyl-l, 3-thiazol-2- yl)acetamide (1.5 g) were added and the mixture was stirred at room temperature for 14 hours. The reaction mixture was poured into ice-water and extracted with ethyl acetate. The organic layer was washed with lN-hydrochloric acid, water and saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel with n-hexane / ethyl acetate (1:1) —> (1:2) as an eluent, and triturated with ethyl ether to give N-{4- [ (Z) -2- (4- nitrophenyl) ethenyl] -1, 3-thiazol-2-yl}acetamide (1.59 g) as a yellow solid. mp. 155-157°C 1H-NMR (DMSO-d6), δ (ppm) : 2.13(3H, s) , 6.64 (IH, d, J=12.5Hz),
6.71 (IH, d, J=12.5Hz), 7.18(1H, s) , 7.79 (2H, d, J=9.0Hz),
8.17(2H, d, J=9.0Hz), 12.02(1H, brs) .
MS: 290(M+H)+
Step 6
Figure imgf000035_0002
A mixture of N-{4- [ (Z) -2- (4-nitrophenyl) ethenyl] -1,3- thiazol-2-yl}acetamide (2 g) and 10% palladium on carbon (400 mg) in methanol (25 ml), tetrahydrofuran (25 ml) and acetic acid (18 ml) was stirred under 4 atm hydrogen at ambient temperature for 5 hours. The reaction mixture was filtered through a celite pad, and the filtrate was concentrated in vacuo. The residue was dissolved in. ethyl acetate. The organic solution was washed with saturated sodium hydrogen carbonate solution and saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel with n-hexane / ethyl acetate (1:2) -» ethyl acetate as an eluent, and triturated with ethyl alcohol / ethyl ether to give N- (4- (2- (4-aminophenyl) ethyl) -1, 3-thiazol- 2-yl) acetamide (539.6 mg) as an off-white solid. mp. 102.5-1040C 1H-NMR (DMSO-de) , δ (ppm) : 2 . 11 ( 3H, s ) , 2 . 75 ( 4H, brs) , 4 . 82 (2H, s ) , 6. 46 (2H, d, J=8 .5Hz) , 6. 69 ( 1H, s ) , 6. 83 ( 2H, d, J=8 .5Hz ) , 12 . 07 ( IH, brs) . MS : 262 (M+H) + Step 7
Figure imgf000036_0001
To a suspension of N- (4- (2- (4-aminophenyl) ethyl) -1,3- thiazol-2-yl) acetamide (26 g) in ethanol (500 ml) was added 4N hydrogen chloride in ethyl acetate (25 ml) and cyanamide (6.3 g) . The mixture was refluxed for 26 hours. The reaction mixture was cooled to ambient temperature and poured into a mixture of ethyl acetate (500 ml) and saturated sodium hydrogen carbonate solution (500 ml) . The resulted precipitate was collected by filtration and washed with water (300 ml) and ethanol (300 ml) to give N-{4- [2- (4-{ [amino (imino)methyl]- amino}phenyl) ethyl]—1, 3-thiazol-2-yl}acetamide (18 g) as white crystals.
1H-NMR (DMSOd6), δ (ppm) : 2.10(3H, s) , 2.85 (4H, s) , 6.79 (IH, s), 6.83(2H, d, J=7Hz), 7.10(2H, d, J=7Hz) . MS: 304(M+H)+
Production Example 1: Synthesis of N-{4-[2-(4- { [amino (imino)methyl]amino}phenyl) ethyl] -5- [3- (methylsulfonyl)benzyl]-1, 3-thiazol-2-yl}acetamide Step 1 A mixture of 3- (methylthio)benzoic acid (15 g) , N,0- dimethylhydroxylamine hydrochloride (8.7 g), 1- hydroxybenzotriazole (3.71 g) and l-ethyl-3- (3- dimethylaminopropyl) carbodiimide (4.07 g) in N,N- dimethylformamide (DMF, 150 ml) was stirred at ambient temperature for 13 hours. The reaction mixture was poured into saturated NaHCO3, and extracted with ethyl acetate (AcOEt, 2 times) . The combined organic layer was washed with water and brine, dried over anhydrous MgSO4, and concentrated in vacuo to give N-methoxy-N-methyl-3- (methylthio)benzamide (18.3 g) as a yellow oil.
1H-NMR (CDCl3) δ (ppm) : 2.50 (3H, s) , 3.36 (3H, s) , 3.56 (3H, s), 7.28-7.45 (3H, m) , 7.54 (IH, s) . MS: 212 (M+H)+ Step 2 To a stirred solution of N-methoxy-N-methyl-3-
(methylthio)benzamide (18 g) in dry tetrahydrofuran (THF, 360 ml) was added dropwise diisobutylaluminum hydride (DIBALH, 170 ml) at -78 0C over 40 min under N2 atmosphere. The reaction mixture was stirred for 2.5 hours at r.t., and then the reaction was quenched with MeOH at 00C. AcOEt and IN-HCl were added to the mixture, and the mixture was extracted. The organic layer was washed with brine, dried over anhydrous MgSO4, and concentrated in vacuo. The residual oil (12.9 g) , methyl (triphenylphosphoranylidene) acetate (28.5 g) and THF (260 ml) were combined at r.t. under N2 atmosphere, and the reaction mixture was refluxed for 2 hours. The solvent was removed in vacuo, and the residue was suspended in AcOEt. The solid was filtered off, and the filtrate was concentrated in vacuo. The residue was purified by flash column chromatography over silica gel with n-hexane / AcOEt (3:1) as an eluent to give methyl (2E) -3- [3- (methylthio)phenyl] acrylate (14.4g) as a colorless wax. 1H-NMR (DMSO-de) δ (ppm) : 2.51 (3H, s) , 3.81 (3H, s) , 6.44 (IH, d, J=16.0Hz), 7.24-7.32 (3H, m) , 7.38 (IH, m) , 7.65 (IH, d, J=16.0Hz) . Step 3
Methyl (2E) -3- [3- (methylthio)phenyl] acrylate (14 g) , methanol (MeOH, 140 ml), acetic acid (AcOH, 70 ml) and then 10% palladium on carbon (6.72 g) were combined under N2 atmosphere. The reaction mixture was stirred at r.t. for 9 hours under H2 atmosphere (4 atm) , and filtered through a celite pad. The filtrate was concentrated in vacuo. The residue was purified by flash column chromatography over silica gel with n-hexane / AcOEt (3:1) as an eluent to give methyl 3- [3- (methylthio)phenyl]propanoate (12.5 g) as a colorless oil. 1H-NMR (DMSO-de) δ (ppm) : 2.48 (3H, s) , 2.62 (2H, t, J=8.0Hz), 2.92 (2H, t, J=8.0Hz), 3.68 (3H, s) , 6.94-7.00 (IH, m) , 7.07-7.14 (2H, m) , 7.15-7.24 (IH, m) . Step 4
28 % Sodium methoxide solution in MeOH (10.8 ml) was added dropwise to the mixture of methyl 3-[3- (methylthio)phenyl]propanoate (11.8 g) and diethyl oxalate (15.2 ml) at 0 0C with stirring. The reaction mixture was stirred at 65 0C for 2 hours under reduced pressure. 15 % aqueous H2SO4 (90 ml) was added to the mixture, and refluxed for 13 hours. After cooled to r.t., the mixture was extracted with AcOEt. The organic layer was washed with water and brine, dried over anhydrous MgSO4, and concentrated in vacuo. The residual oil was dissolved in EtOH (50 ml) , and concentrated H2SO4 (0.5 ml) was added dropwise to the solution. The reaction mixture was refluxed for 6 hours. After cooled to r.t., EtOH was removed in vacuo. AcOEt and water were added to the residue, and the mixture was extracted. The organic layer was washed with water and brine, dried over anhydrous MgSOo and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel with n-hexane / AcOEt (6:1) as an eluent to give ethyl 4- [3- (methylthio)phenyl] -2-oxobutanoate (6.9 g) as a pale yellow oil. 1H-NMR (CDCl3) δ (ppm) : 1.36 (3H, t, J=7.5Hz), 2.48 (3H, s) , 2.92 (2H, t, J=7.0Hz), 3.17 (2H, t, J=7.0Hz), 4.32 (2H, q, J=7.5Hz), 6.94-7.01 (IH, m) , 7.05-7.13 (2H, m) , 7.17-7.26 (IH, m) . Step 5 To a suspension of copper (II) bromide (18.1 g) in AcOEt (140 ml) was added a solution of ethyl 4- [3-
(methylthio)phenyl]-2-oxobutanoate (6.8 g) in 70 ml of CHCl3. The reaction mixture was refluxed for 10.5 hours, cooled to r.t., and filtered through a short pad of silica gel eluting with AcOEt / n-hexane (1:1) . The solvent was removed in vacuo to give ethyl 3-bromo-4- [3- (methylthio)phenyl]-2-oxobutanoate (8.6g) as a pale brown oil.
1H-NMR (CDCl3) δ (ppm) : 1.38 (3H, t, J=7.5Hz), 2.47 (3H, s) , 3.21 (IH, dd, J=14.5, 7.5Hz), 3.50 (IH, dd, J=14.5, 7.5Hz), 4.36 (2H, q, J=7.5Hz), 5.21 (IH, t, J=7.5Hz), 6.98-7.05 (IH, m) , 7.11-7.29 (3H, m) . Step 6
Ethyl 3-bromo-4- [3- (methylthio)phenyl]-2-oxobutanoate (8.5 g) was dissolved in EtOH (85 ml), and then thiourea (3.91 g) was added to the solution. The reaction mixture was refluxed for 2.5 hours under N2 atmosphere. The cooled reaction mixture was evaporated in vacuo. Saturated NaHCO3 and water were added to the residue, and the mixture was extracted with AcOEt. The organic layer was washed with water and brine, dried over anhydrous MgS04, and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel with CHCl3 / AcOEt (1:1) as an eluent to give ethyl 2-amino-5- [3- (methylthio)benzyl]-1,3-thiazole-4-carboxylate (7.1 g) as a brown oil.
1H-NMR (DMSO-de) δ (ppm) : 1-25 (3H, t, J=7.0Hz), 2.45 (3H, s) , 4.21 (2H, q, J=7.0Hz), 4.30 (2H, s) , 6.96-7.29 (4H, m) . MS: 309 (M+H)+ Step 7
Ethyl 2-amino-5- [3- (methylthio)benzyl]-1, 3-thiazole-4- carboxylate (7 g) was dissolved in CH2Cl2 (100 ml) under N2 atmosphere. Then pyridine (3.85 ml) and AcCl (1.78 ml) were added dropwise to the solution at 0 0C. The reaction mixture was stirred at r.t. for 1.5 hours. The precipitate was filtered in vacuo to give ethyl 2- (acetylamino) -5- [3- (methylthio)benzyl] -1, 3-thiazole-4-carboxylate (4.77 g) as a colorless solid, mp. 187.5-188.5 °C 1H-NMR (DMSO-de) δ (ppm) : 1.28 (3H, t, J=7.0Hz), 2.09 (3H, s) , 2.45 (3H, s), 4.28 (2H, q, J=7.0Hz), 4.45 (2H, s) , 7.00-7.23 (3H, m) , 7.26 (IH, t, J=7.5Hz), 12.43 (IH, s) . MS: 351 (M+H)+ • Step 8 Ethyl 2- (acetylamino) -5- [3- (methylthio)benzyl]-1,3- thiazole-4-carboxylate (7.3 g) was suspended in THF (100 ml), and then lithium borohydride (907 mg) was added portionwise to the solution at 0 0C. The reaction mixture was refluxed for 10 hours. Na2SO4 lOH∑O was added to the mixture, and the mixture was stirred at r.t. for 2 hours. The suspension was filtered in vacuo. The filtrate was concentrated in vacuo, and purified by flash column chromatography over silica gel with CHCI3 / MeOH (10:1) as an eluent. The solid was washed with ethyl ether to give N-{4- (hydroxymethyl) -5- [3- (methylthio)benzyl]-
1, 3-thiazol-2-yl}acetamide (5.1 g) as a colorless solid. mp. 140-141.5 0C
1H-NMR (DMSO-de) δ (ppm) : 2.08 (3H, s)., 2.44 (3H, s) , 4.08 (2H, s), 4.48 (2H, d, J=5.5Hz), 5.08 (IH, t, J=5.5Hz), 5.08 (IH, t,
J=5.5Hz), 6.99-7.19 (3H, m) , 11.94 (IH, s) .
MS: 309 (M+H)+
Step 9
N-{4- (Hydroxymethyl) -5- [3- (methylthio)benzyl]-1, 3- thiazol-2-yl}acetamide (5 g) was dissolved in MeOH (5 ml) and
CHCI3 (50 ml) . Then, manganase (IV) oxide (14.1 g) was added to the solution under N2 atmosphere. The reaction mixture was stirred at r.t. for 20 hours, and filtered through a celite pad. The filtrate was concentrated in vacuo. The residual oil was solidified with ethyl ether to give N-{4-formyl-5- [3-
(methylthio)benzyl]-1, 3-thiazol-2-yl}acetamide (4.46 g) as an off-white solid. mp. 148-149.5 0C
1H-NMR (DMSO-de) δ (ppm) : 2.12 (3H, s), 2.45 (3H, s) , 4.50 (2H, s), 6.99-7.25 (3H, m) , 7.27 (IH, t, J=7.5Hz), 10.04 (IH, s) ,
12.35 (IH, brs) .
MS: 307 (M+H)+
Step 10
1- (Bromomethyl) -4-nitrobenzene (959 mg) , triphenylphosphine (1.16 g) and DMF (12 ml) were combined under N2 atmosphere. The reaction mixture was stirred at r.t. for 2.5 hours. Then, potassium tert-butoxide (586 mg) and N-
{4-formyl-5- [3- (methylthio)benzyl]-1, 3-thiazol-2-yl}acetamide (800 mg) were added to the mixture at 0 0C, and the mixture was stirred at r.t. for 15 hours. The reaction mixture was poured into ice-water, and extracted with AcOEt. The organic layer was washed with IN-HCl, water and brine, dried over anhydrous MgSO,}, and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel with CHCl3 / AcOEt (1:1) as an eluent to give a mixture of N-{5-[3- (methylthio)benzyl] -4- [ (E) -2- (4-nitrophenyl)vinyl]-1, 3- thiazol-2-yl}acetamide and N-{5- [3- (methylthio)benzyl]-4- [ (Z) - 2- (4-nitrophenyl)vinyl]-l,3-thiazol-2-yl}acetamide (E : Z = 1 : 2) (1.08 g) as yellow amorphous.
1H-NMR (DMSO-de) δ (ppm) : 2.08 (3Hx2/3, s) , 2.12 (3Hxl/3, s) , 2.44 (3H, s), 4.06 (2Hx2/3, s) , 4.32 (2Hχl/3, s) , 6.73 (lHχ2/3, d, J=12.5Hz), 6.87 (1HX2/3, d, J=12.5Hz), 6.97-8.27 (26/3H, m) , 11.87 (1HX2/3, s) , 12.19 (lHχl/3, s) . MS: 426 (M+H)+ Step 11
Potassium peroxymonosulfate (1.55 g) was suspended in water (2.5 ml) and THF (8 ml), and then a mixture of N-{5-[3- (methylthio)benzyl] -4- [ (E) -2- (4-nitrophenyl) vinyl]-1, 3- thiazol-2-yl}acetamide and N-{5- [3- (methylthio)benzyl]-4- [ (Z) - 2- (4-nitrophenyl)vinyl]-1, 3-thiazol-2-yl}acetamide (E : Z = 1 : 2) (1.07 g) in THF (2 ml) was added dropwise to the suspension at 0 0C. The reaction mixture was stirred at r.t. for 1 hour, and then water was added to the suspension. The mixture was extracted with AcOEt (twice) . The combined organic layer was washed with brine, dried over anhydrous MgSO^ and concentrated in vacuo to give N-{5- [3- (methylsulfonyl)benzyl] - 4-[ (Z) -2- (4-nitrophenyl)vinyl] -1,3-thiazol-2-yl}acetamide (940.7 mg) as brown amorphous.
1H-NMR (DMSO-d6) δ (ppm) : 2.08 (3H, s) , 3.18 (3H, s) , 4.24 (2H, s), 6.73 (IH, d, J=12.5Hz), 6.87 (IH, d, J=12.5Hz), 6.84-7.44 (8H, m), 11.92 (IH, s) . MS : 458 (M+H) +
Step 12
N-{5- [3- (Methylsulfonyl)benzyl] -4- [ (Z) -2- (4- nitrophenyl)vinyl] -1,3-thiazol-2-yl}acetamide (1 g) , 10% palladium on carbon (656 mg) , MeOH (10 ml), THF (10 ml) and
AcOH (1 ml) were combined. The reaction mixture was stirred at r.t. for 2 hours under 4 atm H2 atmosphere, and filtered through a celite pad. The filtrate was concentrated in vacuo, and purified by flash column chromatography over silica gel with CHCl3 / MeOH (20:1) as an eluent to give N-{4-[2-(4- aminophenyl) ethyl] -5- [3- (methylsulfonyl)benzyl]-1, 3-thiazol-2- yl}acetamide (479.5 mg) as yellow amorphous.
1H-NMR (DMSO-de) δ (ppm) : 2.08 (3H, s), 2.59-2.86 (4H, m) , 3.18
(3H, s), 4.02 (2H, s) , 4.84 (2H, brs) , 6.46 (2H, d, J=8.5Hz), 6.78 (2H, d, J=8.5Hz), 7.25-7.88 (4H, m) , 12.03 (IH, s) .
MS: 430 (M+H)+
Step 13
N-{4- [2- (4-Aminophenyl) ethyl] -5- [3-
(methylsulfonyl)benzyl] -1, 3-thiazol-2-yl}acetamide (470 mg) , N,N'-bis (tert-butoxycarbonyl) -lH-pyrazole-1-carboxamidine
(340 mg) and THF (5 ml) were combined under N2 atmosphere.
The reaction mixture was stirred at r.t. for 18 hours, and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel with CHCI3 / AcOEt (1:1) as an eluent to give di-tert-butyl ({[4-(2-{2-
(acetylamino) -5- [3- (methylsulfonyl)benzyl] -1, 3-thiazol-4- yl}ethyl)phenyl]amino}methylidene)biscarbamate (502.9 mg) as yellow amorphous.
1H-NMR (DMSO-de) δ (ppm) : 1.39 (9H, s) , 1.51 (9H, s) , 2.09 (3H, s), 2.85 (4H, s), 3.18 (3H, s) , 4.06 (2H, s) , 7.13 (2H, d,
J=8.0Hz), 7.37-7.45 (IH, m) , 7.41 (2H, d, J=8.0Hz), 7.56 (IH, t, J=8.0Hz), 7.74-7.80 (2H, m) , 9.94 (IH, s) , 11.44 (IH, s) ,
12.05 (IH, s) . MS : 672 (M+H) + Step 14
Di-tert-butyl ({ [4- (2-{2- (acetylamino)-5- [3- (methylsulfonyl)benzyl]-l, 3-thiazol-4- yl}ethyl)phenyl]amino}methylidene)biscarbamate (480 mg) , 4N HCl in 1,4-dioxane solution (8 ml) and MeOH (2 ml) were combined under N2 atmosphere. The reaction mixture was stirred at r.t. for 14 hours. The solvent was removed in vacuo. The residue was dissolved in water and AcOEt. The mixture was made basic (pH=8) with saturated NaHCθ3. The precipitate was collected in vacuo. The solid was washed with CH3CN to give N- {4- [2- (4-{ [amino (imino)methyl] amino}phenyl) ethyl]-5- [3- (methylsulfonyl)benzyl]-1,3-thiazol-2-yl}acetamide (157.1 mg) as an off-white solid. mp. 212-213.5 0C
1H-NMR (DMSO-d6) δ (ppm) : 2.08 (3H, s) , 2.67-2.91 (4H, m) , 3.19 (3H, s), 4.08 (2H, s) , 6.80 (2H, d, J=8.0Hz), 7.04 (2H, d, J=8.0Hz), 7.42 (IH, d, J=8.0Hz), 7.57 (IH, t, J=8.0Hz), 7.77 (IH, s), 7.79 (IH, d, J=8.0Hz) . MS: 472 (M+H)+
Production Example 2: Synthesis of N-{4-[4-(2- { [amino (imino)methyl]amino}ethyl)phenyl] -5- [4- (methylsulfonyl)benzyl]-!, 3-thiazol-2-yl}acetamide hydrochloride Step 1
Ethyl 4-acetylbenzoate (10 g) was dissolved in AcOH (80 ml), and then 90 % pyridinium tribromide (22.2 g) and 33 % hydrobromic acid in AcOH (30 ml) were added to the solution at 0 °C. The reaction mixture was stirred at r.t. for 1 hour, and poured into ice-water. The precipitate was collected in vacuo to give ethyl 4- (bromoacetyl)benzoate (15.1 g) as an off-white solid, mp. 67-68.5 0C 1H-NMR (DMSO-d6) δ (ppm) : 1-34 (3H, t, J=7.0Hz) , 4.36 (2H, q, J=7.0Hz) , 5.00 (2H, s) , 8.09 (2H, d, J=9.0Hz) , 8.14 (2H, d, J=9.0Hz) . Step 2 Ethyl 4- (bromoacetyl)benzoate (15 g) , triphenylphosphine (14.5 g) , CH3CN (200 ml) and pyridine (0.1 ml) were combined under N2 atmosphere. The reaction mixture was stirred at r.t. for 5 hours. The solvent was removed in vacuo. The residual amorphous was solidified with THF / ethyl ether to give {2-[4- (ethoxycarbonyl)phenyl]-2-oxoethyl} (triphenyl)phosphonium bromide (22.7 g) as a colorless solid, mp. 201-202.5 0C
1H-NMR (DMSO-de) δ (ppm) : 1.35 (3H, t, J=7.0Hz), 4.37 (2H, q, J=7.0Hz), 6.31 (2H, d, J=13.0Hz), 7.70-7.96 (15H, m) , 8.14 (2H, d, J=8.5Hz), 8.22 (2H, d, J=8.5Hz) . Step 3
Na2CO3 (5.96 g) was added to {2- [4-
(ethoxycarbonyl)phenyl]-2-oxoethyl} (triphenyl)phosphonium bromide (15 g) , benzene (140 ml) and water (140 ml) in a separatory funnel. The mixture was shaken until the solids dissolved (about 30 min) . The aqueous layer was separated and extracted with benzene. The combined organic layer was washed with brine, dried over anhydrous MgSO4, and concentrated in vacuo. Benzene (110 ml) was added, followed by 4- (methylthio)benzaldehyde (4.71 g) , and the solution was heated at reflux for 22 hours. After cooled to r.t., the mixture was concentrated in vacuo. The residue was purified by flash column chromatography over' silica gel with n-hexane / AcOEt (3:1) as an eluent, and triturated with n-hexane to give ethyl 4-{ (2E) -3- [4- (methylthio)phenyl]-2-propenoyl}- benzoate (5 g) as a yellow solid, mp. 115-115.5 0C 1H-NMR (CDCl3) δ (ppm) : 1.43 (3H, t, J=7.5Hz), 2.53 (3H, s) , 4.42 (2H, q, J=7.5Hz), 7.26 (2H, d, J=8.5Hz), 7.46 (IH, d, J=15.5Hz), 7.57 (2H, d, J=8.5Hz), 7.79 (IH, d, J=15.5Hz), 8.04 (2H, d, J=8.5Hz), 8.17 (2H, d, J=8.5Hz) . MS: 327 (M+H)+ Step 4
Ethyl 4-{3- [4- (methylsulfonyl)phenyl]propanoyl}benzoate was prepared from the compound of Step 3 of Production Example 2 in a manner similar to Step 11 of Production Example 1. mp. 118-119.5 0C i H-NMR (DMSO-d6) δ (ppm) : 1.34 (3H, t, J=7.0Hz), 3.06 (2H, t, J=7.5Hz), 3.19 (3H, s) , 3.51 (2H, t, J=7.5Hz), 4.35 (2H, q, J=7.0Hz), 7.58 (2H, d, J=8.5Hz), 7.84 (2H, d, J=8.5Hz), 8.06 (2H, d, J=8.5Hz), 8.12 (2H, d, J=8.5Hz) . MS: 361 (M+H)+ Step 5
Ethyl 4-{2-bromo-3-[4-
(methylsulfonyl)phenyl]propanoyl}benzoate was prepared from the compound of Step 4 of Production Example 2 in a manner similar to Step 5 of Production Example 1. 1H-NMR (DMSO-d6) δ (ppm) : 1.34 (3H, t, J=7.0Hz), 3.21 (3H, s) , 3.38 (IH, dd, J=14.5, 9.0Hz), 3.70 (IH, dd, J=14.5, 5.0Hz), 4.36 (2H, q, J=7.0Hz), 6.06 (IH, dd, J=9.0, 5.0Hz), 7.58 (2H, d, J=8.5Hz), 7.90 (2H, d, J=8.5Hz), 8.10 (2H, d, J=8.5Hz), 8.22 (2H, d, J=8.5Hz) . MS: 439 (M+H) + Step 6
Ethyl 4-{2-amino-5- [4- (methylsulfonyl)benzyl] -1, 3- thiazol-4-yl}benzoate was prepared from the compound of Step 5 of Production Example 2 in a manner similar to Step 6 of Production Example 1. mp. 205.5-207 °C
1H-NMR (DMSO-d6) δ (ppm) : 1.32 (3H, t, J=7.0Hz), 3.20 (3H, s) , 4.26 (2H, s), 4.31 (2H, q, J=7.0Hz), 7.03 (2H, s) , 7.47 (2H, d, J=8 . 0Hz ) , 7 . 69 ( 2H, d, J=8 . 5Hz ) , 7 . 88 ( 2H, d, J=S 1 OHz ) ,
7 . 97 ( 2H, d, J=8 . 5Hz ) .
MS : 417 (M+H) +
Step 7 Ethyl 4-{2- (acetylamino) -5- [4- (methylsulfonyl)benzyl]-
1, 3-thiazol-4-yl}benzoate was prepared from the compound of
Step 6 of Production Example 2 in a manner similar to Step 7 of Production Example 1.
1H-NMR (DMSO-de) δ (ppm) : 1.31 (3H, t, J=7.0Hz), 2.13 (3H, s) , 3.20 (3H, s), 4.33 (2H, q, J=7.0Hz), 4.42 (2H, s) , 7.49 (2H, d, J=8.0Hz), 7.77 (2H, d, J=8.0Hz), 7.88 (2H, d, J=8.0Hz),
8.03 (2H, d, J=8.0Hz), 12.28 (IH, s) .
MS: 459 (M+H) +
Step 8 N_{4_ [4_ (Hydroxymethyl)phenyl] -5- [4-
(methylsulfonyl)benzyl]-1, 3-thiazol-2-yl}acetamide was prepared from the compound of Step 7 of Production Example 2 in a manner similar to Step 8 of Production Example 1.
1H-NMR (DMSO-de) δ (PP™) : 2.12 (3H, s) , 3.12 (3H, s) , 4.35 (2H, s) , 4.53 (2H, d, J=5.5Hz), 5.22 (IH, t, J=5.5Hz), 7.38 (2H, d,
J=8.5Hz), 7.46 (2H, d, J=8.5Hz), 7.56 (2H, d, J=8.5Hz), 7.87
(2H, d, J=8.5Hz), 12.20 (IH, s) .
MS: 417 (M+H)+
Step 9 N-{4- [4- (Hydroxymethyl)phenyl] -5- [4-
(methylsulfonyl)benzyl]-l, 3-thiazol-2-yl}acetamide (1.25 g) ,
CHCl3 (12 ml), CH3CN (12 ml) and Dess-Martin periodinate (1.91 g) were combined at 0 0C under N2 atmosphere. The reaction mixture was stirred at r.t. for 1 hour, and diluted in CHCl3. The organic solution was washed with saturated NaHCO3, water and brine, dried over anhydrous MgSO^ and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel with CHCl3 / MeOH (20:1) as an eluent to give N-{4- (4-formylphenyl) -5-[4- (methylsulfonyl)benzyl]-1,3- thiazol-2-yl}acetamide (1.99 g) as a brown oil.
1H-NMR (DMSO-d6) δ (ppm) : 2.14 (3H, s) , 3.20 (3H, s) , 4.45 (2H, s), 7.49 (2H, d, J=8.0Hz), 7.85 (2H, d, J=8.5Hz), 7.88 (2H, d, J=8.0Hz), 7.99 (2H, d, J=8.5Hz), 10.04 (IH, s) , 12.28 (IH, s) . MS: 415 (M+H)+ Step 10
N-{4- (4-Formylphenyl) -5- [4- (methylsulfonyl)benzyl] -1,3- thiazol-2-yl}acetamide (1.99 g) , methyl (triphenyl- phosphoranylidene) acetate (3.21 g) and THF (20 ml) were combined at r.t. under N2 atmosphere, and the mixture was refluxed for 1 hour. The solvent was removed in vacuo. The residual solid was washed with AcOEt to give methyl (2E) -3- (4- {2- (acetylamino) -5- [4- (methylsulfonyl)benzyl] -1, 3-thiazol-4- yl}phenyl) acrylate (779.3 mg) as an off-white solid, mp. 217-218.5 0C
1H-NMR (DMSO-de) δ (PPm) : 2.13 (3H, s) , 3.20 (3H, s) , 3.73 (3H, s), 4.41 (2H, s), 6.67 (IH, d, J=16.0Hz), 7.48 (2H, d, J=8.0Hz), 7.65 (2H, d, J=8.5Hz), 7.69 (IH, d, J=16.0Hz), 7.80 (2H, d, J=8.5Hz), 7.88 (2H, d, J=8.0Hz), 12.23 (IH, s) . MS: 471 (M+H)+ Step 11
Methyl (2E) -3- (4-{2- (acetylamino) -5- [4- (methylsulfonyl)benzyl]-!, 3-thiazol-4-yl}phenyl) acrylate (2.3 g) , 10% palladium on carbon (1.96 g) , MeOH (23 ml), THF (23 ml) and AcOH (2.3 ml) were combined under N2 atmosphere. The reaction mixture was stirred at r.t. for 7 hours under H2 atmosphere (4 atm) , and the mixture was filtered through a celite pad. The filtrate was concentrated in vacuo to give methyl 3- (4-{2- (acetylamino) -5- [4- (methylsulfonyl)benzyl]-1, 3- thiazol-4-yl}phenyl)propanoate (1.28 g) as a colorless solid, mp. 1.29-131 0C
1H-NMR (DMSO-d6) δ (ppm) : 2.12 (3H, s) , 2.66 (2H, t, J=7.0Hz), 2.88 (2H, t, J=7.0Hz), 3.20 (3H, s) , 3.58 (3H, s) , 4.35 (2H, s), 7.29 (2H, d, J=8.0Hz), 7.46 (2H, d, J=8.0Hz), 7.52 (2H, d, J=8.0Hz), 7.88 (2H, d, J=8.0Hz), 12.17 (IH, s) . MS: 473 (M+H) Step 12
Methyl 3- (4-{2- (acetylamino) -5- [4- (methylsulfonyl)benzyl] -1, 3-thiazol-4-yl}phenyl) propanoate (1.01 g) , IN-NaOH (5.34 ml) and 1,4-dioxane (10 ml) were combined at 0 0C, and the reaction mixture was stirred at r.t. for 1 hour. The organic solvent was evaporated in vacuo. The residual aqueous solution was washed with AcOEt. The aqueous layer was acidified with IN-HCl. The precipitate was filtered off in vacuo to give 3- (4-{2- (acetylamino) -5- [4- (methylsulfonyl)benzyl]-1, 3-thiazol-4-yl}phenyl)propanoic acid (800.5 mg) as a colorless solid. mp. 208.5-210 0C
1H-NMR (DMSO-de) δ (ppm) : 2.12 (3H, s) , 2.55' (2H, t, J = 7.5 Hz), 2.85 (2H, t, J = 7.5 Hz), 3.20 (3H, s) , 4.35 (2H, s) , 7.30 (2H, d, J = 8.5 Hz), 7.46 (2H, d, J = 8.5 Hz), 7.51 (2H, d, J = 8.5 Hz), 7.87 (2H, d, J = 8.5 Hz), 12.16 (IH, brs) , 12.18 (IH, s) . MS: 459 (M+H) Step 13
3- (4-{2- (Acetylamino) -5- [4- (methylsulfonyl)benzyl] -1, 3- thiazol-4-yl}phenyl)propanoic acid (400 mg) , Et3N (0.182 ml) and t-BuOH (8 ml) were combined under N2 atmosphere. Diphenylphosphoryl azide (0.226 ml) was added dropwise to the solution at r.t. The reaction mixture was refluxed for 10 hours, and cooled to r.t. The mixture was diluted with AcOEt. The organic solution was washed with IN-HCl, water and brine, dried over anhydrous MgSO4, and concentrated in vacuo. The residue was purified by flash column chromatography over NH silica gel with CHCl3 / MeOH (20:1) as an eluent to give tert- butyl [2- (4-{2- (acetylamino) -5- [4- (methylsulfonyl)benzyl] -1,3- thiazol-4-yl}phenyl) ethyl] carbamate (168.3 mg) as colorless amorphous. 1H-MMR (DMSO-d6) δ (ppm) : 1.36 (9H, s) , 2.12 (3H, s) , 2.72 (2H, m) , 3.15 (2H, m) , 3.20 (3H, s) , 4.35 (2H, s) , 6.88 (IH, t, J = 5.5 Hz), 7.26 (2H, d, J = 8.5 Hz), 7.46 (2H, d, J = 8.5 Hz), 7.52 (2H, d, J = 8.5 Hz), 7.88 (2H, d, J = 8.5 Hz), 12.17 (IH, s) . MS: 530 (M+H) Step 14 tert-Butyl [2- (4-{2- (acetylamino) -5- [4- (methylsulfonyl)benzyl]-l, 3-thiazol-4- yl}phenyl) ethyl]carbamate (146.5 mg) , 4N HCl in 1,4-dioxane solution (3 ml) and MeOH (1 ml) were combined under N2 atmosphere. The reaction mixture was stirred at r.t. for 2 hours, and concentrated in vacuo. The residue, di-tert-butyl (lH-pyrazol-l-ylmethylidene)biscarbamate (85.8 mg) , N,N- diisopropylethylamine (0.0964 ml), THF (3 ml) and DMF (1 ml) were combined under N2 atmosphere. The reaction mixture was stirred at r.t. for 2 hours, and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel with CHCl3 / MeOH (20:1) as an eluent to give di- tert-butyl ([2- (4-{2- (acetylamino) -5- [4- (methylsulfonyl)benzyl]-l,3-thiazol-4- yl}phenyl) ethylamino]methylidene)biscarbamate (118.8 mg) as colorless amorphous.
1H-NMR (DMSO-dsJ δ (ppm) : 1.39 (9H, s) , 1.44 (9H, s), 2.12 (3H, s), 2.85 (2H, m), 3.33 (3H, s) , 3.56 (2H, m) , 4.35 (2H, s) , 7.31 (2H, d, J = 8.0 Hz), 7.46 (2H, d, J = 8.0 Hz), 7.54 (2H, d, J = 8.0 Hz), 7.87 (2H, d, J = 8.0 Hz), 8.36 (IH, t, J = 5.5 Hz), 11.49 (IH, s), 12.17 (IH, s) . MS : 672 (M+H)
Step 15
Di-tert-butyl ({2- (4-{2- (acetylamino) -5- [4-
(methylsulfonyl)benzyl]-1, 3-thiazol-4- yl}phenyl) ethylamino}methylidene)biscarbamate (144.7 mg) , MeOH
(1 ml) and 4N HCl in 1,4-dioxane solution (3 ml) were combined under N2 atmosphere. The reaction mixture was stirred at r.t. for 19 hours. The solvent was removed in vacuo. The residue was washed with AcOEt to give N-{4-[4-(2- { [amino (imino)methyl]amino}ethyl)phenyl] -5- [4-
(methylsulfonyl)benzyl]-1, 3-thiazol-2-yl}acetamide hydrochloride (67.3 mg) as a pale brown amorphous solid.
1H-NMR (DMSO-dβ) δ (PP™) : 2.13 (3H, s) , 2.76-2.90 (2H, m) , 3.21
(3H, s), 3.32-3.49 (2H, m) , 4.36 (2H, s) , 7.35 (2H, d, J=8.0Hz), 7.46 (2H, d, J=8.0Hz), 7.54 (2H, d, J=8.0Hz), 7.68
(IH, t, J=5.5Hz), 7.88 (2H, d, J=8.0Hz), 12.18 (IH, s) .
MS: 472 (M+H) free
Production Example 3: Synthesis of N-{4-[2-(4-
{ [amino (imino)methyl]amino}phenyl) ethyl] -5- [4- (aminosulfonyl)benzyl] -1, 3-thiazol-2-yl}acetamide hydrochloride
Step 1
To a suspension of copper (II) bromide (9.75 g) in AcOEt
(150 ml) was added a solution of ethyl 2-oxo-4-phenylbutanoate (3 g) in 75 ml of CHCI3. The reaction mixture was refluxed for
23 hours, cooled to r.t., and filtered through a short pad of silica gel eluting with AcOEt / n-hexane (1:1) . The solvent was removed in vacuo to give ethyl 3-bromo-2-oxo-4- phenylbutanoate (4.2g) as a yellow liquid. 1H-NMR (CDCl3) δ (PPm) : 1.37 (3H, t, J=7.0Hz), 3.25 (IH, dd,
J=14.5, 7.5Hz), 3.54 (IH, dd, J=14.5, 7.5Hz), 4.35 (2H, q,
J=7.0Hz), 5.27 (IH, d, J=7.5Hz), 7.18-7.41 (5H, m) .
Step 2 Ethyl 3-bromo-2-oxo-4-phenylbutanoate (5.8 g) was dissolved in EtOH (110 ml), and then thiourea (3.1 g) was added to the solution. The reaction mixture was refluxed for 2 hours under N2 atmosphere. The cooled reaction mixture was evaporated in vacuo. The residual solid was suspended (pH=8) in saturated NaHCO3 and water. The solid was collected by filtration, and purified by flash column chromatography over silica gel with CHCl3 / MeOH (10:1) as an eluent to give ethyl 2-amino-5-benzyl-l, 3-thiazole-4-carboxylate (808.2 mg) as a yellow wax.
1H-NMR (DMSO-de) δ (ppm) : 1-25 (3H, t, J=7.0Hz), 4.21 (2H, q, J=7.0Hz), 4.33 (2H, s) , 7.02 (2H, s) , 7.11-7.39 (5H, m) . MS: 263 (M+H)+ Step 3 Ethyl 2-amino-5-benzyl-l, 3-thiazole-4-carboxylate (2.1 g) was dissolved in pyridine (21 ml) , and then acetyl chloride (1.71 ml) was added dropwise to the solution at 0 °C under N2 atmosphere. The reaction mixture was stirred at room temperature for 2.5 hr. Water was added to the solution at 0 °C, and the precipitate was filtered off in vacuo. The solid was washed with diethyl ether to give ethyl 2- (acetylamino) -5- benzyl-l,3-thiazole-4-carboxylate (1.92 g) as a brown solid, mp. 178-180 0C 1H-NMR (DMSO-ds) δ (ppm) : 1.28 (3H, t, J=7.0Hz), 2.09 (3H, s) , 4.28 (2H, q, J=7.0Hz), 4.48 (2H, s) , 7.19-7.39 (5H, m) , 12.41 (IH, s) . MS: 305 (M+H)+ Step 4
Ethyl 2- (acetylamino) -5-benzyl-l, 3-thiazole-4-carboxylate (1.0 g) was dissolved in THF (20 ml), and then lithium borohydride (124 mg) was added portionwise to the solution at 0 0C. The reaction mixture was refluxed for 4.5 hr, and the reaction was quenched with MeOH. The mixture was concentrated in vacuo, and purified by flash column chromatography over silica gel with CHCl3 / MeOH (20:1) as an eluent. The residual amorphous substance was dissolved in MeOH (1 ml) and CHCl3 (8 ml) . Then manganase (IV) oxide (1.26 g) was added to the solution under N2 atmosphere. The reaction mixture was stirred at r.t. for 12 hours, and filtered through a celite pad. The filtrate was concentrated in vacuo. The residue was purified by flash column chromatography over silica gel with CHCl3 / MeOH (20:1) as an eluent to give N- (5-benzyl-4-formyl-l, 3- thiazol-2-yl) acetamide (251 mg) as a pale yellow solid, mp. 191-192.5 0C
1H-NMR (DMSO-de) , δ (ppm) : 2.12 (3H, s) , 4.53 (2H, s) , 7.19-7.40 (5H, m), 10.04 (IH, s) , 12.34 (IH, s) . MS: 261 (M+H)+ Step 5
N-{5-Benzyl-4-[ (Z) -2- (4-nitrophenyl)vinyl]-1, 3-thiazol-2- yl}acetamide was prepared from the compound of Step 4 of Production Example 3 in a manner similar to Step 10 of Production Example 1. 1H-NMR (DMSO-ds), δ (ppm) : 2.06, 2.13 (3H, s) , 4.03, 4.18 (2H, s), 6.69 (IH, s), 7.17-7.35 (6H, m) , 7.40, 7.54 (2H, dx2, J = 8.9 Hz), 7.99, 8.20 (2H, dx2, J = 8.9 Hz), 9.97, 10.19 (IH, sx2) . MS: 380 (M+H)+ Step 6
To the solution of N-{5-benzyl-4- [ (Z) -2- (4- nitrophenyl)vinyl] -1, 3-thiazol-2-yl}acetamide in chloroform was added chlorosulfonic acid dropwise under ice-cooling. This was stirred at room temperature for 15 hr and then rotary evaporated to a reduced volume. To the solution was added aq. saturated NaHCO3 solution. The mixture was extracted with THF. The organic layer was dried over MgSO4 and concentrated to give 4- ({2- (acetylamino)-4- [ (E) -2- (4-nitrophenyl)vinyl]-1,3- thiazol-5-yl}methyl)benzenesulfonyl chloride as crude oil. This was used for the next reaction without further purification. MS: 478 (M+H)+ Step 7
To a solution of 4- ({2- (acetylamino) -4- [ (E) -2- (4- nitrophenyl)vinyl] -1, 3-thiazol-5-yl}methyl)benzenesulfonyl chloride (170 mg) in THF (5 ml) was added ammonium hydroxide (28%, 1.5 ml) at 5 0C. The mixture was stirred at 25 0C for 12 hr. The reaction was quenched with aq. saturated ammonium chloride solution. The mixture was extracted with Ethyl acetate, dried over MgSO4, filtered, concentrated in vacuo to give orange powder, m/z 459 (M+H) +
The resulting orange powder was dissolved in MeOH and AcOH (1 ml) . To the solution was added 10 % Pd/C (50 % wet), and the mixture was stirred at 25 0C under hydrogen for 15 hr and filtered through a celite pad. The filtrate was added aq. 0.1N NaOH. The mixture was extracted with ethyl acetate. The organic layer was dried over MgSO4, filtered, concentrated in vacuo. The residue was purified by silicagel column chromatography with chloroform and methanol (20:1) as an eluent to give N-{4- [2- (4-aminophenyl) ethyl] -5- [4- (aminosulfonyl)benzyl] -1,3-thiazol-2-yl}acetamide (33 mg) as white powder.
1H-NMR (200MHz, DMSO-d6) δ (ppm) : 1.88 (3H, s), 3.65-2.76 (4H, m) , 3.93 (2H, s) , 4.84 (2H, s) , 6.46 (2H, d, J=8.3 Hz), 6.78 (2H, d, J=8.3 Hz), 7.22 (2H, d, J=8.3 Hz), 7.28 (2H, s) , 7.72 (2H, d, J=8.3 Hz), 12.00 (IH, s) . MS : 431 (M+H) +
Step 8
Di-tert-butyl ( (Z) -{ [4- (2-{2- (acetylamino) -5- [4- (aminosulfonyl)benzyl] -1, 3-thiazol-4- yl}ethyl)phenyl] amino}methylidene)biscarbamate was prepared from the compound of Step 7 of Production Example 3 in a manner similar to Step 13 of Production Example 1.
1H-NMR (DMSO-de), δ (ppm) : 1.39 (9H, s) , 1.50 (9H, s), 2.08
(3H, s), 2.85 (4H, br) , 4.00 (2H, s) , 7.15 (2H, d) , 7.30 (2H, d), 7.43 (2H, d), 7.72 (2H, d) , 9.95 (IH, s) , 11.44 (IH, s) ,
12.03 (IH, s) .
MS: 673 (M+H)+
Step 9
The title compound was prepared from the compound of Step 8 of Production Example 3 in a manner similar to Step 14 of
Production Example 1.
1H-NMR (DMSO-de), δ (ppm) : 1.95 (3H, s) , 2.86 (4H, s) , 3.99
(2H, s), 7.14 (2H, d, J = 8.5 Hz), 7.25 (2H, d, J = 8.5 Hz),
7.27-7.35 (8H, m) , 7.74 (2H, d, J = 8.5 Hz), 10.30 (IH, s) , 12.03 (IH, s) .
MS: 473 (M+H)+
Production Example 4 : Synthesis of N- (4- [2- (4-
{ [amino (imino)methyl] amino}phenyl) ethyl] -5-{4-
[ (dimethylamino) sulfonyl]benzyl}-l, 3-thiazol-2-yl) acetamide hydrochloride
Step 1
To a solution of 4- ( {2- (acetylamino) -4- [ (E) -2- (4- nitrophenyl) vinyl] -1, 3-thiazol-5-yl}methyl)benzenesulfonyl chloride (435 mg) in THF(IO ml) was added dimethylamine (50 % solution, 400 μl) at 25 0C. The mixture was stirred at
25 0C for 12 hr. The reaction was quenched with aq. ammonium chloride solution. The mixture was extracted with ethyl acetate, and the extract was dried over MgSCj, filtered and concentrated in vacuo to give orange powder.
The resulting orange powder was dissolved in DMF, MeOH and AcOH (10 ml, 5 ml and 2 ml, respectively) . To this soluiton was added 10 % Pd/C (50 % wet, 200 mg) and the mixture was stirred for 1 hr under 3 atm prssure of hydrogen, and then filtered through a celite pad. The filtrate was added aq. 0.1N NaOH solution. The mixture was extracted with ethyl acetate. The organic layer was dried over MgSθ4, filtered and concentrated in vacuo. The residue was purified by silicagel column chromatography with chloroform and methanol (20:1) as an eluent to give N- (4- [2- (4-aminophenyl) ethyl] -5-{4- [ (dimethylamino) sulfonyl]benzyl}- 1, 3-thiazol-2-yl) acetamide (200 mg) as white powder.
1H-NMR (DMSO-de), δ (ppm) : 2.08 (3H, s) , 2.56 (4H, s) , 3.36 (6H, s), 3.99 (2H, s) , 4.84 (2H, s) , 6.45 (2H, d) , 6.75 (2H, d) , 7.27 (2H, d) , 7.64 (2H, d) , 12.03 (IH, s) . MS: 459 (M+H)+ Step 2
Di-tert-butyl [ (Z) - ({4- [2- (2- (acetylamino) -5-{4- [ (dimethylamino) sulfonyl]benzyl}-!,3-thiazol-4- yl) ethyl]phenyl}amino)methylidene]biscarbamate was prepared from the compound of Step 1 of Production Example 4 in a manner similar to Step 13 of Production Example 1.
1H-NMR (DMSO-de), δ (ppm) : 1.38 (9H, s) , 1.50 (9H, s), 2.08 (3H, s), 2.54 (6H, s) , 2.84 (4H, s) , 4.02 (2H, s) , 7.10 (2H, d, J = 8.4 Hz), 7.27 (2H, d, J = 8.4 Hz), 7.43 (2H, d, J = 8.4 Hz), 7.61 (2H, d, J = 8.4 Hz), 9.99 (IH, s) , 11.45 (IH, s) . Step 3
The title compound was prepared from the compound of Step 2 of Production Example 4 in a manner similar to Step 14 of Production Example 1.
1H-NMR (DMSO-dβ), δ (ppm) : 2.09 (3H, s) , 2.57 (6H, s) , 2.84
(4H, s), 4.08 (2H, s), 7.12 (2H, d, J = 8.4 Hz), 7.23 (2H, d, J = 8.4 Hz), 7.40 (2H, d, J = 8.0 Hz), 7.42 (4H, br, J =
8.0 Hz), 8.02 (2H, d, J = 8.0 Hz), 9.86 (IH, s) , 12.05 (IH, s) .
MS: 501 (M+H) +
Production Example 5; Synthesis of N-{4- [4- (4- { [amino (imino)methyl] amino}-3-oxobutyl)phenyl]-1, 3-thiazol-2- yl}acetamide hydrochloride
Step 1
To the solution of ethyl 3-phenylpropanoate (8 g) in
CH2Cl2 (25 ml) was added bromoacetyl chloride (6.0 ml) . This solution was maintained under -5 0C. To the solution was added alumnium chloride (16.2 g) over 15 min. After addition of AlCl3, this was stirred at 0 0C for 30 min. Then the reaction mixture was refluxed for 1 hr. Then the reaction mixture was poured into ice-water and was extracted with CH2Cl2. The organic layer was washed with brine, dried over
MgSθ4, filterd, and concentrated in vacuo to give green liquid of ethyl 3- [4- (bromoacetyl)phenyl]propanoate. This was used for the next reaction without further purification.
1H-NMR (DMSO-d6) , δ (ppm) : 1.23 (3H, t, J = 7.2 Hz), 2.65 (2H, t, J = 7.6 Hz), 3.02 (2H, t, J = 7.6 Hz), 4.13 (2H, q,
J = 7.2 Hz), 4.43 (2H, s) , 7.43 (2H, d, J = 8.1 Hz), 7.92
(2H, d, J = 8.1 Hz) .
Step 2
Ethyl 3- [4- (bromoacetyl)phenyl]propanoate (13 g) was dissolved into ethanol (EtOH, 70 ml) . To the solution was added thiourea (4.8 g) , and the mixture was refluxed for 3 hr, and then rotary evaporated to reduced volume. The resulting concentrated solution was poured into water, and the mixture was extracted with ethyl acetate, and the extract was dried over MgSO4, filtered, and concentrated in vacuo to give ethyl 3- [4- (2-amino-l, 3-thiazol-4-yl)phenyl]propanoate as pale yelllow oil. This was used for the next reaction without further purification. MS: m/z 277 (M+H)+ Step 3
To the solution of ethyl 3- [4- (2-amino-l, 3-thiazol-4- yl)phenyl]propanoate (12.4 g) in CH2CI2 (100 ml) were added acetyl chloride (3.82 ml) and pyridine (5.8 ml) at 25 0C. This was stirred for 12 hr at 25 0C and then concentrated in vacuo. The residue was dissolved in CH2Cl2 and this was washed with aq. NaHC03 solution and ammonium chloride solution. The organic layer was dried over MgSC^, filtered and concentrated in vacuo to give a brownish solid. Resulting brown solid was dissolved in MeOH (80 ml) and THF (50 ml) . To this solution was added IN NaOH (50 ml) and the mixture was stirred at 25 0C for 12 hr and was concentrated to a reduced volume. To the aquous solution was added IN HCl solution to give colourless precipitate. This was collected by filtration, washed with water to give 3-{4-[2- (acetylamino) -1, 3-thiazol-4-yl]phenyl}propanoic acid (12.1 g) as a colourless solid.
1H-NMR (DMSO-d6), δ (ppm) : 2.15 (3H, s) , 2.52 (2H, t, J = 7.5 Hz), 2.83 (2H, t, J = 7.5 Hz), 7.27 (2H, d, J = 8.1 Hz), 7.52 (IH, s), 7.78 (2H, d, J = 8.1 Hz), 12.24 (IH, s) . MS: 291 (M+H) + Step 4
To a solution of 3-{4- [2- (acetylamino) -1, 3-thiazol-4- yl]phenylJpropanoic acid (3 g) in CH2CI2 (30 ml) was added oxalyl chloride (1.35 ml) dropwise at 5 0C. After another 5 minutes, 3 drops of DMF were added. This was stirred for 1 hr at 25 0C. Then, the solvent and the reagent were evaporated. The residue was dissolved into THF (30 ml) . To the ice-cooled solution of the resulting acid chloride was added another solution that was prepared from ethyl isocyanoacetate (2.82 ml) and 1, 8-diazabicyclo [4.5.0]undec- 7-ene (DBU, 4.64 ml) in THF (30 ml) . This was stirred at 25 0C for 2 days. This was quenced with aq. 0. IN HCl and was extracted with ethyl acetate, and the extract was dried over MgSO4, filtered, and concentrated in vacuo. The residue was purified with silicagel column chlomatography with CH2CI2 and MeOH (5/1) as an eluent to give ethyl 5-(2-{4-[2- (acetylamino) -1, 3-thiazol-4-yl]phenyl}ethyl) -1, 3-oxazole-4- carboxylate (2.25 g) as white powder. 1H-NMR (DMSO-de), δ (ppm) : 1.26 (3H, t, J = 7.1 Hz), 2.15 (3H, s), 2.96 (2H, t, J = 7.4 Hz), 3.33 (2H, t, J = 7.4 Hz), 4.22 (2H, q, J = 7.1 Hz), 7.21 (2H, d, J = 8.2 Hz), 7.54 (IH, s), 7.78 (2H, d) , 8.37 (IH, s) , 12.20 (IH, s) . MS: 386 (M+H) + Step 5 To the solution of ethyl 5- (2-{4- [2- (acetylamino) -1, 3- thiazol-4-yl]phenyl}ethyl) -1, 3-oxazole-4-carboxylate (2.14 g) in MeOH (5 ml) was added cone. HCl (10 ml) . This was stirred at 80 0C for 8 hr. Then, this was concentrated in vacuo to give l-amino-4- [4- (2-amino-l, 3-thiazol-4-yl)phenyl]-2-butanone dihydrochloride as a crude solid. This was used for the next reaction without further purification.
1H-NMR (DMS0-d6) , δ (ppm) : 2.93 (4H, m) , 3.95 (2H, m) , 7.02 (IH, s), 7.33 (2H, d, J = 8.4 Hz), 7.63 (2H, d, J = 8.4 Hz), 8.21 (3H, br), 8.77 (2H, br) . Step 6
To the solution of l-amino-4- [4- (2-amino-l, 3-thiazol-4- yl)phenyl] -2-butanone dihydrochloride (1.8 g) in methylene chloride (20 ml) and DMF (20 ml) were added N,N- diisopropylethylamine (DIPEA, 3.3 ml) and di-tert-butyl dicarbamate (1.29 g) . This was stirred at room temperature for 12 hr. To the solution was added water, and the mixture was extracted with CH2CI2. The organic layer was dried over MgSCU, filtered and concentrated. The residual oil was dissolved in pyridine (20 ml) . To this solution was added acetylchloride (0.57 ml) under ice-cooling. This was stirred at 25 °C for 2 hr. The solution was poured into water and organic layer was extracted with ethyl acetate. The extract was dried over MgSO4, the solvent was removed in vacuo and residual yellow oil was purified by silicagel column chromatography with hexane and ethyl acetate (10/1) as an eluent to give tert-butyl (4- {4- [2- (acetylamino) -1, 3-thiazol-4-yl]phenyl}-2- oxobutyl) carbamate (0.3 g) as white powder.
1H-NMR (DMSCHd6), δ (ppm) : 1-38 (9H, s) , 2.15 (3H, s) , 2.76 (4H, br), 3.76 (2H, d, J = 5.8 Hz), 7.07 (IH, t) , 7.25 (2H, d, J = 8.2 Hz), 7.53 (IH, s) , 7.78 (2H, d) , 12.22 (IH, s) . MS: m/z 404 (M+H)+ Step 7 tert-Butyl (4-{4- [2- (acetylamino) -1, 3-thiazol-4- yl]phenyl}-2-oxobutyl) carbamate (260 mg) was treated with 4N HCl in dioxane at room temperature for 2 hr. Then, the solvent was evaporated in vacuo. The residue was triturated with isopropyl ether (IPE) to give N-{4- [4- (4-amino-3- oxobutyl)phenyl]-1, 3-thiazol-2-yl}acetamide hydrochloride (218 mg) as colourless powder. 1H-NMR (DMSOd6), δ (ppm) : 2.16 (3H, s) , 2.89 (4H, d x2) , 3.81
(2H, m) , 7.28 (2H, d, J = 8.2 Hz), 7.54 (IH, s) , 7.80 (2H, d,
J = 8.2 Hz), 8.10 (3H, br) , 12.23 (IH, br) .
MS: 304 (M+H)+
Step 8 Di-tert-butyl { (E) - [ (4-{4- [2- (acetylamino) -1,3-thiazol-4- yl]phenyl}-2-oxobutyl) amino]methylidene}biscarbamate was prepared from the compound of Step 7 of Production Example 5 in a manner similar to Step 13 of Production Example 1.
1H-NMR (DMSO-d6), δ (ppm) : 1.38 (9H, s) , 1.43 (9H, s) , 2.15 (3H, s), 2.84 (4H, s) , 4.24 (2H, d, J = 4.8 Hz), 7.27 (2H, d,
J = 8.2 Hz), 7.52 (IH, s) , 7.79 (2H, d) , 8.72 (IH, br) , 10.15
(IH, s), 11.43 (IH, s), 12.22 (IH, s) .
MS: 546 (M+H)+
Step 9 The title compound was prepared from the compound of Step
8 of Production Example 5 in a manner similar to Step 14 of
Production Example 1.
1H-NMR (DMSO-de), δ (ppm) : 2.16 (3H, s) , 2.73-2.94 (4H, m) ,
3.38 (2H, m) , 6.53 (IH, br) , 7.26 (2H, d, J = 8.0 Hz), 7.32 (2H, s), 7.54 (IH, s) , 7.80 (2H, d, J = 8.0 Hz), 11.50 (IH, s), 12.05 (IH, s), 12.21 (IH, s) .
MS: m/z 346 (M+H) free
Production Example 6: Synthesis of N- (4-{2- [4- (3-
{ [amino (imino)methyl] amino}propyl)phenyl] ethyl}-l, 3-thiazol-2- yl)acetamide hydrochloride
Step 1 To a solution of N- [4- (chloromethyl) -1, 3-thiazol-2- yl] acetamide (23.6 g) in toluene (200 ml) and acetonitril (80 ml) was added triphenylphosphine (35.7 g) at 25 0C. The mixture was stirred at 130 0C for 12 hr. Resulting precipitate was collected by filtration and washed with IPE to give { [2- (acetylamino) -1, 3-thiazol-4- yl]methyl} (triphenyl)phosphonium chloride (35.7 g) as colourless powder.
1H-NMR (DMSO-de), δ (Ppm) : 2.11 (3H, s) , 5.25 (2H, d, J = 15.3 Hz), 6.86 (IH, d, J = 3.8 Hz), 7.68-7.92 (15H, m) ,
12.06 (IH, s) .
Step 2
Methyl (2E) -3- (4-formylphenyl) acrylate was prepared from benzene-1, 4-dicarbaldehyde in a manner similar to Step 10 of production Example 2.
1H-NMR (200MHz, DMSCHd6) δ (ppm) : 3.75 (3H, s), 6.83 (IH, d,
J=16.1 Hz), 7.74 (IH, d, J=16.1 Hz), 7.95 (4H, s) , 10.03 (IH,
S) .
Step 3 Methyl (2E) -3- (4-{ (E) -2- [2- (acetylamino) -1, 3-thiazol-4- yl]vinyl}phenyl) acrylate was prepared from the compound of
Step 1 of Production Example 6 and the compound of Step 2 of
Production Example 6 in a manner similar to Step 3 of
Production Example 2. 1H-NMR (DMSOd6), δ (ppm) : 2.15 (3H, s) , 3.73 (3H, s) , 6.66
(IH, d, J = 16.0 Hz), 7.24 (IH, d, J = 14.5 Hz), 7.55-7.78
(2H, m) , 7.95 (4H, s) , 12.20 (IH, br) .
MS: 329 (M+H) + •
Step 4 Methyl 3- (4-{2- [2- (acetylamino) -1, 3-thiazol-4- yl]ethyl}phenyl)propanoate was prepared from the compound of
Step 3 of Production Example 6 in a manner similar to Step 11 of Production Example 2. 1H-NMR (200MHz, CDCl3) δ (ppm) : 2.24 (3H, s) , 2.61 (2H, t, J=7.8 Hz), 2.92 (2H, t, J=I.8 Hz), 2.94 (4H, s) , 3.67 (3H, s), 6.49 (IH, s), 7.09 (4H, s) . MS: 333(M+H)+ Step 5
Methyl 3-(4-{2-[2- (acetylamino) -1,3-thiazol-4- yl]ethyl}phenyl)propanoate (1.0 g) was dissolved in THF (20 ml) . To the solution was added lithium tetrahydroborate (1.07 g) portionwise at 5 0C. The reaction 'mixture was refluxed for 4.0 hr and Na2SO4 was added, and the mixture was stirred for 12 hr. Precipitate was removed by filtration. The organic solvent was evaporated in vacuo. The residue was purified by silicagel column chromatography with hexane and ethyl acetate (3:2 - 1:1) as an eluent to give N- (4-{2- [4- (3- hydroxypropyl)phenyl] ethyl}-l, 3-thiazol-2-yl) acetamide (200 mg) as white powder.
1H-NMR (DMSO-dβ) , δ (ppm) : 1.87 (2H, m) , 2.24 (3H, s) , 2.68 (2H, t, J = 7.5 Hz), 2.94 (4H, s) , 3.68 (2H, t, J = 7.5 Hz), 6.50 (IH, s) , 7.10 (4H, s) . MS: 305 (M+H) + Step 6
To a solution of N- (4-{2- [4- (3- hydroxypropyl)phenyl]ethyl}-l, 3-thiazol-2-yl) acetamide (180 mg) in THF (5 ml) were added triphenylphosphine (233 mg) and CBr4 (294 mg) at 0 °C. This was stirred at 25 0C for 1 hr and was poured into water. The mixture was extracted with ethyl acetate. The organic layer was dried over MgSO4, filtered, concentrated in vacuo. The residue was purified by silicagel column chromatography with hexane and ethyl acetate (1/2) as an eluent to give N- (4-{2- [4- (3-bromopropyl)phenyl] ethyl}-l, 3- thiazol-2-yl) acetamide (217.2 mg) as colourless powder. 1H-NMR (DMSO-de), δ (ppm) : 2.02 (2H, m) , 2.11 (3H, s), .2.66 (2H, t, J = 7 . 5 Hz ) , 2 . 87 (4H, br) , 3. 49 (2H, t, J = 7. 5 Hz) ,
6. 73 ( IH, s) , 7 . 11 (4H, s) , 12 . 08 ( IH, s ) . MS : 367, 369 (M+H) + Step 7 To a solution of N- (4-{2- [4- (3-bromopropyl)phenyl] ethyl}- 1, 3-thiazol-2-yl) acetamide (175 mg) in DMF (5 ml) was added potassium phthalimide at 25 0C. The mixture was stirred at 50 0C for 2.5 hr and was poured into water. The mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over MgSOo filtered and concentrated in vacuo. The residue was purified by silicagel column chromatography with hexane and ethyl acetate (1:1) as an eluent to give N- [4- (2-{4- [3- (1, 3-dioxo-l, 3-dihydro-2H- isoindol-2-yl)propyl]phenyl}ethyl) -1, 3-thiazol-2-yl] acetamide (174.1 mg) as white powder.
1H-NMR (DMSO-d5), δ (ppm) : 1.95 (2H, m) , 2.11 (3H, s), 2.57 (2H, t, J = 7.1 Hz), 2.82 (4H,. s) , 3.59 (2H, t, J = 6.9 Hz), 6.71 (IH, s), 7.08 (4H, s) , 7.83 (3H, s) . MS: 434 (M+H)+ Step 8
N- [4- (2-{4- [3- (1,3-Dioxo-l, 3-dihydro-2H-isoindol-2- yl)propyl]phenyl}ethyl) -1, 3-thiazol-2-yl]acetamide (87.1 mg) , hydrazine monohydrate (0.174 ml) and MeCN (2 ml) were combined under N2 atmosphere. The reaction mixture was stirred at 50 0C for 1 hour. After cooled to r.t., the mixture was diluted with CHCl3. The precipitate was filtered off. The filtrate was concentrated in vacuo. The residue was purified by flash column chromatography over NH silica gel with CHCI3 / MeOH (20:1) as an eluent to give N- (4-{2- [4- (3- aminopropyl)phenyl] ethyl}-1,-3-thiazol-2-yl) acetamide (50 mg) as colorless oil. 1H-NMR (DMSO-de), δ (ppm) : 1.61 (IH, m) , 2.11 (3H, s) , 2.56 ( 2H, m) , 2 . 87 ( 4H, s ) , 3 . 32 ( 2H, m) , 6 . 72 ( IH, s ) , 7 . 09 ( 4H, s) .
MS : 304 (M+H) +
Step 9 Di-tert-butyl ( (Z) -{ [3- (4-{2- [2- (acetylamino) -1, 3- thiazol-4-yl] ethyl}phenyl)propyl]amino}methylidene) biscarbamate was prepared from the compound of Step 8 of
Production Example 6 in a manner similar to Step 13 of
Production Example 1. 1H-NMR (DMSO-d6), δ (ppm) : 1.38 (9H, s) , 1.47 (9H, s), 1.79 (2H, br), 2.11 (3H, s) , 2.55 (2H, br) , 2.86 (4H, s) , 3.26 (2H, br), 6.72 (IH, s) , 7.11 (4H, s) , 8.30 (IH, br) , 11.45 (IH, s) ,
12.10 (IH, s) .
MS: 546 (M+H) + Step 10
The title compound was prepared from the compound of Step
9 of Production Example 6 in a' manner similar to Step 14 of
Production Example 1.
1H-NMR (DMSO-dβ) , δ (ppm) : 1.74 (2H, m) , 2.11 (3H, s) , 2.58 (2H, t, J = 7.1 Hz), 2.87 (4H, s x2) , 3.09 (2H, m) , 6.73 (IH, s), 7.12 (4H, s), 7.21 (4H, br) , 7.87 (IH, br) , 12.10 (IH, s) .
MS: 346 (M+H) +
Production Example 7: Synthesis of N-{4-[4-(4-
{ [amino (imino)methyl] amino}butyl)phenyl] -1,3-thiazol-2- yl}acetamide hydrochloride
Step 1
To a solution of 4-phenyl-l-butanol (15 g) in CH2Cl2
(150 ml) were added pivaloyl chloride (14.2 ml) and diisopropylethylamine (26.1 ml) at 00C. The mixture was stirred at 25 °C for 2 hr and poured into water. The mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over MgSOo filtered, concentrated in vacuo. The residue was purified by silicagel column chromatography with hexane and ethyl acetate to give 4- phenylbutyl pivalate (21 g) as pale yellow oil.
1H-NMR (DMSO-de), δ (ppm) : 1.19 (9H, s) , 1.63-1.74 (4H, m) , 2.64 (2H, m) , 4.06 (2H, m) , 7.15-7.33 (5H, m) .
MS: m/z 235 (M+H) +
Step 2
4- [4- (2-Bromoacetyl)phenyl]butyl pivalate was prepared from the compound of Step 1 of Production Example 7 in a manner similar to Step 1 of Production Example 5.
1H-NMR (DMSO-de), δ (ppm) : 1.16 (9H, s) , 1.68-1.79 (4H, m) ,
2.72 (2H, t, J = 7.1 Hz), 4.08 (2H, t, J = 5.9 Hz), 4.43 (2H, s), 7.30 (2H, d, J = 8.0 Hz), 7.92 (2H, d, J = 8.0 Hz) .
MS: 355, 357 (M+H) + Step 3
4- [4- (2-Amino-1, 3-thiazol-4-yl)phenyl]butyl pivalate was prepared from the compound of Step 2 of Production Example
7 in a manner similar to Step 2 of Production Example 5.
MS: 333 (M+H) + Step 4
4-{4- [2- (Acetylamino) -1, 3-thiazol-4-yl]phenyl}butyl pivalate was prepared from the compound of Step 3 of
Production Example 7 in a manner similar to Step 7 of
Production Example 1. 1H-NMR (DMSO-d6), δ (ppm) : 1.19 (9H, s) , 1.69 (4H, m) , 2.67
(2H, br) , 4.08 (2H, br) , 7.23 (2H, d, J = 8.0 Hz), 7.72 (2H, d, J = 8.0 Hz),. 10.8 (IH, br) .
MS: m/z 375 (M+H)
Step 5 To a solution of 4-{4- [2- (acetylamino) -1, 3-thiazol-4- yl]phenyl}butyl pivalate (1.5 g) in MeOH (10 ml) was added sodium methoxide in MeOH (28 %, 0.89 ml) under ice-cooling.
This was stirred at 45 0C for 12 hr. The organic solvent was evaporated to reduced volume and aq. IN HCl (10 ml) was added to the residue at 5 0C. The mixture was extracted with ethylacetate. The organic layer was dried over MgSO4, filtered, and concentrated in vacuo. The residue was triturated with IPE to give N-{4- [4- (4-hydroxybutyl)phenyl] -
I, 3-thiazol-2-yl}acetamide as white powder.
1H-NMR (DMSO-dβ), δ (ppm) : 1.37-1.68 (4H, m) , 2.15 (9H, s) , 2.59 (2H, t, J = 7.4 Hz), 3.41 (2H, t, J = 6.3 Hz), 3.81 (IH, br), 7.24 (2H, d, J = 8.0 Hz), 7.79 (IH, d, J = 8.0 Hz), 12.22
(IH, s) .
MS: m/z 291 (M+H)
Step 6 N-{4- [4- (4-Bromobutyl)phenyl]-1, 3-thiazol-2-yl}acetamide was prepared from the compound of Step 5 of Production Example
7 in a manner similar to Step 6 of Production Example 6.
1H-NMR (DMSO-de), δ (ppm) : 1.63-1.89 (4H, m) , 2.15 (3H, s) ,
2.62 (2H, t, J = 7.2 Hz), 3.56 (2H, t, J = 6.4 Hz), 7.25 (2H, d, J = 8.0 Hz) , 7.80 (2H, d, J = 8.0 Hz) , 12.22 (IH, s) .
MS: 353, 355 (M+H) +
Step 7
N- (4-{4- [4- (1, 3-Dioxo-l, 3-dihydro-2H-isoindol-2- yl)butyl]phenyl}-l,3-thiazol-2-yl) acetamide was prepared from the compound of Step 6 of Production Example 7 in a manner similar to Step 7 of Production Example 6.
1H-NMR (DMSOd6), δ (ppm) : 1.62 (4H, br) , 2.15 (3H, s) , 2.62
(2H, br), 3.60 (2H, br) , 7.27 (2H, d) , 7.51 (IH, s) , 7.77 (2H, d) , 7.82-7.89 (4H, m) , 12.22 (IH, s) . MS: m/z 420 (M+H)
Step 8 N-{4- [4- (4-Aminobutyl)phenyl]-1, 3-thiazol-2-yl}acetamide was prepared from the compound of Step 7 of Production Example
7 in a manner similar to Step 8 of Production Example 6.
MS: m/z 290 (M+H) Step 9
Di-tert-butyl { (E) - [ (4-{4- [2- (acetylamino) -1,3-thiazol-4- yl]phenyl}butyl) amino]methylidene}biscarbamate was prepared from the compound of Step 8 of Production Example 7 in a manner similar to Step 13 of Production Example 1. 1H-NMR (DMSO-de), δ (ppm) : 1.37 (9H, s) , 1.47 (9H, s), 1.56
(4H, m), 2.15 (3H, s) , 2.62 (2H, m) , 3.30 (2H, m) , 7.25 (2H, d) , 7.51 (IH, s), 7.29 (2H, d) , 8.30 (IH, t, J = 1.2 Hz),
11.49 (IH, s), 12.21 (IH, s) .
MS: m/z 532 (M+H) Step 10
The title compound was prepared from the compound of Step
9 of Production Example 7 in a manner similar to Step 14 of
Production Example 1.
1H-NMR (DMSO-de), δ (ppm) : 1.13-1.20 (4H, m) , 2.16 (3H, s) , 2.62 (2H, t, J = 7.2 Hz), 3.14 (2H, m) , 7.23 (2H, d, J = 8.0
Hz), 7.53 (IH, s), 7.68 (2H, m) , 7.80 (2H, d, J = 8.0 Hz),
12.23 (IH, s) .
MS: m/z 332 (M+H) free
Production Example 8: Synthesis of N- (4-{2- [3- (2- { [amino (imino)methyl]amino}ethyl)phenyl] ethyl}-l, 3-thiazol-2- yl)acetamide hydrochloride
Step 1
To a suspension of lithium aluminum hydride in dry tetrahydrofuran (50 ml) was added (3-bromophenyl) acetic acid (10 g) in tetrahydrofuran (100 ml) under ice cooling. The mixture was refluxed for 2 hurs. After cooling, to the reaction mixture were added water and aqueous Rochelle salt. The mixture was stirred for another 30 min. Aqueous layer was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and concentrated in vacuo to give 2- (3-bromophenyl) ethanol. This compound was used for the next reaction without further purification.
1H-NMR (200 MHz, CDCl3), δ (ppm) : 1.66 (IH, brs) , 2.84 (2H, dd, J=6.5, 14Hz), 3.85 (2H, dt, J=6.5, 2.6Hz), 7.13-7.39 (4H, m) . Step 2
To a solution of 2- (3-bromophenyl) ethanol (7 g) in N,N- dimethylformamide (100 ml) were added tert-butyldimethylsilyl chloride (5.77 g) and imidazole (2.84 g) at 25 0C. The mixture was stirred at 25 0C for 12 hr. The reaction mixture was poured into water (500 ml) and extracted with ethyl acetate (100 ml x2) . The combined organic layer was dried over magnesium sulfate and concentrated in vacuo. The residue was purified by silica gel column chromatography with mixed solvent of n-hexane and ethyl acetate to give [2- (3- bromophenyl) ethoxy] (tert-butyl)dimethylsilane as colorless oil. 1H-NMR (200 MHz, CDCl3), δ (PPm) : 0.01 (6H, s) , 0.88 (9H, s) , 2.81 (2H, dt, J=6.5, 9.5Hz), 3.81 (2H, dt, J=3.0, 6.5Hz), 7.14-7.39 (5H, brs) . Step 3
To the solution of [2- (3-bromophenyl) ethoxy] (tert- butyl) dimethylsilane (2.45 g) in THF (25 ml) was added n- butyl lithium (1.57 M in hexane, 5.58 ml) at -75 0C, and the mixture was stirred at same temperature for 1 hr. Then, DMF (1.69 ml) was added at the same temperature, and the mixture was stirred for 2 hr. The reaction was quenched with aq. ammonium chloride and allowed to room temperature. The mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over MgSC^, filtered, and concentrated in vacuo. The residue was purified by silicagel column chromatography with hexane and ethyl acetate (20/1 - 10/1) to give 3- (2- { [tert-butyl (dimethyl) silyl] oxyjethyl) - benzaldehyde (0.8 g) as colourless oil.
1H-NMR (DMSO-de), δ (ppm): 0.01 (6H, s) , 0.85 (9H, s) , 2.89 (2H, t, J = 6.6 Hz), 3.83 (2H, t, J = 6.6 Hz), 7.44-7.58 (2H> m) , 7.71-7.74 (2H, m) , 10.00 (IH, s) . Step 4
N-(4-{ (E) -2- [3- (2- { [tert-Butyl (dimethyl) silyl]oxy}ethyl)- phenyl] vinyl }-l, 3-thiazol-2-yl) acetamide was prepared from the compound of Step 3 of Production Example 8 in a manner similar to Step 3 of Production Example 2.
1H-NMR (DMSO-de), δ (ppm): 0.00 (6H, s) , 0.87 (9H, s) , 2.22 (3H, s), 2.83 (2H, t) , 3.82 (2H, t) , 6.84-7.34 (7H, m) , 10.10 (IH, br) . MS: 403 (M+H)+ Step 5
To the solution of N- (4-{ (E) -2- [3- (2-{ [tert- butyl (dimethyl) silyl]oxy}ethyl)phenyl]vinyl}-l, 3-thiazol-2- yl) acetamide (920 mg) in THF (10 ml) was added tetrabutylammonium fluoride (1 M in THF solution, 4.6 ml) at 0 0C. This was stirred at 25 0C for 2 hr and was poured into water. The mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over MgSO4, filtered, and concentrated in vacuo to give N- (4-{ (E) -2- [3- (2- hydroxyethyl)phenyl]vinyl}-l,3-thiazol-2-yl) acetamide (660 mg) as crude oil. This was used for the next reaction without further purification.
1H-NMR (DMSO-ds), δ (ppm) : 2.22 (3H, s) , 2.89 (2H, t, J = 6.5 Hz), 3.25 (IH, m) , 3.89 (2H, t, J = 6.5 Hz), 6.84-7.72 (7H, m) , 10.00 (IH, br) . MS: 289 (M+H)+ Step 6
N- (4-{2-[3-(2-Hydroxyethyl)phenyl]ethyl}-l,3-thiazol-2- yl) acetamide was prepared from the compound of Step 5 of Production Example 8 in a manner similar to Step 11 of Production Example 2.
1H-NMR (DMSO-d6) , δ (ppm) : 2.24 (3H, s) , 2.84 (2H, t, J = 6.4 Hz), 2.95 (4H, s), 3.85 (2H, t, J = 6.4 Hz), 6.50 (IH, s) , 7.01-7.07 (3H, m) , 7.18-7.22 (IH, m) . MS: 291 (M+H) + Step 7
N-(4-{2-[3-(2-Hydroxyethyl)phenyl]ethyl}-l,3-thiazol-2- yl) acetamide (300 mg) , methanesulfonyl chloride (0.12 ml), diisopropyl ethylamine (0.54 ml) and CH2CI2 (7 ml) were combined at 0 0C under N2 atmosphere. The reaction mixture was stirred at room temperature for 1 hour, and the precipitate was filtered off. The filtrate was concentrated in vacuo. The residue was dissolved in DMF. To the solution were added potassium phthalimide (287 mg) and DMF (5 ml) combined under N2 atmosphere. The reaction mixture was stirred at 50 0C for 3 hours. After cooled to r.t., AcOEt and IN-HCl were added to the reaction mixture. The organic layer was washed with water, saturated NaHCO3 and brine, dried over anhydrous MgSO4, and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel with hexane / ethyl acetate (2/3) as an eluent to give N- [4- (2-{3- [2- (1, 3-dioxo-l, 3-dihydro-2H-isoindol-2- yl) ethyl]phenyl}ethyl) -1, 3-thiazol-2-yl] acetamide (433.6 mg) as white powder. 1H-NMR (DMSO-d6) , δ (PP™-) : 2.31 (3H, s) , 2.85-2.99 (6H, m) , 3.89 (2H, dd, J = 7.8, 6.2 Hz), 6.46 (IH, s) , 6.97-7.17 (4H, m) , 7.72 (2H, m) , 7.82 (2H, m) . MS: 420 (M+H)+ Step 8
N- ( 4- { 2- [3- (2-Aminoethyl) phenyl] ethyl } -l , 3-thiazol-2- yl)acetamide was prepared from the compound of Step 7 of
Production Example 8 in a manner similar to Step 8 of Production Example 6.
1H-NMR (DMSOd6), δ (ppm) : 2.11 (3H, s) , 2.61 (2H, m) , 2.75
(2H, m) , 2.88 (4H, s) , 6.72 (IH, s) , 6.99-7.21 (4H, m) .
MS: 290 (M+H)+
Step 9 Di-tert-butyl ( (Z) -{ [2- (3-{2- [2- (acetylamino) -1, 3- thiazol-4-yl] ethyl}phenyl) ethyl] amino}methylidene) biscarbamate was prepared from the compound of Step 8 of
Production Example 8 in a manner similar to Step 13 of
Production Example 1. 1H-NMR (DMSO-de), δ (ppm) : 1.46 (9H, s) , 1.50 (9H, s), 2.27
(3H, s), 2.84 (2H, t, J = 7.0 Hz), 2.95 (4H, s) , 3.66 (2H, dd,
J = 7.0, 6.0 Hz), 5.63 (IH, dd, J = 5.0, 1.5 Hz), 6.47 (IH, s), 6.98-7.05 (3H, m) , 7.15-7.23 (IH, m) , 8.39 (IH, br) , 11.50
(IH, br) . MS: 532 (M+H) +
Step 10
The title compound was prepared from the compound of Step
9 of Production Example 8 in a manner similar to Step 14 of
Production Example 1. J-H-NMR (DMSCHd5), δ (ppm) : 2.12 (3H, s) , 2.75 (2H, t, J = 7.3
Hz), 2.94 (4H, br) , 3.35 (2H, dt, J = 7.3, 6.2 Hz), 6.74 (IH, s), 7.04-7.25 (.8H, m) , 7.70 (IH, t, J = 5.4 Hz), 12.09 (IH, br) .
MS: m/z 332 (M+H) free Production Example 9: Synthesis of 2- (4-{2-[2- (acetylamino) -
1, 3-thiazol-4-yl] ethyljphenyl) -N- [amino (imino)methyl]acetamide
Step 1 A mixture of 3-chloro-2-oxopropyl acetate (5 g) and thiourea (2.5 g) in ethanol (25 ml) was refluxed for 4 hours. The reaction mixture was cooled to ambient temperature and the resulting crystalline precipitate was collected by filtration and washed with ethanol (20 ml) to give (2-amino-l, 3-thiazol- 4-yl)methyl acetate hydrochloride (3.5 g) as white crystals. 1H-NMR (DMSOd6), δ (ppm) : 2.07 (3H, s) , 4.92 (2H, s), 6.87 (IH, s) . MS: 173 (M+H)+ Step 2
To a mixture of (2-amino-l,3-thiazol-4-yl)methyl acetate hydrochloride (56 g) and pyridine (45 g) in dichloromethane (560 ml) was added acetyl chloride (23 g) over a period of 30 minutes at 5°C, and the reaction mixture was stirred for 10 minutes at the same temperature. The reaction mixture was poured into water (500 ml) and extracted with chloroform (1 L) . The organic layer was dried over sodium sulfate and concentrated in vacuo. The residual solid was collected by filtration with isopropyl ether to give (2- (acetylamino) -1, 3- thiazol-4-yl)methyl acetate (47 g) as white crystals.
1H-NMR (CDCl3), δ (ppm) : 2.12 (3H, s) , 2.29 (3H, s) , 5.08 (2H, s) , 6.93 (IH, s) . MS: 215 (M+H)+ Step 3 A mixture of (2- (acetylamino) -1, 3-thiazol-4-yl)methyl acetate (46 g) and potassium carbonate (30 g) in methanol (640 ml) was stirred for 3 hours at ambient temperature. The reaction mixture was concentrated in vacuo. The residue was diluted with chloroform, and the insoluble material was filtered off. The resulting solution was purified by flash column chromatography on silica-gel with methanol / chloroform (1/99) . The resulted solid was collected by filtration with isopropyl ether to give N- (4- (hydroxymethyl) -1, 3-thiazol-2- yl) acetamide (35 g) as white crystals.
1H-NMR (DMSOd6), δ (ppm) : 2.12 (3H, s) , 4.44 (2H, d, J=5.0Hz),
5.20 (IH, t, J=5.0Hz), 6.88 (IH, s) , 12.02 (IH, brs) .
MS: 173 (M+H)+ 5 Step 4
N- (4- (Hydroxymethyl)-l,3-thiazol-2-yl) acetamide (2.8 g) was dissolved in methanol (10 ml) and chloroform (200 ml) .
Then, manganese (IV) oxide (28.3 g) was added to the solution under nitrogen atmosphere. The reaction mixture was stirred at o room temperature for 7 hours, and filtered through a celite pad. The filtrate was concentrated in vacuo. The resulting solid was washed with ethyl ether to give N- (4-formyl-l, 3- thiazol-2-yl) acetamide (2.01 g) as an off-white solid. mp. 195.5-199°C 5 1H-NMR (DMSO-dβ) , δ (ppm) : 2.17(3H, s), 8.28(1H, s) , 9.79(1H, s) , 12.47 (IH, brs) .
Step 5
To the solution of [4- (bromomethyl)phenyl] acetic acid
(5.0 g) in toluene (50 ml) was added triphenylphosphine (5.8 0 g) at 25 0C. This was refluxed for 5 h. After cooling to room temperature, the resulting colourless precipitate was collected by filtration and washed with IPE to give [4-
(carboxymethyl) -benzyl] (triphenyl)phosphonium bromide (10.7 g) as white powder. 5 1H-NMR (DMSO-de), δ (ppm) : 3.52 (2H, s) , 5.13 (2H, d, J = 15.6 ■ Hz), 6.90 (2H, dd, J = 8.1, 2.3 Hz), 7.11 (2H, d, J = 8.1 Hz),
7.58-7.91 (15H, .m) .
MS:' 411 (M+H) +
Step 6 0 To the solution of [4- (carboxymethyl)benzyl] (triphenyl) phosphonium bromide (19.1 g) in DMF (180 ml) was added potassium tert-butoxide (11.9 g) under ice-cooling. This was stirred at 5 0C for 30 min. To the solution was added N- (4- formyl-l,3-thiazol-2-yl)acetamide (6.0 g) in DMF (18 ml) . This was stirred at 25 0C for 3 hr. The mixture was poured into water and was extracted with ethyl acetate. The aquaous phase was acidified (pH 4-5) with IN HCl to give colourless precipitate. The precipitate was collected by filtration to give a mixture of (4-{ (E) -2- [2- (acetylamino) -1, 3-thiazol-4- yl]vinyl}phenyl) acetic acid and (4-{ (Z) -2- [2- (acetylamino) - 1, 3-thiazol-4-yl]vinyl}phenyl) acetic acid (10 g) as white powder.
1H-NMR (DMSO-d6) , δ (ppm) : 2.12, 2.14 (3x5/6, 3xl/6H, s) , 3.52, 3.54 (2x5/6, 2x1/611, s) , 6.46 (5/6H, d, J = 12.7 Hz) , 6.54 (5/6H, d, J = 12.7 Hz) , 6.95 (IH, s), 7.11-7.49 (4+1/6H, m) , 12.09 (IH, br) . MS: 303 (M+H) + Step 7
(4-{2- [2- (Acetylamino) -1,3-thiazol-4- yl] ethyl}phenyl) acetic acid was prepared from the compound of Step 6 of Production Example 9 in a manner similar to Step 11 of Production Example 2.
1H-NMR (DMSO-d6), δ (ppm) : 2.11 (3H, s) , 2.88 (4H, s) , 3.50 (2H, s), 6.74 (IH, s), 7.14 (4H, s) , 12.08 (IH, s) . MS: m/z 305 (M+H) Step 8 To a solution of (4-{2- [2- (acetylamino) -1, 3-thiazol-4- yl]ethylJphenyl) acetic acid (2.0 g) • in DMF (15 ml) was added N,N'-carbonyldiimidazole (1.6 g) . The mixture was stirred at 50.0C for 2 hr, To the mixture was added a solution of guanidine hydrochloride (3.1 g) and sodiume methoxyde (28 % MeOH solution, 6.4 ml) in DMF (5 ml) at 25 0C. The reaction mixture was stirred at 25 °C for 12 hr. The organic solvent was evaporated to reduced volume and the residue was poured into water. To the mixture was added IN HCl to adjust pH to 8.
The mixture was extracted with ethyl acetate. The organic layer was dried over MgSO4, filtered, and concentrated in vacuo. The residue was purified by silicagel (amine coated) column chromatography with CH2Cl2 and MeOH (10/1) as an eluent to give 2- (4-{2- [2- (acetylamino) -1,3-thiazol-4- yl] ethyl}phenyl) -N- [amino (imino)methyl] acetamide (1.4 g) as colourless powder.
1H-NMR (DMSO-de), δ (PPm) : 2.10 (3H, s) , 2.86 (4H, m) , 3.34 (2H, s), 6.74 (IH, s), 7.08 (2H, d, J=8.1 Hz), 7.12 (2H, d,
J=8.1 Hz), 12.22 (IH, br) .
MS: m/z 346 (M+H)
Production Example 10: Synthesis of N-[4- (2-{4-[ (2-
{ [amino (imino)methyl] amino}ethyl) amino]phenyl}ethyl) -1, 3- thiazol-2-yl]acetamide dihydrochloride
Step 1
A mixture of 3-chloro-2-oxopropyl acetate (5 g) and thiourea (2.5 g) in ethanol (25 ml) was refluxed for 4 hours.
The reaction mixture was cooled to ambient temperature and the resulting crystalline precipitate was collected by filtration and washed with ethanol (20 ml) to give (2-amino-l, 3-thiazol-
4-yl)methyl acetate hydrochloride (3.5 g) as white crystals.
1H-NMR (DMSO-de), δ (ppm) : 2.07 (3H, s) , 4.92 (2H, s) , 6.87 (IH, s) . MS: 173 (M+H)+
Step 2
To a mixture of (2-amino-l, 3-thiazol-4-yl)methyl acetate hydrochloride (56 g) and pyridine (45 g) in dichloromethane
(560 ml) was added acetyl chloride (23 g) over a period of 30 minutes at 50C, and the reaction mixture was stirred for 10 minutes at the same temperature. The reaction mixture was poured into water (500 ml) and extracted with chloroform (1 L) .
The organic layer was dried over sodium sulfate and concentrated in vacuo. The residual solid was collected by filtration with isopropyl ether to give (2- (acetylamino) -1, 3- thiazol-4-yl)methyl acetate (47 g) as white crystals.
1H-NMR (CDCl3), δ (ppm) : 2.12 (3H, s) , 2.29 (3H, s) , 5.08 (2H, s) , 6.93 (IH, s) .
MS: 215 (M+H)+
Step 3
A mixture of (2- (acetylamino) -1, 3-thiazol-4-yl)methyl acetate (46 g) and potassium carbonate (30 g) in methanol (640 ml) was stirred for 3 hours at ambient temperature. The reaction mixture was concentrated in vacuo. The residue was diluted with chloroform, and the insoluble material was filtered off. The resulting solution was purified by flash column chromatography on silica-gel with methanol / chloroform (1/99) . The resulted solid was collected by filtration with isopropyl ether to give N- (4- (hydroxymethyl) -1, 3-thiazol-2- yl) acetamide (35 g) as white crystals.
1H-NMR (DMSO-de), δ (ppm) : 2.12 (3H, s) , 4.44 (2H, d, J=5.0Hz), 5.20 (IH, t, J=5.0Hz), 6.88 (IH, s) , 12.02 (IH, brs) . MS: 173 (M+H)+ Step 4
N- (4- (Hydroxymethyl) -1, 3-thiazol-2-yl) acetamide (2.8 g) was dissolved in methanol (10 ml) and chloroform (200 ml) . Then, manganese (IV) oxide (28.3 g) was added to the solution under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 7 hours, and filtered through a celite pad. The filtrate was concentrated in vacuo. The resulting solid was washed with ethyl ether to give N- (4-formyl-l, 3- thiazol-2-yl) acetamide (2.01 g) as an off-white solid. mp. 195.5-199 0C
1H-NMR (DMSO-de), δ (ppm) : 2.17 (3H, s) , 8.28 (IH, s), 9.79 (IH, s), 12.47 (IH, brs) . Step 5
16 1- (Bromomethyl) -4-nitrobenzene (1.9 g) , triphenylphosphine (2.31 g) and N,N-dimethylformamide (20 ml) were combined under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 2.5 hours. Then, potassium tert-butoxide (1.19 g) and N- (4-formyl-l,3-thiazol-2- yl) acetamide (1.5 g) were added and the mixture was stirred at room temperature for 14 hours. The reaction mixture was poured into ice-water and extracted with ethyl acetate. The organic layer was washed with lN-hydrochloric acid, water and saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel with n-hexane / ethyl acetate (1:1) —> (1:2) as an eluent, and triturated with ethyl ether to give N-{4- [ (Z) -2- (4- nitrophenyl) ethenyl]-l,3-thiazol-2-yl}acetamide (1.59 g) as a yellow solid, mp. 155-157 °C
1H-NMR (DMSO-ds), δ (ppm) : 2.13 (3H, s) , 6.64 (IH, d, J=12.5Hz), 6.71 (IH, d, J=12.5Hz), 7.18 (IH, s) , 7.79 (2H, d, J=9.0Hz), 8.17 (2H, d, J=9.0Hz), 12.02 (IH, brs) . MS: 290 (MH-H)+ Step 6
A mixture of N-{4- [ (Z) -2- (4-nitrophenyl) ethenyl]-1,3- thiazol-2-yl}acetamide (2 g) and 10% palladium on carbon (400 mg) in methanol (25 ml), tetrahydrofuran (25 ml) and acetic acid (18 ml) was stirred under 4 atm hydrogen at ambient temperature for 5 hours. The reaction mixture was filtered through a celite pad, and the filtrate was concentrated in vacuo. The residue was dissolved in ethyl acetate. The organic solution was washed with saturated sodium hydrogen carbonate solution and saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel with n-hexane / ethyl acetate (1:2) —» ethyl acetate as an eluent, and triturated with ethyl alcohol / ethyl ether to give N-{4- [2- (4-aminophenyl) ethyl]-I13-thiazol- 2-yl}acetamide (539.6 mg) as an off-white solid. mp. 102.5-104 °C
1H-NMR (DMSO-d6), δ (ppm) : 2.11 (3H, s) , 2.75 (4H, brs) , 4.82 (2H, s) , 6.46 (2H, d, J=8.5Hz), 6.69 (IH, s) , 6.83 (2H, d, J=8.5Hz), 12.07 (IH, brs) . MS: 262 (M+H)+ Step 7
To a suspension of N-{4- [2- (4-aminophenyl) ethyl] -1,3- thiazol-2-yl}acetamide (lOOmg) in toluene were added tert- butyl (2-bromoethyl) carbamate (87.5 mg) and N,N- diisopropylethylamine (52 μl) , and the mixture was stirred at 80 0C for 24 hr. The reaction mixture was allowed to cool to room temperature, water (10 ml) was added, and the organic layer was separated, washed with saturated aqueous NaCl solution, dried over MgSO4, filtered, and concentrated in vacuo to give tert-butyl {2- [ (4-{2- [2- (acetylamino) -1, 3-thiazol-4- yl]ethyl}phenyl) amino] ethyl}carbamate (41.0 mg) as pale brown amorphous.
1H-NMR (CDCl3) δ (ppm) : 1.45 (9H, s) , 2.23 (3H, s) , 2.86(4H, s) , 3.15-3.28(2H, m) , 3.15-3.47(2H, m) , 4.64-5.02 (IH, brs), _ 6.49 (IH, s), 6.52(2H, d, J=8.0Hz), 6.95(2H, d, J=8.0Hz), 9.22- 10.10 (IH, brs) .
MS: 405.2 (M+H)+, 427.3 (M+Na)+ Step 8 tert-Butyl {2- [ (4-{2- [2- (acetylamino) -1, 3-thiazol-4- yl] ethyl}phenyl) amino] ethyl}carbamate (50.7 mg) and 4N-HC1 in dioxane (2 ml) were combined under N2 atmosphere. The reaction mixture was stirred at 20 0C for lhr. The solvent was removed in vacuo. The residue was solidified with AcOEt to give N- [4- (2-{4- [ (2-aminoethyl) amino]phenyl}ethyl) -1, 3-thiazol-2- yljacetamide dihydrochloride (28.9 mg) as a pale brown solid.
1H-NMR (DMS0-d6) δ (ppm) : 2.11(3H, s) , 2.81 (4H, s), 2.92- 3.05(2H, m) , 3.29(2H, t, J=6.2Hz), 6.67 (2H, d, J=7.7Hz), 7.01(2H, d, J=8.1Hz), 7.87-8.24 (3H, brs) , 12.08(lH, s) . MS: 305.2 (M+H)+, 327.2 (M+Na)+ Free Step 9
N- [4- (2-{4- [ (2-Aminoethyl) amino]phenyl}ethyl) -1, 3- thiazol-2-yl]acetamide dihydrochloride (20.3 mg) , N,N'- bis (tert-butoxycarbonyl)-lH-pyrazole-1-carboxamidine (16.7 mg) , N,N-diisopropylethylamine (28.1 μl) , THF (0.5 ml) and DMF (0.1 ml) were combined under N2 atmosphere, and the mixture was stirred at 15 °C for 14 hr. Volatiles were evapolated and the residue was dissolved in MeOH (0.5 ml) . The reaction mixture was stirred at 20 0C for 3 hr, and then AcOEt (20 ml) was added, and the mixture was washed with water and brine, dried over MgSO4, and evaporated to give crude yellow oil (26.9 mg) . The crude oil was purified by preparative silica gel thin-layer chromatography with chloroform / methanol (20:1) as an eluent to give di-tert-butyl [ (Z) - ( {2- [ (4-{2- [2- (acetylamino) -1, 3-thiazol-4- yl]ethyl}phenyl) amino] ethyl}amino)methylidene]biscarbamate as pale yellow oil (23.8 mg) .
1H-NMR (200MHz, CDCl3) δ (PPm) : 1.48 (9H, s) , 1.52 (9H, s), 2.22 (3H, s), 2.75 - 3.01 (4H, m) , 3.20 - 3.38 (2H, m) , 3.55 - 3.76 (2H, m) , 4.15 - 4.68 (IH, brs), 6.51 (IH, s) , 6.55 (2H, d, J = 8.4Hz ), 6.97 (2H, d, J = 8.4Hz), 8.56 (IH, t, J=5.5Hz), 9.91 - 10.46 (IH, brs), 11.46 (IH, s) . MS: 547.28 (M+H) + Step 10 The title compound was prepared from the compound of Step 9 of Production Example 10 in a manner similar to Step 15 of Production Example 2. 1H-NMR (400MHz, DMSOd6)' δ (ppm) : 2.11 (3H, s), 2.81 (4H, s) , 3.15 - 3.23 (2H, m) , 3.28 - 3.38 (2H, m) , 6.6 - 6.75 (3H, m) / 7 (2H, d, J = 8Hz ) , 7.17 (4H, brs) , 7.62 (IH, t, J = 5.1Hz), 12.07 (IH, s) . MS: 347.2 (M+H)+ free
Production Example 11: Synthesis of N- [4- (2-{2- (acetylamino) - 5- [4- (methylsulfonyl)benzyl] -1, 3-thiazol-4-yl}ethyl)phenyl]-2- { [amino (imino)methyl] amino}acetamide hydrochloride Step 1 3- (4-Mercaptophenyl)propanoic acid (5 g) , K2CO3 (11.4 g) and DMF (30 ml) were combined, and iodomethane (5.12 ml) was added dropwise to the mixture at 0 0C under N2 atmosphere. The reaction mixture was stirred at r.t. for 13 hours, and poured into ice-water. The mixture was extracted with AcOEt. The organic layer was washed with water (twice) and brine, dried over anhydrous MgSO4, and concentrated in vacuo to give methyl 3- [4- (methylthio)phenyl]propanoate (4.19 g) as pale yellow oil. 1H-NMR (CDCl3), δ (PPm) : 2.47 (3H, s) , 2.61 (2H, t, J=8.0Hz), 2.91 (2H, t, J=8.0Hz), 3.67 (3H, s) , 7.12 (2H, d, J=8.5Hz), 7.20 (2H, d, J=8.5Hz) . Step 2
28% Sodium methoxide solution in MeOH (3.67 ml) were added dropwise to the mixture of methyl 3— [4— (methylthio)phenyl]propanoate (4 g) and diethyl oxalate (5.17 ml) at 0 0C with stirring. The reaction mixture was stirred at 65 0C for 30 minutes under reduced pressure. 15% Aqueous H2SO4 (35 ml) was added to the mixture, and the mixture was refluxed for 15 hours. After cooled to r.t., the mixture was extracted with AcOEt. The organic layer was washed with water and brine, dried over anhydrous MgSO4, and concentrated in vacuo. The residual oil was dissolved in EtOH (20 ml), and cone. H2SO4
(0.4 ml) was added dropwise to the solution. The reaction mixture was refluxed for 2 hours. After cooled to r.t., EtOH was removed in vacuo. AcOEt and water were added to the residue, and the mixture was extracted. The organic layer was washed with water and brine, dried over anhydrous MgSO4, and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel with n-hexane / AcOEt (6:1) as an eluent to give ethyl 4- [4- (methylthio)phenyl]-2- oxobutanoate (2.43 g) as a yellow liquid. 1H-NMR (CDCl3), δ (ppm) : 1.35 (3H, t, J=7.0Hz), 2.46 (3H, s) , 2.92 (2H, t, J=7.0Hz), 3.16 (2H, t, J=7.0Hz), 4.31 (2H, q, J=7.0Hz), 7.13 (2H, d, J=8.5Hz), 7.20 (2H, d, J=8.5Hz) . Step 3
To a suspension of copper(II) bromide (6.11 g) in AcOEt (110 ml) was added a solution of ethyl 4-[4- (methylthio)phenyl]-2-oxobutanoate (2.3 g) in 55 ml of CHCl3. The reaction mixture was refluxed for 17 hours, cooled to r.t., and filtered through a short pad of silica gel eluting with AcOEt / n-hexane (1:1) . The solvent was removed in vacuo to give ethyl 3-bromo-4- [4- (methylthio)phenyl]-2-oxobutanoate (2.56 g) as yellow oil.
1H-NMR (CDCl3), δ (PPm) : 1.37 (3H, t, J=7.0Hz), 2.47 (3H, s) , 3.20 (IH, dd, J=14.5, 7.5Hz), 3.49 (IH, dd, J=14.5, 7.5Hz), 4.35 (2H, q, J=7.0Hz), 5.22 (IH, d, J=7.5Hz), 7.17 (2H, d, J=8.5Hz), 7.20 (2H, d, J=8.5Hz) . Step 4
Ethyl 3-bromo-4-[4- (methylthio)phenyl] -2-oxobutanoate (2.4 g) was dissolved in EtOH (40 ml), and then thiourea (1.1 g) was added to the solution. The reaction mixture was refluxed for 1 hour under N2 atmosphere. The cooled reaction mixture was evaporated in vacuo. Saturated NaHCO3 and water were added to the residue, and the mixture was extracted with AcOEt. The organic layer was washed with water and brine, dried over anhydrous MgSO,j, and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel with CHCI3 / MeOH (20:1) as an eluent to give ethyl 2-amino-5- [4- (methylthio)benzyl] -1, 3-thiazole-4-carboxylate (2.01 g) as yellow amorphous. 1H-NMR (DMSO-d6) , δ (ppm) : 1-25 (3H, t, J=7.0Hz), 2.44 (3H, s), 4.20 (2H, q, J=7.0Hz), 4.28 (2H, s) , 7.02 (2H, s) , 7.19 (4H, S) .
MS: 309 (M+H)+ Step 5 Ethyl 2-amino-5- [4- (methylthio)benzyl]-1,3-thiazole-4- carboxylate (1.9 g) was dissolved in CH2Cl2 (38 ml) and pyridine (1.05 ml), and then acetyl chloride (0.482 ml) was added dropwise to the solution at 0 0C under N2 atmosphere. The reaction mixture was stirred at r.t. for 1 hour. The organic solution was washed with IN-HCl, water and brine, dried over anhydrous MgSO4, and concentrated in vacuo. The residual solid was washed with IPE to give ethyl 2- (acetylamino) -5- [4- (methylthio)benzyl]-1, 3-thiazole-4-carboxylate (2.01 g) as an off-white solid. mp. 205-206 0C
1H-NMR (DMSO-de) , δ (ppm) : 1 .28 (3H, t, J=7 . 0Hz) , 2 . 09 ( 3H, s ) , 2 . 45 ( 3H, s ) , 4 .27 (2H, q, J=7 . 0Hz ) , 4 .43 (2H, s ) , 7 .22 ( 4H, s ) , 12 .41 ( IH, s) . MS : 351 (M+H) + Step 6
Ethyl 2- (acetylamino)-5- [4- (methylthio)benzyl]-1, 3- thiazole-4-carboxylate (1.0 g) was dissolved in THF (20 ml), and then lithium borohydride (124 mg) was added portionwise to the solution at 0 °C. The reaction mixture was refluxed for 4.5 hours and the reaction was quenched with MeOH. The mixture was concentrated in vacuo, and purified by flash column chromatography over silica gel with CHCl3 / MeOH (20:1) as an eluent. The residual off-white solid (548.5 mg) was dissolved in MeOH (2 ml) and CHCl3 (20 ml) . Then, manganase (IV) oxide (2.48 g) was added to the solution under N2 atmosphere. The reaction mixture was stirred at r.t. for 12 hours, and filtered through a celite pad. The filtrate was concentrated in vacuo. The residue was purified by flash column chromatography over silica gel with CHCI3 / MeOH (20:1) as an eluent to give N-{4-formyl-5- [4- (methylthio)benzyl]-1,3- thiazol-2-yl}acetamide (500.1 mg) as a yellow wax. 1H-NMR (DMSO-de) , δ (ppm) : 2.12 (3H, s) , 2.45 (3H, s) , 4.48 (2H, s), 7.23 (4H, s) , 10.03 (IH, s) , 12.33 (IH, s) . MS: 307 (M+H)+ Step 7
1- (Bromomethyl) -4-nitrobenzene (564 mg) , triphenylphosphine (685 mg) and DMF (9 ml) were combined under N2 atmosphere. The reaction mixture was stirred at r.t. for 2 hours. Then, potassium tert-butoxide (345 mg) and N-{4-formyl- 5- [4- (methylthio)benzyl]-1, 3-thiazol-2-yl}acetamide (470.5 mg) were added to the mixture, and the mixture was stirred at r.t. for 2 hours. The reaction mixture was poured into ice-water, and extracted with AcOEt. The organic layer was washed with water and brine, dried over anhydrous MgSO4, and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel with CHCl3 / AcOEt (1:1) as an eluent to give a mixture of N-{5- [4- (methylthio)benzyl]-4- [ (E) -2- (4-nitrophenyl)vinyl]-1, 3-thiazol-2-yl}acetamide and N- {5- [4- (methylthio)benzyl] -4- [ (Z) -2- (4-nitrophenyl)vinyl] -1, 3- thiazol-2-yl}acetamide (E : Z = 1 : 2) (671 mg) as yellow amorphous. 1H-NMR (DMSO-de), δ (ppm) : 2.08 (3Hx2/3, s) , 2.12 (3Hxl/3, s) , 2.44 (3H, s), 4.04 (2Hx2/3, s) , 4.30 (2Hxl/3, s) , 6.71 (1HX2/3, d, J=12.5Hz), 6.84 (1HX2/3, d, J=12.5Hz), 7.18 (4Hx2/3, s), 7.23 (4Hxl/3, s) , 7.24 (lHxl/3, d, J=15.5Hz), 7.40 (lHxl/3, d, J=15.5Hz), 7.65 (2Hx2/3, d, J=9.0Hz), 7.92 (2Hxl/3, d, J=9.0Hz), 8.12 (2Hx2/3, d, J=9.0Hz), 8.22 (2Hxl/3, d, J=9.0Hz), 11.85 (1HX2/3, brs), 12.16 (lHxl/3, brs) . MS: 426 (M+H)+ Step 8 Potassium peroxymonosulfate (1.41 g) was suspended in water (4 ml) and THF (4 ml), and then a mixture of N-{5-[4- (methylthio)benzyl]-4- [ (E) -2- (4-nitrophenyl)vinyl] -1,3- thiazol-2-yl}acetamide and N-{5- [4- (methylthio)benzyl]-4- [ (Z) - 2- (4-nitrophenyl)vinyl]-l, 3-thiazol-2-yl}acetamide (E : Z = 1 : 2) (650 mg) in THF (9 ml) was added dropwise to the suspension at 0 0C. The reaction mixture was stirred at r.t. for 1 hour, and then water was added to the suspension. The mixture was extracted with AcOEt. The organic layer was washed with water and brine, dried over anhydrous MgSO4, and concentrated in vacuo to give a mixture of N-{5-[4-
(methylsulfonyl)benzyl]-4- [ (E) -2- (4-nitrophenyl) vinyl]-1, 3- thiazol-2-yl}acetamide and N-{5- [4- (methylsulfonyl)benzyl]-4- [ (Z) -2- (4-nitrophenyl) vinyl]-1,3-thiazol-2-yl}acetamide (E : Z = 1 : 2) (693.3 mg) as yellow amorphous. Z : E = 2 : 1
1H-NMR (DMSO-d6) , δ (ppm) : 2.09 (3Hx2/3, s) , 2.13 (3Hxl/3, s) , 3.18 (3H, s), 4.24 (2Hx2/3, s) , 4.49 (2Hxl/3, s) , 6.73 (1HX2/3, d, J=12.5Hz), 6.86 (1HX2/3, d, J=12.5Hz), 7.33 (lHxl/3, d, J=15.5Hz), 7.41-7.97 (5/3H, m) , 7.48 (2Hx2/3, d, J=9.0Hz), 7.55 (2Hxl/3, d, J=9.0Hz), 7.65 (2Hx2/3, d, J=9.0Hz), 7.85 (2Hx2/3, d, J=9.0Hz), 8.14 (2Hx2/3, d, J=9.0Hz), 8.22 (2Hxl/3, d, J=9.0Hz), 11.90 (1HX2/3, s) , 12.22 (lHxl/3, s) . MS: 458 (M+H)+ Step 9
A mixture of N-{5- [4- (methylsulfonyl)benzyl] -4- [ (E) -2- (4- nitrophenyl)vinyl] -1, 3-thiazol-2-yl}acetamide and N-{5-[4- (methylsulfonyl)benzyl]-4- [ (Z) -2- (4-nitrophenyl)vinyl]-1,3- thiazol-2-yl}acetamide (E : Z = 1 : 2) (380 mg) , 10% palladium on carbon (380 mg) , MeOH (3.5 ml), THF (3.5 ml) and AcOH (0.5 ml) were combined. The reaction mixture was stirred under 3 atm H2 at r.t. for 3 hours, and filtered through a celite pad. The filtrate was concentrated in vacuo. IN-NaOH was added to the residue, and the mixture was extracted with AcOEt. The organic layer was washed with water and brine, dried over anhydrous MgSO1J, and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel with CHCl3 / MeOH (30:l→10:l) as an eluent to give N-{4-[2-(4- aminophenyl) ethyl] -5- [4- (methylsulfonyl)benzyl]-1,3-thiazol-2- yl}acetamide (161.8 mg) as off-white amorphous. 1H-NMR (DMSO-d6), δ (ppm) : 2.08 (3H, s) , 2.58-2.87 (4H, m) , 3.18 (3H, s), 3.98 (2H, s) , 4.85 (2H, s) , 6.46 (2H, d, J=8.5Hz), 6.77 (2H, d, J=8.5Hz), 7.27 (2H, d, J=8.5Hz), 7.82 (2H, d, J=8.5Hz), 12.02 (IH, s) . MS: 430 (M+H)+ Step 10
A mixture of N-{4- [2- (4-aminophenyl) ethyl]-5- [4- (methylsulfonyl)benzyl]-1, 3-thiazol-2-yl}acetamide (73.3 mg) , [ (tert-butoxycarbonyl) amino]acetic acid (29.9 mg) , 1- hydroxybenzotriazole (25.4 mg) and l-ethyl-3- (3- dimethylaminopropyl) carbodiimide hydrochloride (34.3 mg) in DMF (1 ml) was stirred at r.t. for 7 hours. The reaction mixture was poured into saturated NaHCO3, and extracted with AcOEt. The organic layer was washed with water and brine, dried over anhydrous MgSO4, and concentrated in vacuo. The residue was purified by preparative silica gel chromatography with CHCl3 / MeOH (20:1) as an eluent to give tert-butyl (2- { [4- (2-{2- (acetylamino) -5- [4- (methylsulfonyl)benzyl] -1, 3- thiazol-4-yl}ethyl)phenyl] amino}-2-oxoethyl) carbamate (75 mg) as an off-white solid. Step 11 tert-Butyl (2-{ [4- (2-{2- (acetylamino) -5- [4-
(methy1sulfonyl)benzyl] -1, 3-thiazol-4-yl}ethyl)phenyl]amino}- 2-oxoethyl) carbamate (61.2 mg) and 4N HCl in 1,4-dioxane solution (1 ml) were combined under N2 atmosphere. The reaction mixture was stirred at r.t. for 1 hour. The solvent was removed in vacuo. The residue was solidified with AcOEt to give N- [4- (2-{2- (acetylamino) -5- [4- (methylsulfonyl)benzyl]- 1, 3-thiazol-4-yl}ethyl)phenyl] -2-aminoacetamide hydrochloride (56.2 mg) as an off-white solid. Step 12
N- [4- (2-{2- (Acetylamino) -5- [4- (methylsulfonyl)benzyl] - 1, 3-thiazol-4-yl}ethyl)phenyl] -2-aminoacetamide hydrochloride (30 mg) , N,N'-bis (tert-butoxycarbonyl) -IH-pyrazole-l- carboxamidine (17.8 mg) , N,N-diisopropylethylamine (20.0 μl) , THF (0.5 ml) and DMF (0.1 ml) were combined under N2 atmosphere. The reaction mixture was stirred at 15 0C for 14 hr, and concentrated in vacuo.' The residue was purified by preparative silica gel thin-layer chromatography with chloroform / methanol (20:1) as an eluent to give di-tert- butyl { (Z)- [ (2-{ [4- (2-{2- (acetylamino) -5- [4-
(methylsulfonyl)benzyl]-l, 3-thiazol-4-yl}ethyl)phenyl] amino}- 2-oxoethyl) amino]methylidene}biscarbamate as a colorless solid (17.3 mg) . 1H-NMR (200MHz, CDCl3) δ (ppm) : 1.50 (18H, s) , 2.24 (3H, s) , 2.74 - 2.94 (4H, m) , 3.05 (3H, s) , 3.85 (2H, s) , 4.21 (2H, d, J = 5.7Hz), 6.9 (2H, d, J = 8.3Hz), 7.08 (2H, d, J = 8.3Hz), 7.35 (2H, d, J = 8.4Hz), 7.75 (2H, d, J = 8.2Hz), 8.99 (IH, t, J = 5.5Hz), 9.32 - 9.48 (IH, brs) , 9.53 (IH, s) , 11.35 (IH, s) . MS : 729 . 29 (M+H) + Step 13 The title compound was prepared from the compound of Step 12 of Production Example 11 in a manner similar to Step 15 of Production Example 2.
1H-NMR (400MHz, DMSOd6) δ (ppm) : 2.09 (3H, s) , 2.84 (4Hx3/4, s), 2.88 (4Hxl/4, s) , 3.17 (3Hx3/4, s) , 3.19 (3Hxl/4, s) , 3.98 - 4.07 (4H, m) , 7.02 - 7.64 (HH, m) , 7.78 (2Hx3/4, d, J = 8.4Hz), 7.84 (2Hxl/4, d, J = 8.4Hz), 10.18 (IH, s) , 12.05 (IH, s) .
MS: 529.2 (M+H) + free Production Example 12: Synthesis of (3R) -1- ( {2- (acetylamino) - 4- [2- (4-{ [amino (imino)methyl]amino}phenyl) ethyl] -1, 3-thiazol- 5-yl}methyl) -N,N-dimethyl-3-pyrrolidinecarboxamide dihydrochloride Step 1 To a solution of N-{4- [ (Z) -2- (4-nitrophenyl)vinyl] - 1, 3-thiazol-2-yl}acetamide (293 mg) in acetic acid (1.8 ml) were added methyl (3R) -3-pyrrolidinecarboxylate hydrochloride (201 mg) and paraformaldehyde (36.5 mg) , and the mixture was stirred at 100 0C (bath temp.) for 2 hr. The solvent was removed in vacuo, the residue was adjusted to pH=9 with saturated aq. NaHCO3, extracted with AcOEt. The organic layer was washed with brine, dried over MgSO4 and evaporated to give methyl (3R) -1- ( {2- (acetylamino) -4- [ (Z) -2- (4-nitrophenyl) vinyl] -1, 3-thiazol-5-yl}methyl) -3- pyrrolidinecarboxylate as orange foam (402.2 mg) , that was used as crude in the next reaction. MS: 431.18 (M+H)+ Step 2
Methyl (3R)-1- ({2- (acetylamino)-4- [ (Z)-2- (4- nitrophenyl)vinyl] -1, 3-thiazol-5-yl}methyl) -3- pyrrolidinecarboxylate (400 mg) , MeOH (7 ml), THF (7 ml) and then 10 % Pd/C (50 % wet) (810 mg) were combined under N2 atmosphere. The mixture was stirred at 15 °C for 10 min under H2 atmosphere (3 atm) . The reaction mixture was filtered through a celite pad, and the filtrate was concentrated in vacuo to give yellow foam (367.1 mg, 101.3 %, MS: 403.20 (M+H)+) .
To a solution of the yellow foam (367.1 mg) in THF (4.5 ml) was added N,N'-bis (tert-butoxycarbonyl) -lH-pyrazole-1- carboxamidine (419 mg) , and the mixture was stirred for 62 hr at 15 0C. Volatiles were evaporated, and the residue (895.9 mg) was purified by flash column chromatography over silica gel with CHCl3 : AcOEt (100:0-100:2) as an eluent to give methyl (3R)-I- t (2- (acetylamino) -4-{2- [4- ({ (Z) -[ (tert- butoxycarbonyl) amino] [ (tert-butoxycarbonyl) imino]methyl}- amino)phenyl] ethyl}-l, 3-thiazol-5-yl)methyl] -3- pyrrolidinecarboxylate (237.8 mg) as pale yellow foam.
1H-NMR (200MHz, CDCl3) δ (ppm) : 1.5 (9H, s) , 1.53 (9H, s) , 1.98 - 2.14 (2H, m) , 2.22 (3H, s) , 2.39 - 2.76 (3H, m) , 2.78 - 3.11 (6H, m) , 3.55 (2H, s) , 3.68 (3H, s) , 7.07 (2H, d, J = 8.5Hz), 7.45 (2H, d, J = 8.5Hz), 9.06 (IH, brs) , 10.24 (IH, s) , 11.64 (IH, s) .
MS: 645.3 (M+H)+, 667.3 (M+Na) + Step 3
Methyl (3R)-l-[ (2- (acetylamino) -4-{2- [4- ({ (Z) -[ (tert- butoxycarbonyl) amino] [ (tert-butoxycarbonyl) imino]methyl} amino)phenyl] ethyl}-!, 3-thiazol-5-yl)methyl] -3- pyrrolidinecarboxylate (232.2 mg) , IN-NaOH (0.9 ml) and dioxane (3 ml) were combined at 0 °C, and the mixture was stirred at 20 0C for 2 hr. To the mixture was added IN-HCl (0.9 ml), and the solvent was evaporated in vacuo. To the residue was added CHCl3. The insoluble salt was removed by filtration, and the filtrate was concentrated in vacuo to give (3R)-l-[ (2- (acetylamino) -4-{2- [4- ({ (Z) -[ (tert- butoxycarbonyl) amino] - [ (tert- butoxycarbonyl) imino]methyl}amino)phenyl] ethyl}-l, 3-thiazol- 5-yl)methyl] -3-pyrrolidinecarboxylic acid (175.5 mg) as a white solid, that was used as crude in the next reaction. MS: 631.29 (M+H)+ Step 4
To a solution of (3R) -1- [ (2- (acetylamino) -4-{2- [4- • ({ (Z) - [ (tert-butoxycarbonyl) amino] [ (tert-butoxycarbonyl) imino]methyl}amino)phenyl] ethyl}-l, 3-thiazol-5-yl)methyl] -3- pyrrolidinecarboxylic acid (60 mg) in 0.5 ml of dichloromethane were added methylamine hydrochloride (10.1 mg) , 1-hydroxybenzotriazole hydrate (HOBt, 19.3 mg) and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI, 52.118 μl) , and then the mixture was stirred for 14 hr at 20 0C. The reaction mixture was diluted with 4ml of dichloromethane and washed with water. The organic layer was dried over diatomaceous earth and evaporated under vaccum to give crude pale yellow oil. The crude oil was purified by preparative silica gel thin-layer chromatography with chloroform / methanol (15:1) as an eluent to give di-tert- butyl { (Z) -[ (4-{2- [2- (acetylamino) -5- ({ (3R) -3- [ (dimethylamino) carbonyl] -l-pyrrolidinyl}methyl) -1, 3- thiazol-4-yl] ethyl}phenyl) amino]methylidene}biscarbamate (45.4 mg) as a white solid.
1H-NMR (400MHz,. CDCl3) δ (ppm) : 1.5 (9H, s) , 1.54 (9H, s) , 1.96 - 2.11 (2H, m) , 2.22 (3H, s) , 2.31 - 2.42 (IH, m) , 2.44 - 2.53 (IH, m) , 2.82 - 2.92 (5H, m) , 2.94 (3H, s) , 3.01 (3H, s), 3.01 - 3.08 (IH, m) , 3.15 - 3.27 (IH, m) , 3.57 (2H, s) , 7.08 (2H, d, J = 8.4Hz), 7.46 (2H, d, J = 8.4Hz), 8.88 (IH, brs), 10.24 (IH, s) , 11.63 (IH, s) . MS: 659.3 (M+H)+, 680.3 (M+Na)+ Step 5
The title comound was prepared from the compound of Step 4 of Production Example 12 in a manner similar to Step 15 of Production Example 2.
1H-NMR (400MHz, DMSOd6) δ (ppm) : 1.72 - 3.74 (2OH, m) , 4.42 - 4.57 (2H, m), 7.12 - 7.18 (2H, m) , 7.27 - 7.35 (2H, m) , 7.43 (4H, brs), 9.91 (1HX3/5, m) , 9.97 (1HX2/5, m) , 10.26 (1HX2/5, m) , 11.01 (1HX3/5, m) , 12.32 (1HX3/5, m) , 12.34 (1HX2/5, m) . MS: 458.4 (M+H)+, 480.2 (M+Na) + free
Production Example 13: Synthesis of (3R) -1- ( {2- (acetylamino) - 4- [2- (4-{ [amino (imino)methyl]amino}phenyl) ethyl] -1, 3-thiazol- 5-yl}methyl) -N-methyl-3-pyrrolidinecarboxamide dihydrochloride Step 1
Di-tert-butyl { (Z)- [ (4-{2- [2- (acetylamino) -5- ({ (3R) -3- [ (methylamino) carbonyl] -1-pyrrolidinyl}methyl) -1, 3-thiazol- 4-yl] ethyl}phenyl) amino]methylidene}biscarbamate was prepared from the compound of Step 3 of Production Example 12 in a manner similar to Step 4 of Production Example 12.
1H-NMR (400MHz, CDCl3) δ (ppm) : 1.5 (9H, s) , 1.54 (9H, s) , 1.88 - 1.99 (IH, m) , 2.09 - 2.21 (IH, m) , 2.24 (3H, s) , 2.25 - 2.37 (2H, m), 2.78 (3H, d, J = 4.7Hz), 2.79 - 2.37 (7H, m) , 3.52 (IH, d, J = 13.9Hz), 3.58 (IH, d, J = 14.2Hz), 6.75 (IH, d, J = 4.4Hz), 7.06 (2H, d, J = 8.4Hz), 7.45 (2H, d, J = 8.4Hz), 8.91 (IH, brs), 10.24 (IH, s) , 11.63 (IH, s) . MS: 644.2 (M+H)+, 666.3 (M+Na)+ Step 2
The title compound was prepared from the compound of Step 1 of Production Example 13 in a manner similar to Step 15 of Production Example 2. 1H-NMR (400MHz, DMSO-d6) : 1.79 - 3.74 (17H, m) , 4.41 - 4.57 (2H, m), 7.11 - 7.18 (2H, m) , 7.27 - 7.35 (2H, m) , 7.42 (4H, brs), 8.13 - 8.25 (IH, m) , 9.88 (1HX2/3, s) , 9.95 (lHxl/3, s) , 10.34 (lHxl/3, brs), 10.99 (1HX2/3, brs), 12.32 (1HX2/3, s) , 12.33 (lHxl/3, s) .
MS: 444.2 (M+H)+, 466.1 (M+Na) + free
Production Example 14: Synthesis of (3S) -1- ( {2- (acetylamino) - 4- [2- (4-{ [amino (imino)methyl]amino}phenyl) ethyl] -1, 3-thiazol- 5-yl}methyl) -N,N-dimethyl-3-pyrrolidinecarboxamide dihydrochloride Step 1
Methyl (3S) -1- ( {2- (acetylamino) -4- [ (Z) -2- (4- nitrophenyl) vinyl] -1, 3-thiazol-5-yl}methyl) -3- pyrrolidinecarboxylate was prepared from N-{4- [ (Z) -2- (4- nitrophenyl) vinyl] -1, 3-thiazol-2-yl}acetamide in a manner similar to Step 1 of Production Example 12. MS: 431.16 (M+H) + Step 2
Methyl (3S)-l-[ (2- (acetylamino) -4-{2- [4- ({ (Z) -[ (tert- butoxycarbonyl) amino] [ (tert-butoxycarbonyl) imino]methyl}- amino)phenyl] ethyl}-!, 3-thiazol-5-yl)methyl] -3- pyrrolidinecarboxylate was prepared from the compound of Step 1 of Production Example 14 in a manner similar to Step 2 of Production Example 12. 1H-NMR (200MHz, CDCl3) 6 (ppm) : 1.5 (9H, s) , 1.53 (9H, s) , 1.99 - 2.14 (2H, m) , 2.22 (3H, s) , 2.38 - 2.75 (3H, m) , 2.79 - 3.07 (6H, m), 3.53 (2H, s) , 3.68 (3H, s) , 7.07 (2H, d, J = 8.5Hz), 7.46 (2H, d, J = 8.5Hz), 9.51 (IH, brs), 10.24 (IH, s) , 11.64 (IH, s) . MS: 645.3 (M+H)+, 667.3 (M+Na)+ Step 3
(3S)-l-[ (2- (Acetylamino) -4-{2- [4- ({ (Z) -[ (tert- butoxycarbonyl) amino] [ (tert-butoxycarbonyl) imino]methyl} amino)phenyl] ethyl}-l, 3-thiazol-5-yl)methyl]-3- pyrrolidinecarboxylic acid was prepared from the compound of
Step 2 of Production Example 14 in a manner similar to Step 3 of Production Example 12.
MS: 631.29 (M+H)+
Step 4
Di-tert-butyl { (Z) -[ (4-{2- [2- (acetylamino) -5- ( { (3S) -3-
[ (dimethylamino) carbonyl] -l-pyrrolidinyl}methyl) -1, 3- thiazol-4-yl] ethyl}phenyl) amino]methylidene}biscarbamate was prepared from the compound of Step 3 of Production Example 14 in a manner similar to Step 4 of Production Example 12.
1H-NMR (400MHz, CDCl3) δ (ppm) : 1.5 (9H, s), 1.54 (9H, s),
1.96 - 2.12 (2H, m) , 2.22 (3H, s) , 2.31 - 2.41 (IH, m) , 2.44 - 2.52 (IH, m) , 2.82 - 2.92 (5H, m) , 2.94 (3H, s) , 3.01 (3H, s), 3.01 - 3.08 (IH, m) , 3.15 - 3.27 (IH, m) , 3.57 (2H, s) ,
7.08 (2H, d, J = 8.4Hz), 7.46- (2H, d, J = 8.8Hz), 8.87 (IH, brs), 10.24 (IH, s) , 11.63 (IH, s) .
MS: 658.3 (M+H) +, 680.3 (M+Na)+ Step 5
The title compound was prepared from the compound of Step
4 of Production Example 14 in a manner similar to Step 15 of
Production Example 2.
1H-NMR (400MHz, DMSCHd6) δ (ppm) : 1.74 - 3.73 (2OH, m) , 4.42 - 4.58 (2H, m) , 7.12 - 7.19 (2H, m) , 7.27 - 7.35 (2H, m) , 7.42
(4H, brs), 9.87 (1HX4/7, s) , 9.93 (1HX3/7, s), 10.22 (1HX3/7, brs ) , 10. 94 ( 1HX4/ 7 , brs ) , 12.32 ( 1HX4/7 , s ) , 12 .34 ( 1HX3/7 , s) ."
MS: 458.4 (M+H)+, 480.2 (M+Na) + free Production Example 15: Synthesis of (3S) -1- ( {2- (acetylamino) -
4- [2- (4-{ [amino (imino)methyl] amino}phenyl) ethyl] -1,3-thiazol-
5-yl}methyl) -N-methyl-3-pyrrolidinecarboxamide dihydrochloride Step 1
Di-tert-butyl { (Z) -[ (4-{2-[2- (acetylamino) -5- ({ (3S) -3-
[ (methylamino) carbonyl] -1-pyrrolidinyl}methyl) -1, 3-thiazol-
4-yl] ethyl}phenyl) amino]methylidene}biscarbamate was prepared from the compound of Step 3 of Production Example 14 in a manner similar to Step 4 of Production Example 12.
1H-NMR (400MHz, CDCl3) δ (ppm) : 1.5 (9H, s) , 1.54 (9H, s) , 1.88
- 1.99 (IH, m) , 2.09 - 2.21 (IH, m) , 2.24 (3H, s) , 2.26 - 2.37
(2H, m), 2.76 - 2.94 (1OH, m) , 3.52 (IH, d, J = 13.9Hz), 3.58 (IH, d, J = 13.9Hz), 6.76 (IH, d, J = 4.4Hz), 7.06 (2H, d, J =
8.4Hz), 7.45 (2H, d, J = 8.4Hz), 8.91 (IH, brs) , 10.25 (IH, s) , 11.64 (IH, s) .
MS: 644.3 (M+H)+, 666.3 (MH-Na) +
Step 2 The title compound was prepared from the compound of Step
1 of Production Example 15 in a manner similar to Step 15 of
Production Example 2.
1H-NMR (400MHz, DMSCHd6) δ (ppm) : 1.79 - 3.76 (17H, m) , 4.41 -
4.57 (2H, m), 7.11 - 7.18 (2H, m) , 7.27 - 7.35 (2H, m) , 7.43 (4H, brs), 8.1 - 8.3 (IH, m) , 9.9 (1HX2/3, s) , 9.98 (lHxl/3, s), 10.37 (lHxl/3, brs), 11.04 (1HX2/3, brs), 12.32 (1HX2/3, s) , 12.33 (lHxl/3, s) .
MS: 444.2 (M+H)+, 467.2 (M+Na) + free
Production Example 16: Synthesis of N- ( {2- (acetylamino) -4-[2- (4-{ [amino (imino)methyl] amino}phenyl) ethyl]-l, 3-thiazol-5- yl}methyl) -N-methyl-4- (methylsulfonyl)benzamide hydrochloride
Step 1
To a solution of N-{4- [ (Z) -2- (4-nitrophenyl)vinyl] -
1, 3-thiazol-2-yl}acetamide (1.0 g) in acetic acid (10 ml) were added N-methylamine hydrochloride (2.33 g) and paraformaldehyde (124 mg) , and the mixture was stirred at
100 0C (bath temp.) for 1 hr. The solvent was removed in vacuo, the residue was adjusted to pH=9 with aq. sat. NaHCO3, the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over MgSCU and evaporated to give N-{5- f (methylamino)methyl] -4- [ (Z) -2- (4- nitrophenyl) vinyl] -1, 3-thiazol-2-yl}acetamide as orange foam (0.92 g) , that was used as crude in the next reaction. MS: 333.29 (M+H)+ Step 2
To a solution of N-{5- [ (methylamino)methyl]-4-[ (Z) -2- (4- nitrophenyl)vinyl] -1, 3-thiazol-2-yl}acetamide (100 mg) in 1 ml of dichloromethane were added 4- (methylsulfonyl)benzoic acid (60.2 mg) , HOBt (61 mg) and EDCI HCl (86.5 mg) , and then the mixture was stirred for 3 hr at 20 0C. The reaction mixture was diluted with 4 ml of dichloromethane and washed with water. The organic layer was dried over diatomaceous earth and evaporated under vaccum to give crude pale yellow oil (144.3 mg, 93.2 %) . The crude oil was purified by preparative silica gel thin-layer chromatography with chloroform / methanol (15:1) as an eluent to give N- ({2- (acetylamino) -4- [ (Z) -2- (4- nitrophenyl)vinyl] -1, 3-thiazol-5-yl}methyl) -N-methyl-4- (methylsulfonyl)benzamide (144.3 mg) .
1H-NMR (200MHz, CDCl3) δ (ppm) : 2.11 (3H, s) , 3.00 (3H, s) , 3.08 (3H, s), 4.79 (2H, s) , 6.53 - 6.99 (2H, m) , 7.3 - 8.28 (8H, m) , 10.06 (IH, brs) . MS: 537.1 (M+Na)+ Step 3
N- ({2- (Acetylamino) -4- [ (Z) -2- (4-nitrophenyl)vinyl] -1, 3- thiazol-5-yl}methyl) -N-methyl-4- (methylsulfonyl)benzamide (131.9 mg) , MeOH (3.5 ml), THF (3.5 ml), AcOH (0.5 ml) and then 10 % Pd/C (50 % wet) (256 mg) were combined under N2 atmosphere. The mixture was stirred at 20 0C for 30 min under H2 atmosphere (3 atm) . The reaction mixture was filtered through a celite pad, and the filtrate was concentrated in vacuo. The residue was adjusted to pH=9 with saturated aq. NaHCO3, and the mixture was extracted with chroloform. The organic layer was washed with brine, dried over MgSO4, and concentrated in vacuo to give N- ({2- (acetylamino) -4- [2- (4-aminophenyl) ethyl] -1, 3-thiazol-5- yl}methyl) -N-methyl-4- (methylsulfonyl)benzamide as colorless oil, that was used as crude in the next reaction. MS: 487.15 (M+H)+ Step 4 To a solution of N- ( {2- (acetylamino) -4- [2- (4- aminophenyl) ethyl] -1, 3-thiazol-5-yl}methyl) -N-methyl-4- (methylsulfonyl)benzamide (103.6 mg) in THF (0.2 ml) was added N,N'-bis (tert-butoxycarbonyl) -lH-pyrazole-1- carboxamidine (99.1 mg) , and the mixture was stirred for 14 hr at 20 0C. Volatiles were evaporated in vacuo and the residue was purified by preparative silica gel thin-layer chromatography with chloroform / methanol (15:1) as an eluent to give di-tert-butyl { (E) -[ (4-{2- [2- (acetylamino) -5- ( {methyl [4- (methylsulfonyl)benzoyl] amino}methyl) -1, 3- thiazol-4-yl] ethyljphenyl) amino]methylidenejbiscarbamate (52.8 mg) .
1H-NMR (400MHz, CDCl3) δ (ppm) : 1.48 (9H, s) , 1.53 (9H, s) , 2.25 (3H, s), 2.55 - 3.02 (7H, m) , 3.06 (3H, s) , 4.2 (2Hx2/7, brs), 4.61 (2Hx5/7, brs) , 6.85 - 6.99 (2Hx2/7, m) , 7.09 (2Hx5/7, d, J = 7.3Hz), 7.37 - 7.51 (2H, m) , 7.53 - 7.7 (2H, m) , 7.99 (2H, d, J = 7.7Hz) , 8.96 (IH, s), 10.24 (IH, s) ,• 11.62 (IH, s) . MS: 729.24 (M+H) + Step 5 The title compound was prepared from the compound of Step 4 of Production Example 16 in a manner similar to Step 15 of Production Example 2.
1H-NMR (400MHz, DMSO-d6) δ (ppm) : 2.13 (3H, s), 2.7 - 2.85 (3H, m) , 2.94 (4H, s) , 3.26 (3H, s) , 4.4 (2Hxl/4, s) , 4.63 (2Hx3/4, s), 7.14 (2H+2Hxl/4, d, J = 8.1Hz), 7.27 (2Hx3/4, d, J = 8Hz), 7.34 (4H, brs), 7.62 (2H, d, J = 8Hz), 7.99 (2H, d, J = 8Hz),
9.68 (IH, s) , 12.13 (IH, s) .
MS: 529.2 (M+H)+, 551.2 (M+Na) + Free
Production Example 17: Synthesis of N- ({2- (acetylamino) -4- [2- (4-{ [amino (imino)methyl]amino}phenyl) ethyl] -1, 3-thiazol-5- yljmethyl) -N,N' ,N'-trimethylterephthalamide hydrochloride
Step 1
N- ({2- (Acetylamino) -4- [ (Z) -2- (4-nitrophenyl)vinyl] -
1, 3-thiazol-5-yl}methyl) -N,N' ,N'-trimethylterephthalamide was prepared from the compound of Step 1 of Production Example 16 in a manner similar to Step 2 of Production Example 16.
1H-NMR (200MHz, CDCl3) δ (ppm) : 2.14 (3H, s) , 2.97 (3H, s) ,
3.00 (3H, s), 3.12 (3H, s) , 4.75 (2H, brs), 6.55 - 6.97 (2H, m) , 7.3 - 8.29 (8H, m) , 10.17 (IH, bs) .
MS: 508.0 (M+H)+, 530.2 (M+Na)+ Step 2
N- ({2- (Acetylamino) -4- [2- (4-aminophenyl) ethyl]-1,3-
•thiazol-5-yl}methyl) -N,N' ,N'-trimethylterephthalamide was prepared from the compound of Step 1 of Production Example 17 in a manner similar to Step 3 of Production Example 16. MS: 480.22 (M+H)+
Step 3
Di-tert-butyl [ (Z)- ({4- [2- (2- (acetylamino) -5-{ [{4-
[ (dimethylamino) carbonyl]benzoyl} (methyl) amino]methyl}-l, 3- thiazol-4-yl) ethyl]phenyl}amino)methylidene]biscarbamate was prepared from the compound of Step 2 of Production Example 17 in a manner similar to Step 4 of Production Example 16.
1H-NMR (400MHz, CDCl3) δ (ppm) : 1.49 (9H, s) , 1.53 (9H, s) , 2.27 (3H, s), 2.6 - 2.88 (4H, m) , 2.95 (6H, s), 3.12 (3H, s), 4.16 - 4.68 (2H, m) , 6.89 - 7.18 (2H, m) , 7.44 (6H, s) ,
10.27 (IH, s), 11.62 (IH, s) .
MS: 722.3 (M+H)+, 744.2 (M+Na)+ Step 4
The title compound was prepared from the compound of
Step 3 of Production Example 17 in a manner similar to Step 15 of Production Example 2.
1H-NMR (400MHz, DMSO-d6) δ (ppm) : 2.13 (3H, s) , 2.76 (3H, s) , 2.84 - 3.06 (1OH, m) , 4.34 - 4.7 (2H, m) , 7.03 - 7.56 (12H, m) , 9.76 (IH, s), 12.12 (IH, s) .
MS: 522.24 (M+H)+ Free
Production Example 18: Synthesis of 4-acetyl-N- ( {2-
(acetylamino) -4- [2- (4-{ [amino (imino)methyl]amino}phenyl) - ethyl] -1, 3-thiazol-5-yl}methyl) -N-methylbenzamide hydrochloride
Step 1
4-Acetyl-N- ({2- (acetylamino) -4- [ (Z) -2- (4- nitrophenyl) vinyl] -1, 3-thiazol-5-yl}methyl) -N- methylbenzamide was prepared from the compound of Step 1 of
Production Example 16 in a manner similar to Step 2 of
Production Example 16.
1H-NMR (200MHz, CDCl3) δ (ppm) : 2.16 (3H, s) , 2.63 (3H, s) ,
2.89 (3H, s), 4.78 (2H, brs) , 6.58 - 6.98 (2H, m) , 7.32 - 8.32 (8H, m) , 10.03 (IH, brs) .
MS: 479.2 (M+H)+, 501.1 (M+Na)+
Step 2
4-Acetyl-N- ({2- (acetylamino) -4- [2- (4-aminophenyl) ethyl] -
1, 3-thiazol-5-yl}methyl)-N-methylbenzamide was prepared from the compound of Step 1 of Production Example 18 in a manner similar to Step 3 of Production Example 16.
MS: 451.17 (M+H)+ Step 3
Di-tert-butyl [ (E)- ({4- [2- (2- (acetylamino) -5-{ [ (4- acetylbenzoyl) (methyl) amino]methyl}-l, 3-thiazol-4- yl) ethyl]phenyl}amino)methylidene]biscarbamate was prepared from the compound of Step 2 of Production Example 18 in a manner similar to Step 4 of Production Example 16. 1H-NMR (200MHz, CDCl3) δ (ppm) : 1.49 (9H, s) , 1.53 (9H, s) , 2.22 (3H, s), 2.62 (3H, s) , 2.64 - 3.12 (7H, m) , 4.05 - 4.77 (2H, m) , 6.11 - 7.18 (2H, m) , 7.31 - 7.65 (4H, m) , 7.98 (2H, d, J = 8.0Hz), 10.23 (IH, s) , 11.62 (IH, s) . MS: 693.1 (M+H)+, 715.3 (M+Na)+ Step 4
The title comound was prepared from the compound of Step 3 of Production Example 18 in a manner similar to Step 15 of Production Example 2.
1H-NMR (400MHz, CD3OD) δ (ppm) : 2.29 (3H, s) , 2.62 (3H, s) , 2.86 (3H, s), 2.96 - 3.18 (4H, m) , 4.44 - 4.65 (2H, m) , 7.02 - 8.19 (9H, m) . MS: 493.17 (M+H)+ Free Production Example 19: Synthesis of N- ( {2- (acetylamino) -4- [2- (4-{ [amino (imino)methyl] amino}phenyl) ethyl] -1, 3-thiazol-5- yl}methyl) -N-methyl-4-nitrobenzamide hydrochloride Step 1
To a solution of N-{5- [ (methylamino)methyl] -4- [ (Z) -2- (4-nitrophenyl) vinyl] -1, 3-thiazol-2-yllacetamide (100 mg) in dichloromethane (1.5 ml) were added N,N- diisopropylethylamine (0.177 ml) and trifluoroacetic anhydride (0.127 ml) at 0 0C, and the mixture was stirred for 2 hours at same temperature. To the reaction mixture was added aq. saturated NaHCO3 (30 ml), and the mixture was extracted with dichloromethane (30 mlx3), the extract was washed with brine, drided over MgSO4 and evaporated in vacuo to give N- ( {2- (acetylamino) -4- [ (Z) -2- (4-nitrophenyl) vinyl] - 1, 3-thiazol-5-yl}methyl) -2,2, 2-trifluoro-N-methylacetamide as pale yellow foam (160.4 mg) , that was used as crude in the next reaction. MS: 429.06 (M+H)+ Step 2
Di-tert-butyl [ (E) - ( {4- [2- (2- (acetylamino) -5- { [methyl (trifluoroacetyl) amino]methyl}-!, 3-thiazol-4- yl)ethyl]phenyl}amino)methylidene]biscarbamate was prepared from the compound of Step 1 of Production Example 19 in a manner similar to Step 2 of Production Example 12. 1H-NMR (400MHz, CDCl3) δ (ppm) : 1.5 (9H, s) , 1.53 (9H, s) , 2.26
- 2.32 (3H, m) , 2.82 - 3.11 (7H, m) , 4.33 - 4.42 (2H, m) , 6.97
- 7.13 (2H, m) , 7.41 - 7.51 (2H, m) , 10.3 (IH, brs) , 11.63 (IH, brs) .
MS: 643.2 (M+H)+
Step 3
To a solution of di-tert-butyl [ (E) - ( {4- [2- (2-
(acetylamino) -5-{ [methyl (trifluoroacetyl) amino]methyl}-l, 3- thiazol-4-yl) ethyl]phenyl}amino)methylidene]biscarbamate
(26.4 mg) in methanol (0.5 ml) was added aq. 10 % K2CO3 (0.25 ml) at 0 0C, and then the mixture was stirred for 1.5 hr at
20 °C. The reaction.mixture was evaporated in vacuo, brine
(50 ml) was added, and the mixture was extracted with CHCl3 (10 mlx3) , the extract was dried over MgSCu and evaporated to give di-tert-butyl ( (E) -{ [4- (2-{2- (acetylamino) -5-
[ (methylamino)methyl] -1, 3-thiazol-4- yl}ethyl)phenyl] amino}methylidene)biscarbamate (20.5 mg) as pale yellow foam, that was used as crude in the next reaction.
MS: 547.3 (M+H) +
Step 4 To a solution of di-tert-butyl ( (E) -{ [4- (2-{2- (acetylamino) -5- [ (methylamino)methyl] -1, 3-thiazol-4- yl}ethyl)phenyl]amino}methylidene)biscarbamate (20 mg) in dichloromethane (0.5 ml) were added 4-nitrobenzoic acid (6.11 mg), HOBt (7.42 mg) and EDCI HCl (10.5 mg) , and then the mixture was stirred for 3 hr at 20 0C. The reaction mixture was diluted with dichloromethane (4 ml) and the solution was washed with water. The organic layer was dried over MgSC>4 and evaporated under vaccum to give crude pale yellow oil. The crude oil was purified by preparative silica gel thin-layer chromatography with chloroform / methanol (15:1) as an eluent and purified by PTLC (0.5 mmx2, CHCl3:MeOH=15:l then CHCl3-.AcOEt=I: 1) to give di-tert-butyl [ (E)- ({4- [2- (2- (acetylamino)-5-{ [methyl (4- nitrobenzoyl) amino]methyl}-l, 3-thiazol-4- yl) ethyl]phenyl}amino)methylidene]biscarbamate (14.3 mg) . 1H-NMR (400MHz, CDCl3) δ (ppm) : 1.4 - 1.62 (18H, m) , 2.18 - 2.3 (3H, m) , 2.54 - 3.1 (7H, m) , 3.97 - 4.75 (2H, m) , 6.68 - 8.37 (8H, m) , 10.23 (IH, brs) , 11.62 (IH, brs) . MS: 696.27 (M+H)+ Step 5
The title compound was prepared from the compound of Step 4 of Production Example 19 in a manner similar to Step 15 of Production Example 2. 1H-NMR (400MHz, DMSO-d6) δ (ppm) : 2.13 (3H, s), 2.69 - 3.04
(7H, m), 4.63 (2H, s) , 7.14 (2H, d, J = 8Hz), 7.27 (2H, d, J = 8.4Hz), 7.31 (4H, s) , 7.63 (2H, d, J = 8.4Hz), 8.29 (2H, d, J = 8.4Hz), 9.63 (IH, s) , 12.12 (IH, s) . MS: 496.1 (M+H) Free Production Example 20: Synthesis of (2E) -3-{2- (acetylamino)-4- [2- (4-{ [amino (imino)methyl]amino}phenyl) ethyl] -1, 3-thiazol-5- yl}-N,N-dimethylacrylamide hydrochloride Step 1
Ethyl 4-chloro-3-oxobutanoate (35 g) was dissolved in dichloromethane (70 ml), and then sulfuryl chloride (17.1 ml) in dichloromethane (20 ml) was added dropwise to the solution at 0 0C over 15 minutes under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 3 hours, and concentrated in vacuo. The residual oil, N' -((E)- . ethanoyl) carbamimidothioic acid (25.1 g) and acetone (600 ml) were combined. The reaction mixture was refluxed for 2.5 hours. After cooled to room temperature, the mixture was concentrated in vacuo. The residual solid was washed with water and isopropyl ether to give ethyl 2- (acetylamino) -4- (chloromethyl) -1, 3-thiazole-5-carboxylate (21.2 g) as a pale yellow solid, mp. 164-165 0C
1H-NMR (DMSO-de) , δ (ppm) : 1.30 (3H, t, J=7.0Hz), 2.19 (3H, s) , 4.29 (2H, q, J=7.0Hz), 5.00 (2H, s) , 12.72 (IH, s) . MS: 263 (M+H)+
Step 2: Ethyl 2- (acetylamino) -4- [ (E) -2- (4- nitrophenyl) ethenyl]-1, 3-thiazole-5-carboxylate
To a stirring solution of ethyl 2- (acetylamino) -4- (chloromethyl) -1,3-thiazole-5-carboxylate (1.0 g, 3.81 mmol) in N,N-dimethylformamide (20 mL) was added triphenylphosphine (1.2 g, 4.57 mmol) at room temperature. The resultant mixture was stirred at 65 0C for 5 hours. To the mixture was added potassium tert-butoxide (555 mg, 4.95 mmol) at 5 0C, and the resultant mixture was stirred at 5 0C for 30 minutes. p-Nitrobenzaldehyde (805 mg, 5.33 mmol) was added at 5 °C. After stirring for 1 hour at room temperature, the reaction was quenched with water, and the mixture was filtered to give the title compound (1.0 g, 72.7%) as a yellow solid. 1H-NMR (CDCl3), δ (ppm) : 1.40 (3H, t, J=7.2Hz), 2.33 (3H, s) , 4.38 (2H, q, J=7.2Hz), 7.59 (IH, d, J=16.0Hz), 7.70 (2H, d, J=8.8Hz), 8.18 (IH, d, J=16.0Hz), 8.22 (2H, d, J=8.8Hz), 8.90 (IH, m) . Step 3
Ethyl 2- (acetylamino) -4- [2- (4-aitιinophenyl) ethyl]-1, 3- thiazole-5-carboxylate was prepared from the compound of Step 2 of Production Example 20 in a manner similar to Step 6 of Production Example 10. 1H-NMR (CDCl3), δ (PPm) : 1.35 (3H, t, J=7.0Hz), 2.27 (3H, s) , 2.84 (2H, m) , 3.28' (2H, m) , 3.56 (2H, m) , 4.31 (2H, q, J=7.0Hz), 6.61 (2H, d, J=8.3Hz), 7.01 (2H, d, J=8.3Hz), 9.12 (IH, m) . Step 4 Ethyl 2- (acetylamino) -4- [2- (4-aminophenyl) ethyl] -1,3- thiazole-5-carboxylate (310 mg) was dissolved in tetrahydrofuran (6 ml) under nitrogen atmosphere. Then, di (tert-butyl) dicarbonate (223 mg) in tetrahydrofuran (1 ml) was added to the solution at room temperature. The reaction mixture was refluxed for 2 hours. After cooled to room temperature, the mixture was concentrated in vacuo. The residual solid was washed with ethyl ether to give ethyl 2- (acetylamino) -4- (2-{4- [ (tert-butoxycarbonyl) amino]phenyl}- ethyl) -l,3-thiazole-5-carboxylate (370.7 mg) as an off-white solid. mp. 213-214 0C
1H-NMR (DMSO-d6), δ (ppm) : 1.26 (3H, t, J=7.0Hz), 1.46 (9H, s) , 2.17 (3H, s), 2..85 (2H, t, J=7.5Hz), 3.23 (2H, t, J=7.5Hz), 4.22 (2H, q, J=7.0Hz), 7.04 (2H, d, J=8.5Hz), 7.33 (2H, d, J=8.5Hz), 9.23 (IH, brs) , 12.55 (IH, brs) . MS: 434 (M+H)+ Step 5
Ethyl 2- (acetylamino) -4- (2-{4- [ (tert-butoxycarbonyl) - amino]phenyl}ethyl) -1, 3-thiazole-5-carboxylate (3 g) , IN- aqueous sodium hydroxide solution (17.3 ml) and ethanol (30 ml) were combined, and the mixture was refluxed for 5 hours. After cooled to room temperature, the organic solvent was removed in vacuo. The aqueous solution was acidified (pH=4) with IN-hydrochloric acid, and extracted with ethyl acetate (twice) . The combined organic layer was dried over anhydrous magnesium sulfate, and concentrated in vacuo. The residual solid was dissolved in pyridine (45 ml), and then acetyl chloride (1.48 ml) was added dropwise to the solution at 0 0C under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 13 hours, and pyridine was removed in vacuo. Water was added to the residue, and the mixture was acidified with IN-hydrochloric acid. The precipitate was collected in vacuo. The solid was washed with water and ethyl ether to give 2- (acetylamino) -4- (2-{4- [ (tert-butoxycarbonyl) - amino]phenyl}ethyl) -1, 3-thiazole-5-carboxylic acid (2.23 g) as an off-white solid, mp. 237-238 0C 1H-NMR (DMSOd6) , δ (ppm) : 1.46 (9H, s) , 2.16 (3H, s) , 2.85 (2H, m) , 3.23 (2H, m) , 7.04 (2H, d, J=8.5Hz), 7.33 (2H, d, J=8.5Hz), 9.24 (IH, s) , 12.46 (IH, s) . MS: 404 (M-H)+ Step 6 To a solution of 2- (acetylamino) -4- (2-{4- [ (tert- butoxycarbonyl) amino]phenyl}ethyl) -1,3-thiazole-5-carboxylic acid in CH2Cl2 (3 ml) and DMF (3 ml) were added N,O- dimethylhydroxyamine hydrochloride (118 mg) , EDCI (0.509 ml) and HOBt (188 mg) , and then the mixture was stirred for 3 days at ambient temperature. The reaction mixture was diluted with AcOEt (50 ml) and washed with water (50 mlx3) . The organic layer was dried over MgSO4 and evaporated under vaccum. The residue was triturated with IPE and collected by filtration to give tert-butyl {4- [2- (2- (acetylamino) -5- { [methoxy(methyl) amino] -carbonyl}-l, 3-thiazol-4- yl) ethyl]phenyl}carbamate (366 mg) as a pale yellow solid. 1H-NMR (CDCl3), δ (ppm) : 1.46 (9H, s) , 2.15 (3H, S) , 2.74-2.93 (2H, m) , 3.12-3.29 (2H, m) , 3.22 (3H, s) , 3.59 (3H, s) , 7.05 (2H, d, J=8.5Hz), 7.33 (2H, d, J=8.5Hz), 9.21 (IH, s), 12.34 (IH, s) .
MS: 471.1 (MH-Na)+ Step 7 To a solution of the compound obtained in Step 6 of Production Example 20 (3.93 g) in THF (80 itiL) was added lithium aluminium hydirde (499 mg) slowly (over 15 min) at 5- 10 0C (under ice-cooling) . The mixture was stirred at 5 0C for 1 hr. 30 inL of aquaous solution of sodium potassium tartrate (1 M) was added slowly under ice-cooling, and then the mixture was stirred for another 0.5 hr at r.t. The mixture was extracted with ethyl acetate, and the organic layer was dried over MgSO4, and concecntrated in vacuo to give pale yellow oil. This oil was triturated with IPE and EtOAc to give tert-butyl (4-{2- [2- (acetylamino)-5-formyl-l,3-thiazol-4- yl]ethyl}phenyl) carbamate as pale yellow powder (2.67g) . 1H-NMR (200MHz, DMSO-d6) , δ (ppm) : 1.46 (9H, s) , 2.19 (3H, s) , 2.90 (2H, t, J=7.3 Hz), 3.22 (2H, t, J=7.3 Hz), 7.01 (2H, d, J=8.5 Hz), 7.32 (2H, d, J=8.5 Hz), 9.22 (IH, s) , 9.77 (IH, s) , 12.68 (IH, s) . MS: 390 (M+H)+ Step 8
To a suspension of tert-butyl (4-{2- [2- (acetylamino) -5- formyl-1, 3-thiazol-4-yl] ethyl}phenyl) carbamate (500 mg) in CHCl3 (10 ml) was added (carbethoxymethylene) triphenyl- phosphorane (894 mg) at 20 0C, and the mixture was stirred for lhr. To the reaction mixture was added brine, the mixture was extracted with CHCl3, dried over MgSO4 and evaporated. The residue was purified by Siθ2-column chromatography (toluene:AcOEt = 1 : 1) to give a mixture of ethyl (2E)-3-[2-(acetylamino)-4-(2-{4-[ (tert- butoxycarbonyl) amino]phenyl}ethyl) -1, 3-thiazol-5-yl] acrylate and ethyl (2Z) -3- [2- (acetylamino) -4- (2-{4- [ (tert- butoxycarbonyl) amino]phenyl}ethyl) -1, 3-thiazol-5-yl] acrylate as a pale yellow solid (495.9 mg) . Step 9
A mixture of ethyl (2E)-3- [2- (acetylamino) -4- (2-{4- [ (tert-butoxycarbonyl) amino]phenyl}ethyl) -1, 3-thiazol-5- yl]acrylate and ethyl (2Z) -3- [2- (acetylamino) -4- (2-{4- [ (tert- butoxycarbonyl) amino]phenyl}ethyl) -1, 3-thiazol-5-yl]acrylate (290 mg) was purified by SiO2-column chromatography (CHCl3:MeOH = 100:0-100:2) to give ethyl (2E) -3- [2- (acetylamino) -4- (2-{4- [ (tert-butoxycarbonyl) amino]phenyl}ethyl) -1, 3-thiazol-5- yl]acrylate (118.6 mg) as a white solid.
1H-NMR (400MHz, DMSO-d6) δ (ppm) : 1.22 (3H, t, J = 7.1Hz), 1.46 (9H, s), 2.16 (3H, s), 2.84 (2H, t, J = 7.3Hz), 2.97 (2H, t, J = 7.3Hz), 4.13 (2H, q, J = 7.1Hz), 5.88 (IH, d, J = 15.4Hz), 7.01 (2H, d, J = 8.4Hz), 7.32 (2H, d, J = 8.4Hz), 7.55 (IH, d, J = 15.4Hz), 9.22 (IH, s) , 12.45 (IH, s) . MS: 457.67 (M+H)+ Step 10
Ethyl (2E) -3- [2- (acetylamino) -4- (2-{4-[ (tert- butoxycarbonyl) amino]phenyl}ethyl) -1, 3-thiazol-5-yl] acrylate (53.8 mg) and trifluoroacetic acid (TFA, 2 ml) were combined at 0 0C. The reaction mixture was stirred at 25 0C for 30 min and concentrated in vacuo. To the residue were added AcOEt (20 ml), THF (1 ml) and aq. saturated NaHCO3 solution (20 ml) . The oraganic layer was separated, dried over magnesium sulfate and evaporated to give crude ethyl (2E) -3- [2- (acetylamino) -4- (2- {4-aminophenyl}ethyl) -1, 3-thiazol-5-yl] acrylate as a yellow oil (46.2 mg, MS: 360.14 (M+H)+)
The crude ethyl (2E) -3- [2- (acetylamino) -4- (2-{4- aminophenyl}ethyl) -1,3-thiazol-5-yl] acrylate (46.2 mg) , N,N'- bis (tert-butoxycarbonyl) -lH-pyrazole-1-carboxamidine (54.5 mg) and THF (0.5 ml) were combined under N2 atmosphere. The reaction mixture was stirred at 20 0C for 17 hr, and then concentrated in vacuo. The residue was purified by preparative silica gel thin-layer chromatography with chloroform / methanol (20:1) as an eluent to give ethyl (2E) -3- (2-
(acetylamino) -4-{2- [4- ( { (Z) - [ (tert-butoxycarbonyl) amino] - [ (tert-butoxycarbonyl) imino]methyl}amino)phenyl] ethyl}-l,3- thiazol-5-yl) acrylate (65.6 mg) . 1H-NMR (200MHz, CDCl3) δ (ppm) : 1.32 (3H, t, J = 7.3Hz), 1.49 (9H, s), 1.53 (9H, s), 2.23 (3H, s) , 2.8 - 3.13 (4H, m) , 4.24 (2H, q, J = 7.2Hz), 6.03 (IH, d, J = 15.6Hz), 7.09 (2H, d, J = 8.5Hz), 7.43 (2H, d, J = 8.5Hz), 7.65 (IH, d, J = 15.6Hz), 9.99 - 10.56 (IH, brs) , 11.64 (IH, s) . MS: 602.2 (M+H)+, 624.2 (M+Na) + Step 11
Ethyl (2E) -3- (2- (acetylamino) -4-{2- [4- ({ (Z) -[ (tert- butoxycarbonyl) amino] [ (tert-butoxycarbonyl) imino]methyl}amino) phenyl] ethyl}-l,3-thiazol-5-yl) acrylate (65.4 mg), IN-NaOH (0.543 ml) and dioxane (1 ml) were combined at 0 0C, and the mixture was stirred at 60 0C for 2 hr. The mixture was adjusted to pH=2 with IN-HCl, and the organic solvent was evaporated in vacuo. The residual aqueous solution was extracted with AcOEt:THF (10:1) . The organic layer was washed with water and brine, dried over MgSO4, and concentrated in vacuo to give crude (2E) -3- (2- (acetylamino) -4-{2- [4- ({ (Z) - [ (tert-butoxycarbonyl) amino]- [ (tert- butoxycarbonyl) imino]methyl}amino)phenyl]ethyl}-l, 3-thiazol-5- yl) acrylic acid as a yellow solid, that was used as crude in the next reaction.
MS: 574.19 (M+H)+ Step 12
Di-tert-butyl ( (Z) -{ [4- (2-{2- (acetylamino) -5- [ (IE) -3- (dimethylamino) -3-oxo-l-propen-l-yl] -1,3-thiazol-4- yl}ethyl)phenyl]amino}methylidene)biscarbamate was prepared from the compound of Step 11 of Production Example 20 in a manner similar to Step 4 of Production Example 12.
1H-NMR (400MHz, CDCl3) δ (ppm) : 1.5 (9H, s) , 1.53 (9H, s) , 2.26
(3H, s), 2.85 - 3.21 (1OH, m) , 6.49 (IH, d, J = 14.6Hz), 7.11
(2H, d, J = 8.4Hz), 7.45 (2H, d, J = 8.4Hz), 7.71 (IH, d, J =
15Hz), 9.15 (IH, brs), 10.25 (IH, s) , 11.63 (IH, s) . MS: 601.0 (M+H)+, 623.2 (M+Na) +
Step 13
The title compound was prepared from the compound of Step
12 of Production Example 20 in a manner similar to Step 15 of
Production Example 2. 1H-NMR (400MHz, DMSO-d6) δ (ppm) : 2.17 (3H, s), 2.85 - 3.03
(7H, m), 3.08 (3H, s) , 6.56 (IH, d, J = 15Hz), 7.14 (2H, d, J
= 8.4Hz), 7.25 (2H, d, J = 8.4Hz), 7.35 (4H, s) , 7.39 (IH, d,
J = 15Hz), 9.71 (IH, s), 12.36 (IH, s) .
MS: 401.2 (M+H)+, 423.3 (MH-Na)+ Free Production Example 21: Synthesis of N-{4- [2- (2-amino-lH- benzimidazol-7-yl) ethyl] -1, 3-thiazol-2-yl}acetamide
Step 1
To NaBH4 (678 mg) in THF (10 ml) a»t 0 0C under N2 was added 2, 3-dinitrobenzoic acid (2 g) in THF (4 ml) dropwise over 15 min, then added boron trifluoride diethyl ether complex (3.23 ml) dropwise over 30 min. The reaction mixture was stireed for 2 hr at 20 °C, and then the reaction was quenched with IN-HCl (40 ml), and the mixture was extracted with ethyl acetate (20 mix3) . The combined organic layers were washed with water and brine, dried over MgSO4, filtered and evaporated to give 2, 3-dinitrobenzylalcohol (2.52 g) as a yellow solid, and that was used as crude in the next reaction.
1H-NMR (200MHz, CDCl3) δ (ppm) : 4.81 (2H, s) , 7.73 (IH, t, J = 8Hz), 8.02 (IH, d, J - 8Hz), 8.09 (IH, d, J = 8Hz) . Step 2 Crude 2, 3-dinitrobenzylalcohol (2.52 g) was added slowly to 48 % hydrobromic acid (66 ml), and the mixture was stirred for 6 h at 90 0C. The reaction mixture was cooled to 20 0C, diluted with water (60 ml) and extracted with tert-butyl methyl ether (40 mlx3) . The combined organic layers were washed with water and aq. NaHCO3 solution, dried over Na2SO,j, filtered and evaporated to give l-bromomethyl-2, 3- dinitrobenzene (2.34 g) as a yellow solid.
1H-NMR (200MHz, CDCl3) δ (ppm) : 4.48 (2H, s) , 7.71 (IH, t, J = 8Hz), 7.9 (IH, dd, J = 1.3, 8Hz), 8.14 (IH, dd, J = 1.5, 8Hz) . Step 3
To a solution of l-bromomethyl-2, 3-dinitrobenzene (2.29 g) in acetone (60 g) was added triphenylphosphine (2.31 g) , and the mixture was refluxed for 3 hr (bath temp.=70 0C) . The reaction mixture was cooled to 20 0C, the resulting precipitate was collected by filtration and washed with diethyl ether to give (2, 3-dinitrobenzyl) triphenyl- phosphonium bromide as a yellow solid.
1H-NMR (200MHz, DMSO-d6) : 5.29 (2H, d, J = 15Hz), 7.47 - 8.01 (17H, m) , 8.3 (IH, d, J = 8Hz) . MS: 443.2 (M-Br-)+ Step 4 (2, 3-Dinitrobenzyl) triphenylphosphonium bromide (615 mg) and DMF (2 ml) were combined under N2 atmosphere, and then potassium tert-butoxide (145 mg) was added to the suspension at 0 0C. The reaction mixture was stirred at 0 0C for 10 min, and N- (4-formyl-l, 3-thiazol-2-yl) acetamide (200 mg) was added to the mixture at 0 0C. The reaction mixture was stirred at 20 0C for 2 hr. To the reaction mixture was added ethyl acetate (50 ml), and the mixture was washed with water (20 mlx3) and brine. The organic layer was dried over magnesium sulfate and evaporated to give crude brown oil (750 mg) . The crude oil was purified by flash column chromatography over silica gel with CHCI3 / AcOEt (1:1) as an eluent to give N-{4- [ (Z) -2- (2, 3-dinitrophenyl)vinyl] -1, 3- thiazol-2-yl}acetamide (135.6 mg) as orange foam. 1H-NMR (400MHz, DMSO-d6) δ (ppm) : 2.09 (3H, s) , 6.45 (IH, d, J = 12.2Hz), 6.83 (IH, d, J = 12.3Hz), 7.12 (IH, s) , 7.79 (IH, dd, J = 8, 8Hz), 7.89 (IH, d, J = 7.5Hz), 8.27 (IH, dd, J = I, 8.1Hz) , 11.8 (IH, s) . MS: 335.0 (M+H) +, 357.1 (M+Na)+ Step 5
N-{4- [2- (2, 3-Diaminophenyl) ethyl]-1, 3-thiazol-2- . yl}acetamide was prepared from the compound of Step 4 of Production Example 21 in a manner similar to Step 3 of Production Example 16. 1H-NMR (400MHz, DMSO-d6) δ (ppm) : 2.11 (3H, s) , 2.7 - 2.86 (4H, m) , 4.18 (2H, s) , 4.41 (2H, s) , 6.28 - 6.36 (2H, m) , 6.41 (IH, dd, J = 2.2, 7Hz), 6.77 (IH, s) , 12.07 (IH, s) . MS: 277.09 (M+H)+ Step 6 To a suspension of N-{4- [2- (2, 3-diaminophenyl) ethyl] -1,3- thiazol-2-yl}acetamide (21.6 mg) in MeOH (0.2 ml) was added cyanic bromide (12.4 mg) , and then the mixture was stirred at 20 °C for 14 hr. To the reaction mixture was added aq. IN-NaOH (0.117 ml), and the mixture was concentrated in vacuo. To the residue was added CHCl3:MeOH=IO: 1 (10 ml), and the insoluble material was removed by filtration. The filtrate was purified by preparative NH-silica gel thin-layer chromatography with chloroform / methanol (10:1) as an eluent to give a solid (16.4 mg) . The solid was washed with CH2Cl2 to give N-{4-[2-(2- amino-lH-benzimidazol-7-yl) ethyl] -1, 3-thiazol-2-yl}acetamide (15.4 mg) as an off-white solid. 1H-NMR (400MHz, DMSO-d6) δ (ppm) : 2.11 (3H, s) , 2.85 - 3 (2H, m) , 3 - 3.15 (2H, m) , 5.81 - 6.21 (2H, m) , 6.59 - 6.85 (3Hf m) , 6.9 - 6.98 (IH, m) , 10.56 - 10.96 (IH, m) , 12.07 (IH, s) . MS: 302.2 (M+H)+, 324.1 (M+Na) + Production Example 22: Synthesis of N-{4-[3-(4- { [amino (imino)methyl]amino}phenyl)propyl]-l, 3-thiazol-2- yl}acetamide hydrochloride Step 1
N-{4- [3- (4-Nitrophenyl)propyl] -1, 3-thiazol-2- yl}acetamide (100 mg) and 10 % palladium on carbon (50 % wet) (98.2 mg) in methanol (2 ml), tetrahydrofuran (2 ml) and acetic acid (0.3 ml) were stirred under 3 atin. hydrogen atmosphere at 20 0C for 5 hours. The reaction mixture was filtered through a celite pad, and the filtrate was concentrated in vacuo. The residue was dissolved in ethyl acetate. The organic solution was washed with saturated sodium hydrogen carbonate solution and saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated in vacuo to give N-{4-[3-(4- aminophenyl)propyl] -1, 3-thiazol-2-yl}acetamide (94.3 mg) as pale yellow oil, that was used as crude in the next reaction. MS: 276.21 (M+H)+
Step 2 Di-tert-butyl { (Z) -[ (4-{3- [2- (acetylamino) -1, 3-thiazol-4- yl]propyl}phenyl) amino]methylidene}biscarbamate was prepared from the compound of Step 1 of Production Example 22 in a manner similar to Step 4 of Production Example 16. 1H-NMR (200MHz, CDCl3) 5 (ppm) : 1.5 (9H, s) , 1.53 (9H, s) , 1.86 - 2.07 (2H, m) , 2.22 (3H, s) , 2.62 (2H, t, J = 8Hz), 2.66 (2H, t, J = 8Hz), 6.53 (IH, s) , 7.12 (2H, d, J = 8.4Hz), 7.48 (2H, d, J = 8.4Hz), 10.26 (IH, s) , 11.64 (IH, s) . MS: 518.2 (M+H)+, 540.3 (M+Na)+ Step 3
The title compound was prepared from the compound of Step 2 of Production Example 22 in a manner similar to Step 15 of Production Example 2. 1H-NMR (400MHz, DMSO-d6) δ (ppm) : 1.86 - 1.98 (2H, m) , 2.11 (3H, s), 2.57 - 2.65 (4H, m) , 6.75 (IH, s) , 7.15 (2H, d, J = 8.3Hz), 7.27 (2H, d, J = 8.3Hz), 7.41 (4H, s) , 9.82 (IH, s) , 12.03 (IH, s) . MS: 318.3 (M+H) + free Production Example 23: Synthesis of N-(4-{3-[4- ( { [amino (imino)methyl] amino}methyl)phenyl]propyl}-l, 3-thiazol- 2-yl) acetamide hydrochloride Step 1
To a solution of methyl 4- (4-oxopentyl)benzoate (6.395 g) in MeOH (64 ml) was added Br2 (1.35 ml), and the mixture was stirred for 2 hr at 20 0C. To the reaction mixture were added thiourea (2.21 g) and K2CO3 (10 g) , the mixture was stirrd for 2 hr. at 50 °C, and then cooled to 20 0C, and CHCl3 (256 ml) was added. The resulting precipitate was removed by filtration. The filtrate was evaporated, and to the residue was added CHCl3 (200 ml) , and the insoluble material was removed by filtration, and the filtrate was evaporated in vacuo to give crude brown oil. The crude oil was purified by flash column chromatography over silica gel with CH2Cl2 / MeOH (100: 0-100:2) as an eluent to give methyl 4-[3-(2- amino-1, 3-thiazol-4-yl)propyl]benzoate (1.68 g) as brown oil. 1H-NMR (200MHz, CDCl3) δ (ppm) : 1.89 - 2.09 (2H, m) , 2.57 (2H, t, J = 7.6Hz), 2.71 (2H, t, J = 7.6Hz), 3.9 (3H, s) , 5.19 (2H, brs), 6.08 (IH, s) , 7.26 (2H, d, J = 8.2Hz), 7.95 (2H, d, J = 8.2Hz) . MS: 277.14 (M+H)+ Step 2
Methyl 4- [3- (2-amino-l,3-thiazol-4-yl)propyl]benzoate (1.68 g) was dissolved in CH2Cl2 (16.8 ml) under N2 atmosphere. Then, pyridine (1.57 ml) and AcCl (0.692 ml) were added dropwise to the solution at 0 0C. The reaction mixture was stirred at 20 0C for 30 min. The organic solution was washed with IN-HCl, water and brine, then dried over MgSOo and concentrated in vacuo to give crude brown oil (2.52 g, 130 %) . The crude oil was purified by flash column chromatography over silica gel with CHCl3 / MeOH (100:0-100:2) as an eluent to give methyl 4-{3- [2- (acetylamino) -1, 3-thiazol-4-yl]propyl}benzoate (1.974 g) as a pale yellow solid.
1H-NMR (200MHz, CDCl3) δ (ppm) : 1.92 - 2.11 (2H, m) , 2.27 (3H, s), 2.68 (2H, t, J = 7.3Hz), 2.71 (2H, t, J = 7.3Hz), 3.91 (3H, s), 6.52 (IH, s) , 7.25 (2H, d, J = 8Hz), 7.96 (2H, d, J = 8Hz) .
MS: 319.11 (M+H)+ Step 3
To a stirred solution of methyl 4-{3- [2- (acetylamino) - l,3-thiazol-4-yl]propyl}benzoate (1.968 g) in dry THF (40 ml) was added dropwise diidobutylalminum hydride, 1.0 M solution in toluene (18.5 ml) over 10 min at -78 0C under N2 atmosphere. The reaction mixture was stirred at -78 0C for
10 min, at 20 0C for 2 hr, and then the reaction was quenched with MeOH. IN-HCl was added to the mixture and the mixture was extracted with AcOEt. The organic layer was washed with brine, dried over MgSO4, and concentrated in vacuo to give crude yellow oil (1.36 g) . The crude oil was purified by flash column chromatography over silica gel with CHCI3 / AcOEt (100:0-1:1) as an eluent to give N- (4-{3- [4- (hydroxymethy1)phenyl]propyl}-l, 3-thiazol-2-yl) acetamide (523 mg) as a yellow solid.
1H-NMR (200MHz, CDCl3) δ (ppm) : 1.99 (2H, quintet, J = 7.7Hz), 2.13 (3H, s) , 2.65 (4H, t, J = 7.5Hz), 4.66 (2H, s) , 6.54 (IH, s), 7.15 (2H, d, J = 8Hz), 7.27 (2H, d, J = 8Hz) . MS: 291.3 (M+H)+, 313.1 (M+Na)+ Step 4
N- (4-{3- [4- (Hydroxymethy1)phenyl]propyl}-l, 3-thiazol-2- yl)acetamide (100 mg) , CH2Cl2 (1 ml) and DMF (1 ml) were combined under N2 atmosphere, and then Et3N (60.0 μl) and methanesulfonyl chloride (30.7 μl) were added to the suspension at 0 0C. The reaction mixture was stirred at 20 0C for 16 hr. CHCl3 and water were added to the mixture. The organic layer was washed with brine, dried over MgSO^ and concentrated in vacuo to give crude N- (4-{3- [4- (chloromethyl)phenyl]propyl}-!, 3-thiazol-2-yl) acetamide as
011 (MS: 309.03 (M+H)+) . To the crude N-(4-{3-[4-
(chloromethyl)phenyl]propyl}-l, 3-thiazol-2-yl) acetamide in DMF (1 ml) was added phthalimide potassium salt (63.7 mg) and the mixture was stirred at 50 °C for 7 h, then water was added to the reaction mixture, the mixture was extracted with ethyl acetate, and the extract was washed with brine, dried over magnesium sulfate and evaporated to give crude N- [4- (3-{4- [ (1, 3-dioxo-l, 3-dihydro-2H-isoindol-2- yl)methyl]phenyl}propyl) -1, 3-thiazol-2-yl] acetamide (147.7 mg) , that was used as crude in the next reaction.
1H-NMR (200MHz, CDCl3) δ (ppm) : 1.84 - 2.06 (2H, m) , 2.25 (3Hf s), 2.62 (2H, t, J = 7.5Hz), 2.66 (2H, t, J = 7.5Hz), 4.81 (2H, s), 6.51 (IH, s) , 7.12 (2H, d, J = 8Hz), 7.35 (2H, d, J = 8Hz), 7.63 - 7.93 (4H, m) . MS: 420.2 (M+H) +, 442.1 (M+Na)+ Step 5
To a solution of N- [4- (3-{4- [ (1, 3-dioxo-l,3-dihydro-2H- isoindol-2-yl)methyl]phenyl}propyl) -1, 3-thiazol-2-yl]acetamide (140 mg) in acetonitrile (1.4 ml) was added hydrazine iaonohydrate (162 μl), and the mixture was stirred at 50 0C for 30 min. Volatiles were evaporated. To the mixture was added chloroform (1 ml) and the insoluble material was removed by filtration to give N- (4-{3- [4- (aminomethyl)phenyl]propyl}-l, 3- thiazol-2-yl) acetamide as crude pale yellow foam (103.4 mg) , that was used as crude in the next reaction. MS: 290.10 (M+H)+ Step 6
Di-tert-butyl { (Z) -[ (4-{3-[2- (acetylamino) -1, 3-thiazol-4- yl]propyl}benzyl) amino]methylidene}biscarbamate was prepared from the compound of Step 5 of Production Example 23 in a manner similar to Step 4 of Production Example 16. 1H-NMR (400MHz, CDCl3) δ (ppm) : 1.48 (9H, s) , 1.52 (9H, s), 1.97 - 2.07 (2H, m) , 2.3 (3E, s) , 2.59 - 2.74 (4H, m) , 4.6 (2H, d, J = 5.1Hz), 6.55 (IH, s) , 7.16 (2H, d, J = 8.4Hz), 7.23 (2H, d, J = 8Hz), 8.56 (IH, s) , 10.23 (IH, brs) , 11.54 (IH, s) . MS : 532.3 (M+H) +
Step 7
The title compound was prepared from the compound of Step
6 of Production Example 23 in a manner similar to Step 15 of Production Example 2.
1H-NMR (400MHz, DMSO-d6) δ (ppm) : 1.85 - 1.95 (2H, m) , 2.11 (3H, s), 2.54 - 2.63 (4H, m) , 4.34 (2H, d, J = 6.2Hz), 6.75 (IH, s), 7.22 (4H, s), 7.32 (4H, brs) , 8.08 (IH, t, J =
5.9Hz) , 12.04 (IH, s) . MS: 332.2 (M+H)+ Free
Production Example 24: Synthesis of N- (4-{3- [4- (2-
{ [amino (imino)methyl]amino}ethyl)phenyl]propyl}-l, 3-thiazol-2- yl) acetamide
Step 1 To a solution of N- (4-{3- [4- (hydroxymethyl)phenyl] propyl}-!, 3-thiazol-2-yl) acetamide (423 mg) in chloroform
(10 ml) and MeOH (0.6 ml) was added MnO2 (3.80 g) at 20 0C under N2 atmosphere, and the mixture was stirred for 2 days.
The reaction mixture was filtered through a celite pad. The filtrate was evaporated to give N-{4- [3- (4- formylphenyl)propyl] -1, 3-thiazol-2-yl}acetamide (409.4 mg) as a pale yellow solid, that was used as crude in the next reaction.
MS: 289.04 (M+H)+ Step 2
To a suspension of N-{4- [3- (4-formylphenyl)propyl] -1,3- thiazol-2-yl}acetamide (409.4 mg) in chloroform (8 ml) was added (carbethoxymethylene) triphenylphosphorane (989 mg) at 20
0C, and the mixture was stirred for 1 hr. The reaction mixture was evaporated. The residue was purified by column chromatography over silica gel with hexane / ethyl acetate
(1:1-1:2) as an eluent to give ethyl (2E) -3- (4-{3- [2-
(acetylamino) -1,3-thiazol-4-yl]propyl}phenyl) acrylate (463.9 mg) as a pale yellow solid.
1H-NMR (400MHz, DMSO-de) 5 (ppm) : 1.26 (3H, t, J = 7.1Hz), 1.87 - 1.98 (2H, m), 2.11 (3H, s) , 2.54 - 2.68 (4H, m) , 4.18 (2H, q, J = 7.1Hz), 6.58 (IH, d, J = 15.7Hz), 6.76 (IH, s), 7.25 (2H, d, J = 8Hz), 7.58 - 7.68 (3H, m) , 12.04 (IH, s) . MS: 359.2 (M+H)+ Step 3
Ethyl (2E) -3- (4-{3- [2- (acetylamino) -1, 3-thiazol-4- yl]propyllphenyl) acrylate (100 mg) , MeOH (2 ml), THF (2 ml) and then 10 % Pd/C (50 % wet) (97.6 mg) were combined under N2 atmosphere. The mixture was stirred at 20 0C for 1 hr under H2 atmosphere (3 atm) . The reaction mixture was filtered through a celite pad, and the filtrate was concentrated in vacuo to give ethyl 3-(4-{3-[2- (acetylamino) -1, 3-thiazol-4-yl]propyl}phenyl) propanoate
(109.8 mg) as colorless oil, that was used as crude in the next reaction.
1H-NMR (400MHz, DMSO-d6) δ (ppm) : 1.14 (3H, t, J = 7.1Hz), 1.83 - 1.95 (2H, m) , 2.1 (3H, s) , 2.52 - 2.62 (6H, m) , 2.76 - 2.84 (2H, m) , 4.03 (2H, q, J = 7.1Hz), 6.74 (IH, s) , 7.09 (2H, d, J = 8.4Hz), 7.13 (2H, d, J = 8Hz) , 12.03 (IH, s) . MS: 361.3 (M+H) + Step 4
To a solution of ethyl 3- (4-{3- [2- (acetylamino) -1,3- thiazol-4-yl]propyllphenyl)propanoate (95.8 mg) in dioxane (958 μl) was added IN-NaOH (664.394 μl) at 0 0C, then the mixture was stirred for 30 min at 20 °C. Volatiles were evaporated in vacuo. The residue was dissolved in water (20 ml) and washed with AcOEt (20 ml) . The aqueous layer was adjusted to pH=2, and the resulting precipitate was collected by filtration to give 3- (4-{3- [2- (acetylamino) - 1, 3-thiazol-4-yl]propyl}phenyl)propanoic acid (79.3 mg) as a white solid.
1H-NMR (200MHz, DMSCHd6) δ (PPm) : 1.77 - 2 (2H, m) , 2.1 (3H, s), 2.43 - 2.65 (6H, m) , 2.78 (2H, t, J = 7.3Hz), 6.75 (IH, s), 7.09 (2H, d, J = 8.5Hz), 7.14 (2H, d, J = 8.5Hz), 12.03 (2H, s) .
MS: 333.3 (M.+H)+, 355.1 (M+Na) +
Step 5 tert-Butyl [2- (4-{3- [2- (acetylamino) -1, 3-thiazol-4- yl]propyl}phenyl) ethyl]carbamate was prepared from the compound of Step 4 of Production Example 24 in a manner similar to Step 13 of Production Example 2.
1H-NMR (400MHz, DMSO-d6) δ (ppm) : 1.36 (9H, s) , 1.84 - 1.95
(2H, m), 2.10 (3H, s) , 2.53 - 2.69 (6H, m) , 3.06 - 3.15 (2H, m) , 6.74 (IH, s) , 6.86 (IH, t, J = 5.7Hz), 7.1 (4H, s) , 12.02
(IH, s) .
MS: 404.2 (M+H)+, 426.2 (M+Na) +
Step 6 tert-Butyl [2- (4-{3- [2- (acetylamino) -1, 3-thiazol-4- yl]propyl}phenyl) ethyl]carbamate (36.9 mg) and 4N HCl in dioxane (1 ml) were combined under N2 atmosphere. The reaction mixture was stirred at 25 0C for 4 hr. Volatiles were evaporated in vacuo to give a white solid. To the solid in DMF
(0.9 ml) were added N,N-diisopropylethylamine (60.524 μl) and N,N1-bis (tert-butoxycarbonyl)-lH-pyrazole-1-carboxamidine
(85.136 mg) , and the mixture was stirred for 48 hr at 25 0C.
Volatiles were evaporated, and the residue was purified by preparative silica gel thin-layer chromatography with chloroform / ethyl acetate (2:1) as an eluent to give di-tert- butyl ( (Z)-{ [2-(4-{3-[2-(acetylamino)-l,3-thiazol-4- yl]propyl}phenyl) ethyl] amino}methylidene)biscarbamate (44.6 mg) as colorless oil. 1H-NMR (400MHz, CDCl3) δ (ppm) : 1.47 (9H, s) , 1.5 (9H, s) , 1.93 - 2.04 (2H, m), 2.25 (3H, s) , 2.56 - 2.71 (4H, m) , 2.84 (2H, t, J = 7.3Hz), 3.6 - 3.7 (2H, m) , 6.53 (IH, s) , 7.1 (2H, d, J = 8.4Hz), 7.13 (2H, d, J = 8.4Hz), 8.33 - 8.42 (IH, m) , 11.47 (IH, brs) .
MS: 546.46 (M+H) + Step 7
Di-tert-butyl ( (Z) -{ [2- (4-{3- [2- (acetylaitiino) -1, 3- thiazol-4-yl]propyl}phenyl) ethyl] amino}methylidene) biscarbamate (39.1 mg) and 4N HCl in dioxane (2 ml) were combined under N2 atmosphere. The reaction mixture was stirred at 20 0C for 14 hr. The solvent was removed in vacuo. The residue was dissolved in water, the solution was adjusted to pH=9 with aq. saturated NaHCO3, extracted with AcOEt:THF=I:1, the extract was dried over MgSO4 and evaporated to give a colorless oil (25 mg) . The oil was purified by preparative NH- silica gel thin-layer chromatography with chloroform / methanol (4:1) as an eluent to give N- (4-{3- [4- (2- { [amino (imino)methyl]amino}ethyl)phenyl]propyl}-l, 3-thiazol-2- yl)acetamide (7.7 mg) as a colorless oil.
1H-NMR (400MHz, CDCl3:CD3OD=I :1) δ (ppm) : 1.98 (2H, quintet, J = 7.6Hz), 2.23 (3H, s) , 2.57 - 2.73 (4H, m) , 2.86 (2H, t, J = 7.1Hz), 3.41 (2H, t,. J = 7.1Hz), 6.55 (IH, s) , 7.15 (4H, s) . MS: 346.38 (M+H)+ Production Example 25: Synthesis of N- (4-{2- [4- (2-
{ [amino (imino)methyl] amino}ethyl)phenyl] ethyl}-!,3-thiazol-2- yl)acetamide
Di-tert-butyl ( (Z) -{ [2- (4-{2- [2- (acetylamino) -1, 3- thiazol-4-yl]ethylJphenyl) ethyl]amino}methylidene) biscarbamate (443.1 mg) and 4N HCl in 1,4-dioxane solution (10 ml) were combined under N2 atmosphere. The reaction mixture was stirred at 20 0C for 14 hours. The solvent was removed in vacuo. The residue .was dissolved in water. The solution was made basic (pH=9) by saturated sodium hydrogen carbonate aqeous solution. The precipitate was filtered in vacuo to give N- (4-{2- [4- (2-{ [amino (imino)methyl] amino}ethyl)phenyl] ethyl}- 1, 3-thiazol-2-yl) acetamide (667.7 mg) as a white solid. 1H-NMR (400MHz, DMSO-d6) δ (ppm) : 2.02 (3H, brs), 2.64 - 2.96 (6H, m) , 3.13 - 3.5 (2H, m) , 6.55 (IH, brs), 7.14 (4H, s) , 8.32 (4H, brs) . MS: 332.2 (M+H) + Production Example 26: Synthesis of 3- (4-{2- [2- (acetylamino) - 1,3-thiazol-4-yl]ethyl}phenyl) -N- [amino(imino)methyl] propanamide Step 1
To a solution of methyl 3- (4-{2- [2- (acetylamino) -1, 3- thiazol-4-yl] ethyl}phenyl)propanoate (2.73 g) in dioxane (27 ml) was added IN-NaOH (22.5 ml) at 0 0C, and then the mixture was stirred for 30 min at 20 °C. Volatiles were evaporated in vacuo. The residue was dissolved in water (20 ml) and washed with AcOEt (20 ml) . The aqueous layer was adjusted to pH=2, and the resulting precipitate was collected by filtration to give 3- (4-{2- [2- (acetylamino) -1, 3-thiazol-4- yl] ethylIphenyl)propanoic acid (2.672 g) as a white solid. 1H-NMR (200MHz, DMSO-d6) δ (ppm) : 2.11 (3H, s) , 2.43 - 2.56 (2H, m) , 2.77 (2H, t, J = 7.8Hz), 2.87 (4H, s), 6.73 (IH, s) , 7.11 (4H, s) , 12.09 (2H, s) . MS: 319.09 (M+H)+ Step 2
To a solution of 3- (4-{2- [2- (acetylamino) -1, 3-thiazol-4- yl]ethyl}phenyl)propanoic acid (100 mg) in DMF (2 ml) was added 1, l'-carbonyldiimidazole (56 mg) . The mixture was stirred at 50 °C for 2 hr. To the mixture was added a mixture of guanidine hydrochloride (150 mg) , DMF (1 ml) and 28 % sodium methoxide in MeOH (0.307 ml) at 20 0C. The reaction mixture was stirred at 20 0C for 15 hr, and concentrated in vacuo. The residue was dissolved in water, and the solution was adjusted to pH=8 with IN-HCl. The precipitate was collected. The solid was washed with water, CH3CN and AcOEt to give 3- (4-{2- [2- (acetylamino) -1,3-thiazol-4-yl]ethyl}phenyl) - N- [amino (imino)methyl]propanamide (101.3 mg) as a white powder.
1H-NMR (200MHz, DMSO-d6) δ (ppm) : 2.11 (3H, s), 2.36 (2H, t, J = 7.8Hz), 2.76 (2H, t, J = 8Hz), 2.86 (4H, s) , 6.73 (IH, s) , 6.95 (4H, brs), 7.08 (4H, s) , 11.99 (IH, brs) . MS: 360.3 (M+H) +
Production Example 27: Synthesis of N- [4- (2-{4- [2- (4,5- dihydro-lH-imidazol-2-ylamino) ethyl]phenyl}ethyl) -1, 3-thiazol- 2-yl]acetamide Step 1 To a solution of phthalimide potassium salt (46.2 g) in N,N-dimethylformamide (300 ml) was added dropwise 4- (2- bromoethyl)benzaldehyde (40.92 g) in N,N-dimethylformamide
(50 ml) at 60 0C and the mixture was stirred for 2 hr. The reaction mixture was cooled to 20 0C, and then poured into water (1.5 L) . The resulting presipitate was collected by filtration to give a yellow solid. The solid was dissolved in chloroform (250 ml) and the insoluble material was removed by filtration. The filtrate was concentrated in vacuo. The residue was washed with diethyl ether and collected by filtration to give 4- [2- (1, 3-dioxo-l, 3-dihydro- 2H-isoindol-2-yl) ethyl]benzaldehyde (19.65 g) as an off- white solid.
1H-NMR (200MHz,' DMSO-de) δ (ppm) : 3.04 (2H, t, J = 7Hz), 3.88 (2H, t, J = 7Hz), 7.44 (2H, d, J = 8.5Hz), 7.75 - 7.89 (6H, m) , 9.94 (IH, s) . MS: 280.1 (M+H) + Step 2 { [2- (Acetylamino) -1,3-thiazol-4- yl]methyl} (triphenyl)phosphonium chloride (46.9 mg) and DMF (190 ml) were combined under N2 atmosphere, and then potassium tert-butoxide (12.8 g) was added to the suspension at 0 0C. The reaction mixture was stirred at 0 0C for 15 min, and 4- [2- (1, 3-dioxo-l, 3-dihydro-2H-isoindol-2-yl) ethyl]benzaldehyde (19.28 g) was added to the mixture at 0 °C. The reaction mixture was stirred at 20 0C for 2 hr. The reaction mixture was poured into water, and the resulting precipitate was collected by filtration to give a crude brown solid. The brown solid was washed with CHCN:IPE=I:1, then CHCN to give N- [4- ((E) -2-{4- [2- (1,3-dioxo-l, 3-dihydro-2H-isoindol-2- yl)ethyl]phenyl}vinyl)-l,3-thiazol-2-yl]acetamide (24.88 g) as a beige solid. 1H-NMR (400MHz, DMSO-d6) δ (ppm) : 2.15 (3H, s), 2.94 (2H, t, J = 7.1Hz), 3.83 (2H, t, J = 7.1Hz), 7.12 (IH, d, J = 15.8Hz), 7.14 (IH, d, J = 15.8Hz), 7.16 (IH, s) , 7.19 (2H, d, J = 8Hz), 7.44 (2H, d, J = 8.4Hz), 7.8 - 7.88 (4H, m) , 12.22 (IH, s) . MS: 418.1 (M+H)+ Step 3
N- [4- ( (E) -2-{4- [2- (l,3-Dioxo-l,3-dihydro-2H-isoindol-2- yl) ethyl]phenyl}vinyl) -1, 3-thiazol-2-yl] acetamide (24.88 g) , DMF (800 ml), MeOH (80 ml), AcOH (8 ml) and then 10 % Pd/C (50 % wet) (24.4 g) were combined under N2 atmosphere. The mixture was stirred at 20 °C for 16 hr under H2 atmosphere (4 atm) . The catalyst was renewed every 4 hr in a period of reaction time. The reaction mixture was filtered through a celite pad, and the filtrate was concentrated in vacuo. The residue was washed with IPE (200 ml) and purified by flash column chromatography .over silica gel with CHCl3 / AcOEt (1:1) as an eluent. The fractions containing the object compound were combined, and evaporated under reduced pressure. The residue was washed with IPE (200 ml) and collected by filtration to give N- [4- (2-{4- [2- (1, 3-dioxo- l,3-dihydro-2H-isoindol-2-yl) ethyl]phenyl}ethyl) -1, 3- thiazol-2-yl] acetamide (17.86 g) as an off-white solid. 1H-NMR (400MHz, DMSO-d6) δ (PPm) : 2.11 (3H, s) , 2.78 - 2.92 (6H, m) , 3.79 (2H, t, J = 7.3Hz), 6.66 (IH, s), 7.08 (2H, d, J = 8.9Hz), 7.1 (2H, d, J = 8.8Hz), 7.79 - 7.89 (4H, m) , 12.08 (IH, s) .
MS: 420.2 (MH-H)+, 442.1 (M+Na) + Step 4
To a solution of N- [4- (2-{4- [2- (1, 3-dioxo-l, 3-dihydro- 2H-isoindol-2-yl) ethyl]phenyl}ethyl) -1, 3-thiazol-2- yl] acetamide (2.06 g) in acetonitrile (20 ml) was added hydrazine monohydrate (2.38 ml), and the mixture was stirred at 50 0C for 2 hr. Volatiles were evaporated. To the mixture was added chloroform (10 ml), and the insoluble material was removed by filtration to give crude pale yellow foam (1.49 g, 104.8 %) . The crude oil was purified by flash column chromatography over NH2-silica gel with CHCI3 / MeOH (10:0-10:2) as an eluent to give N- (4-{2- [4- (2- aminoethyl)phenyl] ethyl}-!, 3-thiazol-2-yl) acetamide (1.1304 g) as a pale yellow solid. 1H-NMR (400MHz, DMSOd6) δ (Ppm) : 2.11 (3H, s) , 2.58 (2H, t, J = 7.3Hz), 2.72 (2H, t, J = 7.1Hz), 2.81 - 2.94 (4H, m) , 6.73 (IH, s), 7.08 (2H, d, J = 8.4Hz), 7.11 (2H, d, J = 8.4Hz) . MS: 290.2 (M+H) + Step 5 N- (4-{2- [4- (2-Aminoethyl)phenyl] ethyl}-l, 3-thiazol-2- yl) acetamide (150 mg) , ethyl 2- (methylthio) -4, 5-dihydro-lH- imidazole-1-carboxylate (117.1 mg) , AcOH (0.6 ml) and EtOH (3 ml) were combined under N2 atmosphere, and the mixture was refluxed for 24 hr. After cooled to 20 0C, the reaction mixture was diluted with AcOEt. The solution was made basic by aq. sat. NaHCO3 solution. The resulting precepitate was collected by filtration to give N- [4- (2-{4- [2- (4,5-dihydro-lH- imidazol-2-ylamino) ethyl]phenyl}ethyl) -1, 3-thiazol-2- yl] acetamide (111 mg) as a white solid.
1H-NMR (400MHz, DMS0-d6) δ (ppm) : 2.11 (3H, s) , 2.76 (2H, t, J = 7.5Hz), 2.81 - 2.94 (4H, m) , 3.37 (2H, t, J = 7.1Hz), 3.12 - 3.82 (4H, m), 6.71 (IH, s) , 7.12 (2H, d, J = 8.4Hz), 7.15 (2H, d, J = 8.4Hz), 9.84 (IH, brs) . MS: 358.3 (M+H)+
Production Example 28: Synthesis of N- [4- (2-{4- [2- (ethanimidoylamino) ethyl]phenyl}ethyl) -1, 3-thiazol-2- yl] acetamide
N- (4-{2- [4- (2-Aminoethyl)phenyl] ethyl}-l,3-thiazol-2- yl) acetamide (100 mg) , methyl ethanimidothioate hydroiodide (150.0 mg) and MeOH (2 ml) were combined, and the mixture was stirred for 3 hr at 20 °C. Volatiles were evaporated in vacuo. The residue was purified by flash column chromatography over NH-silica gel with CHCl3 / MeOH (5:0-5:1) as an eluent to give a white foam. The foam was triturated with IPE to give N- [4- (2-{4- [2- (ethanimidoylamino) ethyl]- phenyl}ethyl) -1, 3-thiazol-2-yl] acetamide (97.4 mg) as a white solid. 1H-NMR (400MHz, DMSO-d6) δ (ppm) : 1.83 (3H, s) , 2.09 (3H, s) , 2.72 (2H, t, J = 7.5Hz), 2.8 - 2.93 (4H, m) , 3.18 (2H, t, J = 7 . 5Hz) , 6. 69 ( IH, s ) , 7 . 11 (2H, d, J = 8 .4Hz ) , 7 . 13 (2H, d, J = 8 .4Hz) . MS : 331 .3 (M+H) +
Production Example 29; Synthesis of N-[4- (2-{4- [2- (4,5- dihydro-1, 3-thiazol-2-ylamino) ethyl]phenyl}ethyl) -1, 3-thiazol- 2-yl] acetamide
N- (4-{2- [4- (2-Aminoethyl)phenyl]ethyl}-l, 3-thiazol-2- yl) acetamide (100 mg) , 2- (methylthio) -4, 5-dihydro-l, 3- thiazole (92.1 mg) , cone. HCl (0.04 ml) and 2-methoxyethanol (1.5 ml) were combined under N2 atmosphere, and the mixture was stirred at 120 0C for 24 hr. After cooled to 20 0C, the reaction mixture was dissolved in water (0.5 ml), and the solution was adjusted to pH=10 by aq. K2CO3, and resulting precipitate was collected by filtration to give N- [4- (2-{4- [2- (4, 5-dihydro-l, 3-thiazol-2-ylamino) ethyl]phenyl}ethyl) - 1, 3-thiazol-2-yl] acetamide (111.47 mg) as a beige solid. 1H-NMR (400MHz, DMSO-d6) δ (ppm) : 2.11 (3H, s), 2.73 (2H, t, J = 7.5Hz), 2.82 - 2.93 (4H, m) , 3.21 (2H, t, J = 7.1Hz), 3.31 (2H, t, J = 7.5Hz), 3.82 (2H, t, J = 7.3Hz), 6.73 (IH, s) , 7.09 (2H, d, J = 8.8Hz), 7.12 (2H, d, J = 8.8Hz) . MS: 375.2 (M+H)+
Production Example 30: Synthesis of N- (4-{2- [4- (2- { [imino (methylamino)methyl] amino}ethyl)phenyl] ethyl}-l, 3- thiazol-2-yl) acetamide Step 1
N- (4-{2- [4- (2-Aminoethyl)phenyl] ethyl}-1, 3-thiazol-2- yl) acetamide (200 mg) was dissolved in acetone (2.8 ml) under N2 atmosphere, and then isothiocyanic acid benzoyl ester (93.2 μl) was added dropwise to the solution at 0 °C. The reaction mixture was stirred at 20 0C for 1 hr. Water was added to the mixture, and the precipitate was filtered in vacuo to give a crude yellow solid (237.9 mg, 76 %) . The crude solid was purified by flash column chromatography over silica gel with CHCl3 / MeOH (100:0-100:2) as an eluent to give N- ({ [2- (4-{2- [2- (acetylamino) -1, 3-thiazol-4- yl] ethyl}phenyl) ethyl] amino}carbonothioyl)benzamide (152.8 mg) as a pale yellow solid.
1H-NMR (400MHz, DMSO-d6) δ (ppm) : 2.11 (3H, s) , 2.81 - 2.96 (6H, m) , 3.82 (2H, q, J = 6.7Hz), 6.72 (IH, s) , 7.15 (2H, d, J = 8Hz), 7.19 (2H, d, J = 8Hz), 7.51 (2H, t, J = 7.7Hz) , 7.63 (IH, t, J = 7.5Hz), 7.91 (2H, d, J = 7.7Hz), 10.93 (IH, t, J = 5.3Hz), 11.34 (IH, s) , 12.09 (IH, s) . MS: 453.3 (M+H)+, 475.1 (M+Na)+ Step 2
To a suspension of N- ({ [2- (4-{2- [2- (acetylamino) -1,3- thiazol-4-yl]ethylJphenyl) ethyl]amino}carbonothioyl)benzamide (140 mg) in EtOH (1.5 ml) was added dropwise aq. 6N NaOH
(154.7 μl) at 0 °C. The reaction mixture was stirred for 2 hr at 20 0C, and neutralized with IN-HCl at 0 0C. The precipitate was collected by filtration to give N-{4- [2- (4-{2- [ (aminocarbonothioyl) amino] ethyljphenyl) ethyl] -1, 3-thiazol-2- yl}acetamide (98.6 mg) as a pale yellow solid.
1H-NMR (400MHz, DMSO-d6) δ (ppm) : 2.11 (3H, s) , 2.68 - 2.79 (2H, m) , 2.82 - 2.95 (4H, m) , 3.12 - 3.65 (2H, m) , 6.74 (IH, s), 6.96 (2H, brs), 7.14 (4H, s) , 7.46 - 7.71 (IH, m) , 12.08 (IH, s) . MS : 349. 1 (M+H) +, 371 . 2 (M+Na) + Step 3
To a solution of N-{4- [2- (4-{2-
[ (aminocarbonothioyl) amino] ethyl}phenyl) ethyl] -1, 3-thiazol- 2-yl}acetamide (50 mg) in MeOH (0.5 ml) was added iodomethane (10.72 μl) , and the mixture was refluxed for 5 hr. Volatiles were evaporated and the residue was solidified with AcOEt. The resulting precipitate was collected by filtration to give methyl N- [2- (4-{2- [2- (acetylamino) -1, 3- thiazol-4-yl] ethyl}phenyl) ethyl] imidothiocarbamate hydroiodide (71.2 mg) as a colorless oil. MS: 363.27 (M+H) + Free Step 4
Methyl N- [2- (4-{2- [2- (acetylamino) -1, 3-thiazol-4- yl] ethyl}phenyl) ethyl] imidothiocarbamate hydroiodide (71.2 mg) and 2M methylamine solution in THF (726 μl) were combined at 0 0C under N2 atmosphere. ' The reaction mixture was stirred for 24 hr at 20 0C. Volatiles were evaporated. The residue was dissolved in water and MeOH, and the solution was adjusted to pH=8 with aq. saturated NaHCθ3. MeOH was evaporated, and then water and AcOEt were added. The resulting precipitate was collected' by filtration to give N- (4-{2- [4- (2-{ [imino (methylamino)methyl] amino}ethyl) - phenyl]ethyl}-l, 3-thiazol-2-yl) acetamide (42.8 mg) as a white solid.
1H-NMR (400MHz, DMSO-d6) δ (ppm) : 2.02 (3H, s) , 2.64 - 2.79 (5H, m) , 2.79 - 2.92 (4H, m) , 3.32 (2H, t, J = 7.7Hz), 6.53 (IH, s), 7.13 (4H, s), 8.86 (3H, bs) . MS: 346.3 (M+H)+
Production Example 31: Synthesis of 2- [4- (2-{2- (acetylamino) - 5- [4- (methylsulfonyl)benzyl] -1, 3-thiazol-4-yl}ethyl)phenyl]-N- [amino (imino)methyl] acetamide Step 1
To the solution of [4- (carboxymethyl)benzyl] (triphenyl) phosphonium bromide (1.76 g) in DMF (30 ml) was added potassium tert-butoxide (1.10 g) at 0 °C, and the mixture was stirred for 30 min at same temperature. To the solution was added N-{4-formyl-5- [4- (methylthio)benzyl]-1, 3-thiazol-2- yl}acetamide (1.00 g) (prepared in Step 6 of Production Example 11), and the mixture was stirred for 3hr at 20 0C. The reaction mixture was poured in ice-0.IN-HCl, and the resulting precipitate was collected by filtration. The obtained powder was dissolved with IN-NaOH (40 ml) and washed with AcOEt. The aqueous layer was adjusted to pH=3 with cone, hydrochloric acid, and the resulting precipitate was collected by filtration to give a mixture of [4- ( (E) -2-{2- (acetylamino) -5- [4- (methylthio)benzyl] -1, 3-thiazol-4-yl}vinyl)phenyl]acetic acid and [4- ( (Z)-2-{2- (acetylamino)-5- [4- (methylthio)benzyl]- l,3-thiazol-4-yl}vinyl)phenyl] acetic acid (E:Z=1:2) (1.18 g) as yellow powder.
1H-NMR (400MHz, DMSO-d5) δ (ppm) : 2.07 (3Hx2/3, s) , 2.11 (3Hxl/3, s), 2.43 (3Hx2/3, s) , 2.43 (3Hxl/3, s) , 3.54 (2Hx2/3, s), 3.58 (2Hxl/3, s) , 3.89 (2Hx2/3, s) , 4.23 (2Hxl/3, s) , 6.53 (1HX2/3, d, J = 12.4Hz), 6.63 (1HX2/3, d, J = 12.4Hz), 7.08 (2Hx2/3, d, J = 8.4Hz), 7.16 (2Hx2/3, d, J = 8Hz), 7.17 (2Hx2/3, d, J = 8.4Hz), 7.22 (4Hxl/3, s) , 7.23 (lHxl/3, d, J = 15.4Hz), 7.26 (2Hxl/3, d, J = 8.1Hz), 7.26 (2Hx2/3, d, J = 8.1Hz), 7.38 (lHxl/3, d, J = 15.7Hz), 7.56 (2Hxl/3, d, J = 8Hz), 11.98 (1HX2/3, s) , 12.11 (lHxl/3, s) , 12.41 (IH, brs) . S: 439.0 (M+H)+, 461.0 (M+Na) + Step 2
[4- ( (E) -2-{2- (Acetylamino) -5- [4- (methylsulfonyl)benzyl]- 1,3-thiazol-4-yl}vinyl)phenyl] acetic acid was prepared from the compounds of Step 1 of Production Example 31 in a manner similar to Step 11 of Production Example 1. 1H-NMR (400MHz,. DMSO-de) δ (ppm) : 2.08 (3Hx2/5, s), 2.12 (3Hx3/5, s), 3.18 (3H, s) , 3.54 (2Hx2/5, s) , 3.58 (2Hx3/5, s), 4.09 (2Hx2/5, s) , 4.42 (2Hx3/5, s) , 6.54 (1HX2/5, d, J = 12.4Hz), 6.64 (1HX2/5, d, J = 12.4Hz), 7.15 (2Hx2/5, d, J = 8Hz), 7.25 (1HX3/5, d, J = 14.3Hz), 7.26 (2Hx2/5+2Hx3/5, d, J = 8Hz), 7.41 (2Hx2/5, d, J = 8.4Hz), 7.42 (1HX3/5, d, J = 15.7Hz), 7.54 (2Hx3/5, d, J = 8.4Hz), 7.58 (2Hx3/5, d, J = 8Hz), 7.83 (2Hx2/5, d, J = 8.4Hz), 7.87 (2Hx3/5, d, J = 8Hz), 12.04 (1HX2/5, s) , 12.17 (1HX3/5, s) , 12.4 (IH, s) . MS: 471.1 (M+H)+, 493.0 (MH-Na) + Step 3
A mixture of [4- ( (E) -2-{2- (acetylamino) -5- [4- (methylsulfonyl)benzyl]-1, 3-thiazol-4-yl}vinyl)phenyl]acetic acid and [4- ( (Z) -2-{2- (acetylamino) -5- [4- (methylsulfonyl)benzyl] -1, 3-thiazol-4-yl}vinyl)phenyl]acetic acid (1.010 g) , MeOH (15 ml), THF (60 ml) and then 10 % Pd/C (50 % wet) (1.01 g) were combined under N2 atmosphere. The mixture was stirred at 20 0C for 12 hr under H2 atmosphere (4 atm) . The reaction mixture was filtered through a celite pad, and to the filtrate was added 10 % Pd/C (1.01 g) under N2 atmosphere. The mixture was stirred at 20 0C for 12 hr under H2 atmosphere (4 atm) . The reaction mixture was filtered through a celite pad, and the filtrate was concentrated in vacuo. The residue was washed with Et2O and collected by filtration to give [4- (2-{2- (acetylamino) -5- [4- (methylsulfonyl)benzyl] -1, 3- thiazol-4-yl}ethyl)phenyl] acetic acid (532.8 mg) as an off- white solid.
1H-NMR (400MHz, DMSO-d6) δ (ppm) : 2.08 (3H, s), 2.85 (4H, s) , 3.18 (3H, s), 3.52 (2H, s) , 4.01 (2H, s) , 7.08 (2H, d, J = 8Hz), 7.15 (2H, d, J = 8Hz), 7.32 (2H, d, J = 8.4Hz), 7.81 (2H, d, J = 8.4Hz), 12.06 (2H, brs) . MS: 473.2 (MH-H)+, 495.1 (M+Na) + Step 4
To a solution of [4- (2-{2- (acetylamino) -5- [4- (methylsulfonyl)benzyl]-l, 3-thiazol-4-yl}ethyl)phenyl]acetic acid (100 mg) in DMF (1 ml) was added 1, 1'-carbonyldiimidazole (37.7 mg) . The mixture was stirred at 50 0C for 2 hr. To the mixture was added a mixture of guanidine hydrochloride (101.1 mg) and 28% sodium methoxide solution in MeOH (0.216 ml) at 25 0C. The reaction mixture was stirred at 25 0C for 15 hr, and concentrated in vacuo. The residue was dissolved in water, and the solution was adjusted to pH=8 with IN-HCl, and extracted with AcOEt/MeOH. The organic layer was dried over MgSO4 and evaporated. The residue was purified by flash column chromatography over silica gel with CHCI3 / MeOH (20:0-20:1) as an eluent, and triturated with diethyl ether to give 2-[4-(2- {2- (acetylamino) -5- [4- (methylsulfonyl)benzyl]-1, 3-thiazol-4- yl}ethyl)phenyl]-N- [amino (imino)methyl] acetamide (49.2 mg) as a pale yellow solid.
1H-NMR (400MHz, DMSO-d6) δ (ppm) : 2.07 (3H, s) , 2.83 (4H, s) , 3.18 (3H, s), 3.36 (2H, s) , 4 (2H, s) , 6.57 (2H, brs) , 7.03 (2H, d, J = 8Hz), 7.12 (2H, d, J = 8Hz), 7.3 (2H, d, J = 8Hz), 7.81 (2H, d, J = 8Hz), 7.82 (2H, brs), 12.03 (IH, brs) . MS: 514.2 (M+H)+
The compounds according to the present invention useful as VAP-I inhibitors are listed in the following tables.
Figure imgf000131_0001
Figure imgf000132_0001
Figure imgf000133_0001
Figure imgf000134_0001
Example 1
Inhibitory effect of the present compound on VAP-I enzyme (SSAO) activity in human.
VAP-I enzyme (SSAO) activity in human plasma was determined by a radiochemical-enzyme assay using 14C- benzylamine as an artificial substrate. The enzyme suspension prepared from blood plasma was pre-incubated with a control compound (Reference Example 1) in 96-well microplate at room temperature for 30 min. The enzyme suspension was then incubated with 14C-benzylamine (2xlO~5 mol/1 final concentration) in a final volume of 50 μl at 37°C for 1 hour. The enzyme reaction was terminated by adding 2 mol/1 (50 μl) citric acid. The oxidized products were directly extracted into a 200 μl toluene scintillator, and its radioactivity was measured by a scintillation spectrometer. Inhibition activity was expressed as IC50 ' (μmol/1) value.
Test compounds (i.e., the present compounds) inhibited the enzyme activity of human plasma SSAO in comparison with the control compound as shown in Table 1. Table 1. Inhibitory effect (IC50 values, μM) of test compounds
Figure imgf000135_0001
INDUSTRIAL APPLICABILITY
The present invention provides a compound of the formula (I), (II), (III) or (IV), or a pharmaceutically acceptable salt thereof useful as a VAP-I inhibitor, a pharmaceutical composition, a method for preventing or treating a VAP-I associated disease, especially macular edema such, as diabetic macular edema and non-diabetic macular edema, which method comprises administering to a patient in need thereof a VAP-I inhibitor in an amount sufficient to treat the patient suffering from the VAP-I associated disease, and the like.
This application is based on a provisional patent application No. 2004904196 filed in Australia, the contents of which are all hereby incorporated by reference.

Claims

1. A compound of the formula (I), (II), (III) or (IV):
Figure imgf000136_0001
wherein
R1 is alkylcarbonyl ; Xi is a bond or lower alkylene;
Yi is a bond, lower alkylene, -CH2-CO- , -CH2-CH2-CO-, -CH2-CH2-CO-CH2- or -NH-CH2-CH2- ; and Zi is -NH2, -NH ( lower alkyl ) or lower alkyl ; provided that when Xi is ethylene, then Yx should be C2-C6 alkylene, -CH2-CO-, -CH2-CH2-CO- , -CH2-CH2-CO-CH2- or -NH-CH2-CH2-, when Xi is a bond, then Yi should be a bond, methylene, C3-C6 alkylene, -CH2-CO-, -CH2-CH2-CO- , -CH2-CH2-CO-CH2- or -NH-CH2-CH2-, and when R1 is acetyl, Xi is ethylene, Yi is ethylene and Z1 is -NH2, then Yi should be attached to ortho or meta position of the phenyl group;
Figure imgf000136_0002
wherein
R1 is alkylcarbonyl ;
Figure imgf000136_0003
wherein Ra is (lower alkyl) sulfonyl, aminosulfonyl or di (lower alkyl) aminosulfonyl, wherein Rb is mono- or di- (lower alkyl) amino,
Figure imgf000137_0001
wherein Rc is lower alkyl and Rd is (lower alkyl) sulfonyl, di (lower alkyl) aminocarbonyl, alkylcarbonyl or nitro, or -CH=CH-CO-di (lower alkyl) amino; X2 is a bond or lower alkylene;
Y2 is a bond, lower alkylene, -CH2-CO- or -NH-CO-CH2-; and Z2 is -NH2; provided that when R1 is acetyl, X2 is ethylene, Y2 is a bond and Z2 is -NH2, then R2 should not be 3- (methanesulfonyl)benzyl, 4- (methanesulfonyl)benzyl, 4- (ethanesulfonyl)benzyl and 2- (dimethylaminocarbonyl)pyrrolidin-1-ylmethyl;
Figure imgf000137_0002
wherein
R1 is alkylcarbonyl;
Figure imgf000137_0003
X3 is lower alkylene; and
Y3 is lower alkylene;
Figure imgf000137_0004
wherein R1 is alkylcarbonyl; and X4 is lower alkylene; or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1, wherein R1 is acetyl, or a pharmaceutically acceptable salt thereof.
3. The compound of claim 1, wherein Zi is -NH2, or a pharmaceutically acceptable salt thereof.
4. The compound of claim 1, wherein the compound is
N-{4- [2- (4-{ [amino (imino)methyl] amino}phenyl) ethyl] -5- [4- (aminosulfonyl)benzyl] -1, 3-thiazol-2-yl}acetamide, N-{4- [4- (4-{ [amino (imino)methyl] amino}butyl)phenyl] -1,3- thiazol-2-yl}acetamide, 2- (4-{2- [2- (acetylamino) -1,3-thiazol-4-yl] ethyl}phenyl) -N- [amino (imino)methyl]acetamide,
(3R) -1- ({2- (acetylamino) -4- [2- (4-{ [amino (imino)methyl]amino}- phenyl) ethyl]-1, 3-thiazol-5-yl}methyl) -N,N-dimethyl-3- pyrrolidinecarboxamide, (3S) -1- ({2- (acetylamino) -4- [2- (4-{ [amino (imino)methyl]amino}- phenyl) ethyl]-1, 3-thiazol-5-yl}methyl) -N,N-dimethyl-3- pyrrolidinecarboxamide,
N- ( {2- (acetylamino) -4- [2- (4-{ [amino (imino)methyl]amino}- phenyl) ethyl]-1, 3-thiazol-5-yl}methyl) -N-methyl-4- (methylsulfonyl)benzamide, or
N- ( {2- (acetylamino) -4- [2- (4-{ [amino (imino)methyl]amino}- phenyl) ethyl]-1, 3-thiazol-5-yl}methyl) -N-methyl-4- nitrobenzamide, or a pharmaceutically acceptable salt thereof.
5. The compound of claim 1 or a pharmaceutically acceptable salt thereof for use as a medicament.
6. A pharmaceutical composition, which comprises, as an active ingredient, the compound of claim 1 or a pharmaceutically acceptable salt thereof.
7. A use of the compound of claim 1 or a pharmaceutically acceptable salt thereof for preparing a medicament as a VAP-I inhibitor.
8. The use of claim 7, wherein the compound is N_{4_[2- (4-{ [amino (imino)methyl]aminoIphenyl) ethyl]-5- [4-
(aminosulfonyl)benzyl] -1,3-thiazol-2-yl}acetamide,
N-{4- [4- (4-{ [amino (imino)methyl]amino}butyl)phenyl] -1,3- thiazol-2-yl}acetamide,
2- (4-{2- [2- (acetylamino) -1,3-thiazol-4-yl] ethyl}phenyl) -N- [amino (imino)methyl]acetamide,
(3R) -1- ({2- (acetylamino)-4- [2- (4-{ [amino (imino)methyl]amino}- phenyl)ethyl]-l,3-thiazol-5-yl}methyl)-N,N-dimethyl-3- pyrrolidinecarboxamide,
(3S) -1- ({2- (acetylamino) -4-[2- (4-{ [amino (imino)methyl]amino}- phenyl) ethyl]-l, 3-thiazol-5-yl}methyl) -N,N-dimethyl-3- pyrrolidinecarboxamide,
N- ( {2- (acetylamino) -4- [2- (4-{ [amino (imino)methyl] amino}- phenyl) ethyl]-1, 3-thiazol-5-yl}methyl) -N-methyl-4-
(methylsulfonyl)benzamide, or N- ( {2- (acetylamino) -4-[2-(4-{ [amino (imino)methyl] amino}- phenyl) ethyl]-1,3-thiazol-5-yl}methyl) -N-methyl-4- nitrobenzamide.
9. A use of the compound of claim 1 or a pharmaceutically acceptable salt thereof for preparing a medicament for the prophylaxis or treatment of a VAP-I associated disease.
10. The use of claim 9, wherein said VAP-I associated disease is selected from the group consisting of cirrhosis, essential stabilized hypertension, diabetes, arthrosis, endothelium damage (in diabetes, atherosclerosis and hypertension) , a cardiovascular disorder associated with diabetes and uremia, pain associated with gout and arthritis, retinopathy (in diabetes patients) , an (connective tissue) inflammatory disease or condition (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and osteoarthritis or degenerative joint disease, Reiter's syndrome, Sjogren's syndrome, Behcet's syndrome, relapsing polychondritis, systemic lupus erythematosus, discoid lupus erythematosus, systemic sclerosis, eosinophilic fasciitis, polymyositis, dermatomyositis, polymyalgia rheumatica, vasculitis, temporal arteritis, polyarteritis nodosa, Wegener's granulomatosis, mixed connective tissue disease, and juvenile rheumatoid arthritis) , a gastrointestinal inflammatory disease or condition [Crohn's disease, ulcerative colitis, irritable bowel syndrome (spastic colon) , fibrotic conditions of the liver, inflammation of the oral mucosa (stomatitis) , and recurrent aphtous stomatitis] , a central nervous system inflammatory disease or condition (multiple sclerosis, Alzheimer's disease, and ischemia-reperfusion injury associated with ischemic stroke) , a pulmonary inflammatory disease or condition (asthma, adult respiratory distress syndrome, and chronic obstructive pulmonary disease) , a
(chronic) skin inflammatory disease or condition (psoriasis, allegic lesions, lichen planus, pityriasis rosea, contact dermatitis, atopic dermatitis, and pityriasis rubra pilaris) , a disease related to carbohydrate metabolism (diabetes and complications from diabetes) including microvascular and macrovascular disease (atherosclerosis, vascular retinopathies, retinopathy, nephropathy, nephrotic syndrome and neuropathy (polyneuropathy, mononeuropathies and autonomic neuropathy) , foot ulcers, joint problems, and increased risk of infection), a disease related to aberrations in adipocyte differentiation or function or smooth muscle cell function (atherosclerosis and obesity) , a vascular disease [atheromatous ateriosclerosis, nonatheromatous ateriosclerosis, ischemic heart disease including myocardial infarction and peripheral arterial occlusion, Raynaud's disease and phenomenon, and thromboangiitis obliterans (Buerger' s disease) ] , chronic arthritis, inflammatory bowel diseases, skin dermatoses, diabetes mellitus, SSAO-mediated complication [diabetes
(insulin dependent diabetes mellitus (IDDM) and non-insulin dependent diabetes mellitus (NIDDM) ) and vascular complication (heart attack, angina, strokes, amputations, blindness and renal failure) ] , macular edema (diabetic and non-diabetic macular edema) , hepatitis and transplantation.
11. The use of claim 10, wherein said VAP-I associated disease is macular edema.
12. The use of claim 11, wherein said macular edema is diabetic macular edema.
13. The use of claim 11, wherein said macular edema is non- diabetic macular edema.
14. A VAP-I inhibitor, which comprises the compound of claim 1 or a pharmaceutically acceptable salt thereof.
15. A method for preventing or treating macular edema, which method comprises administering to a subject in need thereof a
VAP-I inhibitor in an amount sufficient to treat said subject for macular edema.
16. The method of claim 15, wherein the VAP-I inhibitor is N-{4- [2- (4-{ [amino (imino)methyl]amino}phenyl) ethyl]-5- [A-
(aminosulfonyl)benzyl] -1, 3-thiazol-2-yl}acetamide, N-{4- [4- (4-{ [amino (imino)methyl] amino}butyl)phenyl] -1, 3- thiazol-2-yl}acetamide,
2- (4-{2- [2- (acetylamino) -1, 3-thiazol-4-yl]ethyl}phenyl) -N- [amino (imino)methyl]acetamide,
(3R) -1- ( {2- (acetylamino) -4- [2- (4-{ [amino (imino)methyl]amino}- phenyl) ethyl]-1,3-thiazol-5-yl}methyl)-N,N-dimethyl-3- pyrrolidinecarboxamide,
(3S) -1- ({2- (acetylamino) -4- [2- (4-{ [amino (imino)methyl]amino}- phenyl) ethyl]-1, 3-thiazol-5-yl}methyl) -N,N-dimethyl-3- pyrrolidinecarboxamide,
N- ( {2- (acetylamino) -4- [2- (4-{ [amino (imino)methyl]amino}- phenyl) ethyl]-1, 3-thiazol-5-yl}methyl) -N-methyl-4- (methylsulfonyl)benzamide, or
N- ( {2- (acetylamino) -4- [2- (4-{ [amino (imino)methyl]amino}- phenyl) ethyl]-I13-thiazol-5-yl}methyl) -N-methyl-4- nitrobenzamide, or a pharmaceutically acceptable salt thereof.
17. A method for preventing or treating a VAP-I associated disease, which method comprises administering an effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof to a mammal.
18. The method of claim 17, wherein said VAP-I associated disease is selected from the group consisting of cirrhosis, essential stabilized hypertension, diabetes, arthrosis, endothelium damage (in diabetes, atherosclerosis and hypertension) , a cardiovascular disorder associated with diabetes and uremia, pain associated with gout and arthritis, retinopathy (in diabetes patients) , an (connective tissue) inflammatory disease or condition (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and osteoarthritis or degenerative joint disease, Reiter' s syndrome, Sjogren's syndrome, Behςet's syndrome, relapsing polychondritis, systemic lupus erythematosus, discoid lupus erythematosus, systemic sclerosis, eosinophilic fasciitis, polymyositis, dermatomyositis, polymyalgia rheumatica, vasculitis, temporal arteritis, polyarteritis nodosa, Wegener's granulomatosis, mixed connective tissue disease, and juvenile rheumatoid arthritis) , a gastrointestinal inflammatory disease or condition [Crohn's disease, ulcerative colitis, irritable bowel syndrome (spastic colon) , fibrotic conditions of the liver, inflammation of the oral-mucosa (stomatitis), and recurrent aphtous stomatitis] , a central nervous system inflammatory disease or condition (multiple sclerosis, Alzheimer's disease, and ischemia-reperfusion injury associated with ischemic stroke) , a pulmonary inflammatory disease or condition (asthma, adult respiratory distress syndrome, and chronic obstructive pulmonary disease) , a
(chronic) skin inflammatory disease or condition (psoriasis, allegic lesions, lichen planus, pityriasis rosea, contact dermatitis, atopic dermatitis, and pityriasis rubra pilaris) , a disease related to carbohydrate metabolism (diabetes and complications from diabetes) including microvascular and macrovascular disease (atherosclerosis, vascular retinopathies, retinopathy, nephropathy, nephrotic syndrome and ne.uropathy (polyneuropathy, mononeuropathies and autonomic neuropathy), foot ulcers, joint problems, and increased risk of infection) , a disease related to aberrations in adipocyte differentiation or function or smooth muscle cell function (atherosclerosis and obesity) , a vascular disease [atheromatous ateriosclerosis, nonatheromatous ateriosclerosis, ischemic heart disease including myocardial infarction and peripheral arterial occlusion, Raynaud' s disease and phenomenon, and thromboangiitis obliterans (Buerger's disease)], chronic arthritis, inflammatory bowel diseases, skin dermatoses, diabetes mellitus, SSAO-mediated complication [diabetes (insulin dependent diabetes mellitus (IDDM) and non-insulin dependent diabetes mellitus (NIDDM) ) and vascular complication (heart attack, angina, strokes, amputations, blindness and renal failure) ] , macular edema (diabetic and non-diabetic macular edema), hepatitis and transplantation.
19. The method of claim 18, wherein said VAP-I associated disease is macular edema.
20. The method of claim 19, wherein said macular edema is diabetic macular edema.
21. The method of claim 19, wherein said macular edema is non-diabetic macular edema.
PCT/JP2005/014136 2004-07-27 2005-07-27 Thiazole derivatives having vap-1 inhibitory activity WO2006011631A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP05768525A EP1786792B1 (en) 2004-07-27 2005-07-27 Thiazole derivatives having vap-1 inhibitory activity
US11/572,772 US20070254931A1 (en) 2004-07-27 2005-07-27 Thiazole Derivatives Having Vap-1 Inhibitory Activity
CA002575411A CA2575411A1 (en) 2004-07-27 2005-07-27 Thiazole derivatives having vap-1 inhibitory activity
JP2007504792A JP4978464B2 (en) 2004-07-27 2005-07-27 Thiazole derivatives having VAP-1 inhibitor activity
DE602005013793T DE602005013793D1 (en) 2004-07-27 2005-07-27 THIAZONE DERIVATIVES WITH VAP-1-HEMMENDER EFFECT

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2004904196 2004-07-27
AU2004904196A AU2004904196A0 (en) 2004-07-27 Thiazole Derivatives Having VAP-1 Inhibitory Activity

Publications (2)

Publication Number Publication Date
WO2006011631A2 true WO2006011631A2 (en) 2006-02-02
WO2006011631A3 WO2006011631A3 (en) 2006-04-20

Family

ID=35734947

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2005/014136 WO2006011631A2 (en) 2004-07-27 2005-07-27 Thiazole derivatives having vap-1 inhibitory activity

Country Status (10)

Country Link
US (1) US20070254931A1 (en)
EP (1) EP1786792B1 (en)
JP (1) JP4978464B2 (en)
KR (1) KR20070050932A (en)
CN (1) CN101031555A (en)
AT (1) ATE427941T1 (en)
CA (1) CA2575411A1 (en)
DE (1) DE602005013793D1 (en)
ES (1) ES2324922T3 (en)
WO (1) WO2006011631A2 (en)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009001857A1 (en) * 2007-06-25 2008-12-31 R-Tech Ueno, Ltd. Composition for ophthalmic disease associated with hypoxia or ischemia
WO2009051223A1 (en) 2007-10-19 2009-04-23 R-Tech Ueno, Ltd. Pharmaceutical composition for treatment of cataract
KR20110022574A (en) 2008-05-30 2011-03-07 가부시키가이샤 아루떼꾸 우에노 Benzene or thiophene derivative and use thereof as vap-1 inhibitor
WO2011029996A1 (en) 2009-09-08 2011-03-17 Biotie Therapies Corp. Use of vap-1 inhibitors for treating fibrotic conditions
JP2011510007A (en) * 2008-01-18 2011-03-31 アラーガン インコーポレイテッド Selective subtype alpha 2 adrenergic agonist and methods of use thereof
WO2012120195A1 (en) 2011-03-08 2012-09-13 Biotie Therapies Corporation New pyridazinone and pyridone compounds
WO2012124696A1 (en) 2011-03-15 2012-09-20 アステラス製薬株式会社 Guanidine compound
WO2013057944A1 (en) 2011-10-19 2013-04-25 興和株式会社 Novel spiroindoline compound, and medicinal agent comprising same
US8507690B2 (en) 2008-01-31 2013-08-13 R-Tech Ueno, Ltd. Thiazole derivative and use thereof as VAP-1 inhibitor
US8735595B2 (en) * 2006-02-15 2014-05-27 Abbvie Inc. Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome
US8748627B2 (en) 2006-02-15 2014-06-10 Abbvie Inc. Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome
WO2014199171A1 (en) 2013-06-12 2014-12-18 Proximagen Limited New therapeutic uses of enzyme inhibitors
CN104478828A (en) * 2014-12-10 2015-04-01 漳州片仔癀药业股份有限公司 2-amino-7-substituted benzothiazole compound as well as preparation method and application thereof
AU2009307656B2 (en) * 2008-10-21 2015-07-02 Cymabay Therapeutics, Inc. Aryl GPR120 receptor agonists and uses thereof
WO2015159112A1 (en) 2014-04-15 2015-10-22 Pécsi Tudományegyetem Semicarbazide-sensitive amine oxidase inhibitors for use as analgesics in traumatic neuropathy and neurogenic inflammation
WO2015189534A1 (en) 2014-06-12 2015-12-17 Proximagen Limited Vap-1 inhibitors for treating muscular dystrophy
WO2016194390A1 (en) 2015-06-05 2016-12-08 R-Tech Ueno, Ltd. Pharmaceutical composition for use in the treatment of cancer
US10214523B2 (en) 2015-01-09 2019-02-26 Kyowa Hakko Kirin Co., Ltd. Production method of thiazole derivative
EP3777846A1 (en) 2015-12-07 2021-02-17 BenevolentAI Cambridge Limited Vap-1 inhibitors for treating pain
TWI746551B (en) * 2016-05-12 2021-11-21 德商百靈佳殷格翰國際股份有限公司 Pyridinyl derivatives, pharmaceutical compositions and uses thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090170770A1 (en) * 2007-11-06 2009-07-02 Ali Hafezi-Moghadam Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap 1) inhibitor
AU2016301745B2 (en) * 2015-08-06 2020-07-16 Ube Industries, Ltd. Substituted guanidine derivative
US11396514B2 (en) * 2016-12-28 2022-07-26 Ube Corporation Substituted guanidine compounds

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4511574A (en) * 1981-01-08 1985-04-16 Mitsui Toatsu Kagaku Kabushiki Kaisha N-(4-Phenyl-2-thiazolyl)carbamate derivatives
WO1996030350A1 (en) * 1995-03-27 1996-10-03 Fujisawa Pharmaceutical Co., Ltd. Amidine derivatives
WO2004067521A1 (en) * 2003-01-27 2004-08-12 Astellas Pharma Inc. Thiazole derivatives and their use as vap-1 inhibitors
WO2004087138A1 (en) * 2003-03-31 2004-10-14 Sucampo Ag Method for treating vascular hyperpermeable disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4699928A (en) * 1984-07-13 1987-10-13 Merrell Dow Pharmaceuticals Inc. Fluoroallylamine derivatives
IT1181871B (en) * 1985-04-01 1987-09-30 Consiglio Nazionale Ricerche SELECTIVE INHIBITORS OF BENZYLAMINOXIDE COMPARED TO OTHER AMINOXIDE
US4650907A (en) * 1985-12-05 1987-03-17 Merrell Dow Pharmaceuticals Inc. Nonaromatic fluoroallylamine MAO inhibitors
US4916151A (en) * 1985-12-05 1990-04-10 Merrell Dow Pharmaceuticals Inc. Method of treating parkinson's syndrome
US4965288A (en) * 1988-02-25 1990-10-23 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4943593A (en) * 1988-02-25 1990-07-24 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5021456A (en) * 1988-02-25 1991-06-04 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5059814A (en) * 1988-11-30 1991-10-22 The California Institute Of Technology Winner-take-all circuits for neural computing systems
JPH0848664A (en) * 1994-08-05 1996-02-20 Hisamitsu Pharmaceut Co Inc New guanidinobenzoic acid ester derivative
HUP0301336A3 (en) * 2000-07-05 2005-04-28 Biotie Therapies Corp Inhibitors of copper-containing amine oxidases and their use for preparation of pharmaceutical compositions
WO2002038153A1 (en) * 2000-11-09 2002-05-16 Biovitrum Ab New use of 4, 5, 6, 7-tetrahydroimidazo-[4,5-c]pyridine derivatives
EP1737450B1 (en) * 2004-03-18 2009-09-16 R-Tech Ueno, Ltd. Aqueous composition comprising a thiazole derivative

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4511574A (en) * 1981-01-08 1985-04-16 Mitsui Toatsu Kagaku Kabushiki Kaisha N-(4-Phenyl-2-thiazolyl)carbamate derivatives
WO1996030350A1 (en) * 1995-03-27 1996-10-03 Fujisawa Pharmaceutical Co., Ltd. Amidine derivatives
WO2004067521A1 (en) * 2003-01-27 2004-08-12 Astellas Pharma Inc. Thiazole derivatives and their use as vap-1 inhibitors
WO2004087138A1 (en) * 2003-03-31 2004-10-14 Sucampo Ag Method for treating vascular hyperpermeable disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MATTAMMAL M B ET AL: "MASS SPECTROMETRY OF 2,4-SUBSTITUTED CARCINOGENIC THIAZOLES AND THEIR METABOLITES" September 1985 (1985-09), JOURNAL OF HETEROCYCLIC CHEMISTRY, HETEROCORPORATION. PROVO, US, PAGE(S) 1157-1163 , XP009010468 ISSN: 0022-152X the whole document compound 8 *

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8748627B2 (en) 2006-02-15 2014-06-10 Abbvie Inc. Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome
US8735595B2 (en) * 2006-02-15 2014-05-27 Abbvie Inc. Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome
WO2009001857A1 (en) * 2007-06-25 2008-12-31 R-Tech Ueno, Ltd. Composition for ophthalmic disease associated with hypoxia or ischemia
JPWO2009001857A1 (en) * 2007-06-25 2010-08-26 株式会社アールテック・ウエノ Composition for ophthalmic diseases associated with hypoxia or ischemia
EP2599498A1 (en) 2007-06-25 2013-06-05 R-Tech Ueno, Ltd. Composition for ophthalmic disease associated with hypoxia or ischemia
WO2009051223A1 (en) 2007-10-19 2009-04-23 R-Tech Ueno, Ltd. Pharmaceutical composition for treatment of cataract
EP2213303A1 (en) * 2007-10-19 2010-08-04 R-Tech Ueno, Ltd. Pharmaceutical composition for treatment of cataract
JPWO2009051223A1 (en) * 2007-10-19 2011-03-03 株式会社アールテック・ウエノ Pharmaceutical composition for the treatment of cataract
EP2213303A4 (en) * 2007-10-19 2011-12-28 R Tech Ueno Ltd Pharmaceutical composition for treatment of cataract
JP2011510007A (en) * 2008-01-18 2011-03-31 アラーガン インコーポレイテッド Selective subtype alpha 2 adrenergic agonist and methods of use thereof
EP2676955A1 (en) 2008-01-31 2013-12-25 R-Tech Ueno, Ltd. Thiazole Derivative and use thereof as VAP-1 Inhibitor
US8507690B2 (en) 2008-01-31 2013-08-13 R-Tech Ueno, Ltd. Thiazole derivative and use thereof as VAP-1 inhibitor
EP2639229A2 (en) 2008-01-31 2013-09-18 R-Tech Ueno, Ltd. Thiazole Derivative and use thereof as VAP-1 Inhibitor
US8999989B2 (en) 2008-05-30 2015-04-07 R-Tech Ueno, Ltd. Benzene or thiophene derivative and use thereof as VAP-1 inhibitor
US9603833B2 (en) 2008-05-30 2017-03-28 R-Tech Ueno, Ltd. Benzene or thiophene derivative and use thereof as VAP-1 inhibitor
KR20110022574A (en) 2008-05-30 2011-03-07 가부시키가이샤 아루떼꾸 우에노 Benzene or thiophene derivative and use thereof as vap-1 inhibitor
JP2014205687A (en) * 2008-05-30 2014-10-30 株式会社アールテック・ウエノ Benzene or thiophen derivative and its use as vap-1 inhibitor
EP2886534A1 (en) 2008-05-30 2015-06-24 R-Tech Ueno, Ltd. Benzene or thiophene derivative and use thereof as VAP-1 inhibitor
AU2009307656B2 (en) * 2008-10-21 2015-07-02 Cymabay Therapeutics, Inc. Aryl GPR120 receptor agonists and uses thereof
US10576148B2 (en) 2009-09-08 2020-03-03 Biotie Therapies Corp. Use of VAP-1 inhibitors for treating fibrotic conditions
US9795671B2 (en) 2009-09-08 2017-10-24 Biotie Therapies Corp. Use of VAP-1 inhibitors for treating fibrotic conditions
WO2011029996A1 (en) 2009-09-08 2011-03-17 Biotie Therapies Corp. Use of vap-1 inhibitors for treating fibrotic conditions
WO2012120195A1 (en) 2011-03-08 2012-09-13 Biotie Therapies Corporation New pyridazinone and pyridone compounds
WO2012124696A1 (en) 2011-03-15 2012-09-20 アステラス製薬株式会社 Guanidine compound
KR20140014153A (en) 2011-03-15 2014-02-05 아스테라스 세이야쿠 가부시키가이샤 Guanidine compound
US9051283B2 (en) 2011-03-15 2015-06-09 Astellas Pharma Inc. Guanidine compound
EP3002278A1 (en) 2011-03-15 2016-04-06 Astellas Pharma Inc. Guanidine compound
TWI547491B (en) * 2011-03-15 2016-09-01 Astellas Pharma Inc Guanidine compounds
KR101879011B1 (en) * 2011-03-15 2018-07-16 아스테라스 세이야쿠 가부시키가이샤 Guanidine compound
US9556160B2 (en) 2011-03-15 2017-01-31 Astellas Pharma Inc. Guanidine compound
US8716470B2 (en) 2011-03-15 2014-05-06 Astellas Pharma Inc. Guanidine compound
WO2013057944A1 (en) 2011-10-19 2013-04-25 興和株式会社 Novel spiroindoline compound, and medicinal agent comprising same
WO2014199171A1 (en) 2013-06-12 2014-12-18 Proximagen Limited New therapeutic uses of enzyme inhibitors
WO2015159112A1 (en) 2014-04-15 2015-10-22 Pécsi Tudományegyetem Semicarbazide-sensitive amine oxidase inhibitors for use as analgesics in traumatic neuropathy and neurogenic inflammation
WO2015189534A1 (en) 2014-06-12 2015-12-17 Proximagen Limited Vap-1 inhibitors for treating muscular dystrophy
CN104478828A (en) * 2014-12-10 2015-04-01 漳州片仔癀药业股份有限公司 2-amino-7-substituted benzothiazole compound as well as preparation method and application thereof
US10214523B2 (en) 2015-01-09 2019-02-26 Kyowa Hakko Kirin Co., Ltd. Production method of thiazole derivative
US10618894B2 (en) 2015-01-09 2020-04-14 Kyowa Kirin Co., Ltd. Production method of thiazole derivative
RU2738937C2 (en) * 2015-01-09 2020-12-18 Киова Кирин Ко., Лтд. Method of producing a thiazole derivative
US10894790B2 (en) 2015-01-09 2021-01-19 Kyowa Kirin Co., Ltd Production method of thiazole derivative
WO2016194390A1 (en) 2015-06-05 2016-12-08 R-Tech Ueno, Ltd. Pharmaceutical composition for use in the treatment of cancer
EP3777846A1 (en) 2015-12-07 2021-02-17 BenevolentAI Cambridge Limited Vap-1 inhibitors for treating pain
TWI746551B (en) * 2016-05-12 2021-11-21 德商百靈佳殷格翰國際股份有限公司 Pyridinyl derivatives, pharmaceutical compositions and uses thereof

Also Published As

Publication number Publication date
US20070254931A1 (en) 2007-11-01
ES2324922T3 (en) 2009-08-19
WO2006011631A3 (en) 2006-04-20
KR20070050932A (en) 2007-05-16
ATE427941T1 (en) 2009-04-15
DE602005013793D1 (en) 2009-05-20
CN101031555A (en) 2007-09-05
JP4978464B2 (en) 2012-07-18
CA2575411A1 (en) 2006-02-02
JP2008508188A (en) 2008-03-21
EP1786792A2 (en) 2007-05-23
EP1786792B1 (en) 2009-04-08

Similar Documents

Publication Publication Date Title
EP1786792B1 (en) Thiazole derivatives having vap-1 inhibitory activity
JP2008508188A5 (en)
US7442715B2 (en) Thiazole derivatives
US20080015202A1 (en) Thiazole Derivatives Having Vap-1 Inhibitory Activity
EP1608365B1 (en) Method for treating vascular hyperpermeable disease
AU2009209885B2 (en) Thiazole derivative and use thereof as VAP-1 inhibitor
US8247412B2 (en) Urea derivatives methods for their manufacture and uses thereof
JP2008512346A5 (en)
ES2220504T3 (en) DERIVATIVES OF AMINOTIAZOL AND ITS USE AS CRF RECEIVING LINKS.
US10689374B1 (en) Pyrimidine-thiazolidinone derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007504792

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 11572772

Country of ref document: US

Ref document number: 2575411

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005768525

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020077004487

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200580031703.X

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005768525

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11572772

Country of ref document: US